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Abstract 
The elderly form a physiological heterogeneous group. This thesis is 
concerned with the activity of plasma aspirin esterase and several other 
plasma esterases in the fit, community-dwelling and frail hospitalized elderly. 
I, 
Several studies have produced evidence to suggest that drug metabolism is 
altered in the frail elderly and some of this work has centred around the 
plasma esterases. Kinetic analysis of plasma from young people, and fit and 
frail elderly people showed that the reduced plasma aspirin esterase in the 
latter group was most likely due to a reduced amount of cholinesterase 
enzyme (a reduced maximal activity) rather than that of a compromised 
affinity of the enzyme (increased Km). 
Purification of whole plasma achieved the removal of 97% of the albumin 
component of plasma aspirin esterase. Subsequent kinetic analysis confirmed 
that there was no change in the Km value of plasma aspirin esterase in the 
three groups as a result of isolating the cholinesterase enzyme. Following 
this, it was postulated that the reduced activity of several plasma esterases in 
the frail elderly may be due to their often poor nutritional status. 
A group of frail elderly people were randomised and half received a 
supplemented hospital diet. Plasma aspirin esterase, cholinesterase, 
paraoxonase, phenylacetate esterase, red blood cell intracellular esterase and 
red blood cell acetylcholinesterase in addition to anthropometric 
measurements were measured at 0,4 and 8 weeks of the study period. The 
control group did not gain weight whereas the group who received a 
supplemented diet gained an average 1.3Kg (non-significant). The post study 
weight and TSF measurements between the fed and control groups differed 
signifcantly at p<0.05. 
There were no significant changes in any of the esterases at 8 weeks 
however plasma cholinesterase did show a significant increase in activity at 4 
week (p < 0.05) and plasma paraoxonase showed a trend towards an 
improved activity. 
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CHAPTER 1 
Clinical and Pharmacological Ageing 
1 
Chapter 1 
Clinical and Pharmacological Ageing 
The meaning of the term 'elderly' or 'aged' is open to discussion. Classification 
as 'old' is commonly based upon our expectations or knowledge of the average 
lifespan of the species under scrutiny. 
Ageing can be regarded as the loss of the ability of an organism to adapt to its 
surroundings over a period of time (Evans, 1985). In human society this is 
complicated by the more severe challenges elderly people are expected to face, 
usually in the form of poverty (Fox et al, 1973). 
Observation and breeding experiments have shown that every species of animal 
has a maximum life span. The vast improvements in public health, expecially 
during the last century have extended the average human life expectancy to 77 
years (Walford, 1976) but there has been no change in the maximum lifespan 
recorded (Evans, 1985). 11 
For most purposes people are defined as elderly when they reach 65 years of 
age. This is an imprecise definition since individuals from the middle years 
onwards show very different biological characteristics in response to variations 
in genetic, social and environmental factors (Woodhouse et al, 1988). With 
advancing years, the body is less able to maintain and repair body tissue with the 
result that cells die and organ function declines. This process occurs at different 
rates in different organs and individuals suffer varying degrees of organ failure 
as age progresses (Exton-Smith, 1985). 
2 
Rather than being a unifying concept therefore, the elderly are a very 
heterogenous population and generalities regarding chronological age associated 
concepts are simplistic and can be unsatisfactory. An appreciation of biological 
differences between the elderly is essential in pharmacological investigations of 
this age-group. 
1.1 Definition of Frailty 
Woodhouse et al (1988) proposed definitions of 'fit' and 'frailty' which have 
been used to define such populations throughout this course of study: 
"The fit elderly are individuals, over 65 years of age, living independently at 
home or in sheltered accommodation. They are freely ambulant and without 
significant hepatic, renal, cardiac, respiratory or metabolic disorder on either 
clinical examination or laboratory investigation. They do not receive regular 
prescribed medication. 
The frail elderly are individuals, over 65 years of age, dependent on others for 
activities of daily living, and often in institutional care. They are not 
independently mobile - whilst they do not have overt cardiac, respiratory, 
hepatic, renal or metabolic disease minor abnormalities may be revealed on 
laboratory investigation. They may require regular prescribed drug therapy. 
Conditions contributing to frailty commonly include Alzheimer's disease, multi- 
infarct cerebrovascular disease, Parkinsonism, osteoporosis, osteoarthritis, and 
healed fracture events". 
3 
Although the definition is based primarily upon social and functional criteria it 
has proved useful in illustrating two extremes of the elderly population. The 
frail elderly have probably become evident as a sub-population of those over 65 
years in the developed world during this century. This is a result of much 
improved social and medical care which has vastly altered the average age to 
which we can expect to live as inhabitants of a developed country. 
ýy. 
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Chapter 2 
Drug Use in the Elderly Population 
2.1 Adverse Drug Reactions 
Over recent years concern has grown over the increasing use of medicines by 
elderly people. The elderly, as a population, require more drug therapy than the 
young because of the age-related increase in pathology. Adverse reactions to 
these medications occur not only because of the multiple pathology of old age, 
but also because of the age-related changes in drug clearance and polypharmacy. 
The ability to clear the drug may fall due to compromised renal and/or hepatic 
function and with multiple drug therapy chances of a drug-interaction are 
increased. 
The incidence of adverse drug reactions (ADRs) in the elderly has been studied 
most extensively in hospitalized elderly. A large muliticentre investigation 
arranged by the British Geriatrics Society in 1975 found that of 1998 elderly 
patients admitted to Geriatric Units, 81.3 % were taking drugs. ADRs were 
noted in 15.3 % of these patients and in 10.3 % an ADR was the deemed to be the 
reason for their hospital admission (William and Chopin, 1980). In this study, 
ADRs were being particularly recorded by the clinicians. It is interesting to 
speculate upon how many of these, in more routine circumstances, would have 
gone unnoticed. 
Fewer community based studies than hospital based have been reported. They 
are very important however, for example because of the less stringent controls 
S 
on multiple prescribing for the elderly in the community. In 1985, the 
proportion of elderly people in the UK population was 18 % and they received 
39% of all the prescription items dispensed (Cartwright et al 1988). 
This is in direct contrast to a disproportionately low consultation rate by elderly 
people with their GP (General Household Survey, 1986), reflecting the number 
of repeat prescriptions issued to this group. 
In many studies of ADRs drugs with a wide therapeutic index which are often 
implicated eg antibiotics, laxatives and analgesics (Brown and Castleden, 1990). 
Castleden and Pickles (1988) correlated the frequency of ADR reporting with 
patient age. Of interest was the fact that in 75% of ADR reports involving a 
gastrointestinal tract (GIT) trauma, a non steroidal anti inflammatory drug 
(NSAID), was suspected and 91 % of GIT bleeds and perforations in patients 
over 60 years were NSAID related. NSAIDs were also more frequently taken 
by older people admitted to hospital with GI bleeds than in age matched controls 
(Somerville, 1986). 
ýl 
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Chapter 
Aspirin 
3.1 Clinical and Pharmacological Aspects of Aspirin Use 
Aspirin (acetylsalicylic acid) is almost entirely administered orally. This first,, 
pass metabolism by hepatic enzymes is an essential part of its pharmacoidnetics. 
It has analgesic, antipyretic, anti-inflammatory and anti-platelet properties, all of 
which can be attributed to inhibition of prostaglandin synthesis (Ferreira and 
Vane, 1974). The analgesia is due to peripheral and central effects, and that of 
antipyrea to central action only. 
Doses required for analgesia vary between 600 mg to 1000 mg given every three 
hours, to a maximum daily dose of 8g (BNF 1991). Salicylates, in general, 
inhibit the synthesis of prostaglandins in inflamed tissues and prevent 
sensitisation of pain receptors to the action of substances such as bradykinin 
which mediates the pain response (Vane, 1974). 
The antiplatelet properties of aspirin have received particular attention in recent 
years (UK TIA, 1988). Platelets and blood-vessel walls contain cyclo-oxygenase 
enzymes that convert arachidonic acid into thromboxanes and prostaglandins 
respectively through intermediary pathways. The end-product in platelets is 
Thromboxane A2 (TX A2) (Hamberg et al, 1975) and that in the vessels is 
prostacyclin (Moncada et al, 1976). TXA2 is considered prothrombotic because 
it induces platelets to aggregate (Hamberg et al, 1975) and vessels to constrict 
( Ellis et al, 1976 ). Prostacyclin is thought to inhibit platelet aggregation since it 
7 
prevents the normal effects of platelets (Moncada et al , 1976) and is a 
vasodilator (Bergman et al, 1981). 
Aspirin intially reacts with a supplemental binding site in cyclooxygenase 
(Cerletti et al, 1982) and then irreversibly acetylates an amino acid residue of the 
active site ( Roth and Siok, 1978). This effect lasts for-the lifespan of the platelet 
but in contrast the nucleated endothelial cells of the vessel walls synthesise new 
enzyme and the effect lasts only a few hours ( Jaffe and Weksler, 1979) . 
De Gaetano et al (1982) suggest that platelet TXA2 synthesis may be more 
sensitive to the effects of aspirin than endothelial cell prostaglandin formation. 
Low doses of aspirin differentially inhibit TXA2 synthesis and result in platelet 
disaggregation. "i, 
Aspirin has a very short half-life of only 12-20 minutes (Eadie, 1987) before it is 
converted to salicylate. The selected dose of aspirin should aim to maximally 
inhibit platelet formation of TX A2 but minimally effect prostacyclin formation. 
The most recent comprehensive cohort study was the Antiplatelet Trialist's 
Collaboration (1988) which carried out 31 randomised trials of anti-platelet 
treatment for patients with a history of transient ischaemic attacks (TIA), 
occlusive stroke, unstable angina or myocardial infarction. The aspirin dose 
used (300-325 mg or 900-1500 mg daily) was still probably far in excess of that 
required or desirable considering the risk of gastrotoxicity. 
8 
3.2 Adverse Effects of Aspirin 
Many patients cannot tolerate aspirin at high doses. Frequent side effects of the 
main metabolite, salicylate, include tinnitis (Mongan et al, 1973), nausea, 
gastrointestinal irritation, haematemesis and melaena (BNF 1991). At such high 
doses however, small adjustments in aspirin dosage may be sufficient to 
eliminate toxic symptoms and yet maintain therapeutic plasma levels. The 
reason for this is discussed in 3.5. 
Reye's Syndrome was first described in 1963 (Reye et al 1963). It is an acute 
encephalopathy associated with fatty degeneration of the viscera (especially the 
liver). It has been reported to occur after infectious illnesses, particularly 
chickenpox and influenza A or B, and usually in small children. Aspirin 
consumption has been implicated as a possible precurser of this complication, 
especially since it is often used in these disorders (Hurwitz et al 1985). Junior 
aspirin products have been removed from general sale to the public in the US 
and UK. 
Some individuals are particularly sensitive to the effects of aspirin, and develop 
an aspirin sensitive urticaria or asthma. Asad et at (1983,1984) showed that the 
plasma of these patients contained elevated levels of prostaglandins (PGF2) and 
histamine. Plasma aspirin esterase activity was reduced in this group compared 
with a control group of non-aspirin sensitive individuals (p < 0.01, aspirin 
sensitive asthma; aspirin sensitive urticaria, p<0.001 ; Williams et al, 1987). 
The reason for this did not appear to be due to genetically determined atypical 
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enzyme or a lack of induction of plasma aspirin esterase as the result of aspirin 
abstention (Rainsford et al, 1980). 
3.3 Use of Aspirin by Elderly People 
Aspirin is widely used for its analgesic and anti-inflammatory properties. 
Because of its availability and cheapness as an "Over the Counter" (OTC) 
medication, it is perhaps more liable to misuse than many prescriptions only 
drugs (POM) and is commonly perceived by members of the public as a "safe" 
drug. In a General Practice survey by Law and Chalmers (1976), 39% of self- 
prescribed medication in a population of 151 people of 75 years and over were 
found to be analgesics. Aspirin and senna were the most regularly taken, self- 
prescribed drugs. - 
ýf F 
Regular prescribed use of aspirin is more likely in the elderly who suffer from 
chronic and painful osteo- and rheumatoid arthritis more frequently. Such 
disorders require a long term commitment to aspirin or similar NSAIDs at quite 
high doses (Karsh, 1990) of up to a maximum of 8g daily (BNF 1991). In` 
recent years low dose aspirin has seen increasing use as a successful antiplatelet 
agent in secondary prevention of a variety of cardiovascular related disorders, 
(UK - TIA Study Group, 1988). Used as such it is given at sub-analgesic doses 
but regularly and for a long period of time (Hanley 1982). 
3.4 Absorption of Aspirin 
Labelling legislation requires aspirin supplied to the general public to bear the 
instructions 'with or after food'. Koch et al (1978) investigated the absorption of 
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a single 650 mg dose of aspirin after various meals each consisting 
predominantly of one of the three major food groups with large or small volumes 
of water. 
The absorption rate of aspirin was greatest when taken with food and the high fat 
diet seemed to promote the greatest absorption. This may be the result of an 
increased bile flow and improved drug solubilization. Various enteric coated 
(EC) formulations of aspirin have been introduced to minimize the 
gastrointestinal problems associated with aspirin. With doses of 300 mg aspirin 
EC it is possible to eliminate mucosal injury completely and to substantially 
reduce it with higher doses (Hawthorne et al, 1991). These authors and Ross 
Lee (1982) found EC formulations resulted in much lower peak concentrations 
of aspirin. This is of great importance when it is used for analgesic and anti- 
inflammatory purposes but only very small plasma concentrations are required to 
inhibit platelet aggregation (De Gaetano et al, 1982)., 
Proost et al (1983) showed that a pH buffered formulation of aspirin produced 
higher levels of aspirin in vivo than a comparable dose of plain aspirin tablets 
(BP). This is contrary to the expected result as an alkali medium could be 
expected to provide more of the ionized species and hence slower absorption ;, 
(Rowland et al, 1972). In addition buffered aspirin formulations cause less 
damage to the GI mucosa. 
Rowland et al (1972) compared the availability of aspirin administered as a 650 
mg tablet in 250 ml water with 650 mg aspirin given intravenously (IV). The 
amount of drug reaching the site of action after ingestion was only 68 % of that 
obtained following IV administration. Incomplete absorption was excluded by 
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the investigators as the Area Under the Curve (AUC) was the same following 
either route. Esterase activity in the GI fluid was also rejected since the mean 
half lives of aspirin at 370C in samples of gastric and duodenal juices were 16 
and 17 hours respectively. Esterase activity in the gut wall seemed the most 
likely explanation. Builder et al (1977) investigated the possible role of gut 
mucosal aspirin esterase activity in the aetiology of chronic peptic ulcer. Tissue 
samples from different parts of the stomach and from both sexes varying in age, 
gastric disease type, and aspirin intake were studied. No difference in mucosal 
aspirin esterase activity was found in these groups. Aspirin esterase activity in 
the gut wall is thus unlikely to protect against gastric ulcers or to significantly 
alter the inter-individual variation in aspirin absorption. Rowland et al (1972) 
examined the whole GIT in rabbits and demonstrated aspirin esterase activity 
along the entire length. The results are given as the percentage of aspirin 
hydrolysed by each part of the GIT. Thus comparisons of absolute activity are 
not possible. In this case the duodenum shows the maximum activity but this is 
probably due to the large surface area. 
In the same study wide variations were found in the absorption half-life of 
aspirin due to intra-individual differences in stomach emptying times, gastric 
blood flow, the amount of fluid in the stomach and degree of intestinal motility. 
These findings have been confirmed by Levy (1980)' who examined data by 
Hollister (1972). 
`ý. 
3.5 The Pharmacokinetics of Aspirin 
The pharmacoidnetics of salicylate are a major consideration in the elimination 
of aspirin from the body. The main metabolites are shown in Fig. 3.1. 
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Figure 3.1 Metabolism of Aspirin 
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The hydrolysis product salicylic acid is eliminated by the formation of salicyluric 
acid (glycine conjugate), salicylphenol glucuronide, salicylacyl glucuronide and 
gentisic acid (Levy, 1980), a small proportion is excreted unchanged (Levy, 
1965). 
The conjugates of salicylate are cleared more rapidly through the kidney and are 
thus a more effective pathway for excretion (Schachter and Manis, 1958). Renal 
excretion of salicylate is dependent on urine pH, being higher in alkaline than 
acid urine. Concurrent administration of antacids for dypepsia significantly 
reduces plasma levels due to the more rapid renal excretion of the drug (Levy et 
al, 1975). 
Antiplatelet therapy requires small doses of aspirin and subsequent elimination of 
salicylate proceeds by first order kinetics. The major metabolite in this instance 
is salicyluric acid (Levy 1965). 
When the dose is increased to 1g or more per day the formation of salicyluric 
acid becomes saturated and consequently its contribution (as a zero-order 
process) becomes negligible to the elimination of salicylate. In such 
circumstances elimination continues by the first order processes of excretion of 
unchanged salicylate and salicyl glucuronide formation. (Levy, 1965). 
Salicyluric acid only becomes a significant elimination product when the 
administered dose is reduced in size or during the terminal phase of salicylate 
elimination following a large dose. At small doses the half life of salicylate 
elimination is around 2.9 hour when all processes proceed by first order kinetics. 
At high doses the elimination half-life increases to 22 hours due to the now 
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negligible contribution of salicyluric acid to the elimination process (Levy, 
1965). 
The steady-state level of salicylate does not increase in proportion when dosing 
frequency is increased due to the saturation of the enzymatic processes involved 
in the formation of the principle metabolite (Levy 1975). 
The complexity of salicylate pharmacokinetics helps to explain the substantial 
interindividual differences in steady-state plasma or serum salicylate 
concentrations in healthy, normal subjects receiving the same daily dose of 
aspirin (Levy, 1979; Gibson et al, 1975). 
The survival of aspirin in vivo is also dependent upon the presence of blood 
esterases. These have been found in red blood cells (arylesterases) (Costello and 
Green, 1982) and plasma (cholinesterases) (Rainsford et al, 1980; Morikawa et 
al, 1979). Costello and Green (1982) suggested that it is the activity of the 
erythrocyte arylesterase which controls the overall rate of aspirin hydrolysis in 
the blood. 
The role of esterases in aspirin metabolism will be discussed in more detail in 
Chapter 4. 
3.6 The Effect of Old Age on Salicylate Pharmacokinetics 
Salicylate is 80-90% bound to plasma proteins especially albumin. Hence, any 
condition which results in hypoalbuminaemia, including old age may result in 
high levels of free salicylate with resulting toxicity (Karsh, 1990). 
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Roberts et al (1983) found little difference between the pharmacoidnetics 
parameters of aspirin/salicylate in elderly people. - The higher peak salicylate 
concentration in young people was attributed to the higher apparent volume of 
distribution in the elderly. 
An unpublished study by Baillie et al (personal communication) compared 
aspirin pharmacokinetics in fit elderly with those of the frail elderly and found a 
reduced AUC for aspirin and salicylate in the latter. One explanation of the 
results could be impaired aspirin absorption which, if confirmed may be an 
important observation in view of the widespread therapeutic use of aspirin in this 
group. 
Age per se does not appear to be an important factor in aspirin absorption. 
Salem and Stevenson (1977) found the AUC of salicylate elimination in a group 
of elderly was approximately twice that for young subjects. Netter et al (1985) 
and Castleden et al (1977) found a tendency for an increased AUC. This implies 
that salicylate clearance is slower in the elderly. Netter et at (1985) found no 
statistically significant difference between salicylate clearance in young and 
elderly subjects. However there did appear to be a greater variability in the 
kinetics, with a greater number of elderly individuals showing a reduced 
salicylate clearance. 
Ho et al (1985) found higher concentrations of salicyluric acid plasma 
concentrations in the elderly. This was substantiated with correlations between 
the renal clearance of salicyluric acid, free salicylate and renal clearance. 
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3.7 Summa 
The changes in pharmacokinetics which occur with ageing cannot fully explain 
the increased predisposition of the elderly to toxicities such as confusion or GI 
bleeding (Somerville, 1986). Altered end organ sensitivity may account for the 
correlation between some toxic side effects, ingested dose and serum salicylate 
concentrations (Owen et al 1989). 
The fall in serum albumin with age is probably not of significant magnitude to 
affect salicylate concentrations (Wallace et al, 1976), although its effect cannot 
be discounted completely (Netter, 1985). 
Renal function declines with age (Davies and Shock, 1950) and thus renally 
excreted salicylate and the metabolites may exhibit a slower renal elimination 
rate. Certain drugs such as uricosuric agents compete for tubular secretion and 
can hence increase salicylate concentrations (Karsh, 1990). 
The elderly kidney is more sensitive to the inhibition of renal prostaglandin by 
aspirin. This can result in a reduced renal blood flow and glomerular filtration 
which, in turn reduces salicylate excretion, hence a cycle due to age and aspirin 
use can quickly raise salicylate concentrations to toxic levels (Baily and Jones, 
1989). 
Aspirin is a very valuable drug but like any other ingested foreign compound is 
not without risk. Before being prescribed, whether for chronic low dose 
antiplatelet therapy or in higher doses for analgesic/anti-inflammatory effects, an 
assessment of risk versus benefit must be made. Concurrent medication, 
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previous history of GI disturbances and the patient's age must all be considered. 
When used for self-limited conditions (for which most over-the-counter 
purchases are made) duration of therapy should be minimal. When used for 
long-term treatment, the patient should be reviewed at regular intervals. 
CHAPTER 4 
Esterases 
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Chapter 4 
Esterases 
4.1 Nomenclature 
A simple, clear classification of esterases is extremely difficult to set out since 
many have overlapping substrate specificity and will hydrolyse more than one 
substrate, albeit to varying degrees. 
Esters, amides, hydrazides and carbamates can be hydrolysed by various esterase 
enzymes present in body tissues and fluids. The reaction catalyzed by esters is 
as follows: 
RCOORI + H2O -----> RCOOH + R1OH 
RCOORI is the hydrolysable substrate, RCOOH and R1OH are the products. 
Their classification by the International Enzyme Commission (EC) is based on 
the substrate type for which the esterase shows the greatest affinity. 
Of those listed in Table 4.1, arylesterase, cholinesterase (formerly 
pseudocholinesterase) and acetylcholinesterase (formerly cholinesterase) are 
found in the blood. Acetylcholinesterase is found membrane bound to red blood 
cells, arylesterase in the plasma and red blood cell lysate and cholinesterase in 
the plasma alone. 
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Table 4.1 
Classification of Esterases 
EC number Systematic Trivial name Typical name 
name 
3.1.1.1 carboxylic ester carboxylesterase aliphatic esters 
h drolase 
3.1.1.2 aryl ester arylesterase aromatic esters 
hydrolase 
3.1.1.3 glycerol- ester lipase triglycerides 
hydrolase 
3.1.1.6 acetic ester acetylesterase acetic esters 
3.1.1.7 acetylcholine acetylcholin- acetylcholine 
hydrolase esterase 
3.1.1.8 acylcholine cholinesterase acylcholine 
ac l- h drolase 
The E. C number is the International Enzyme Commission Classification 
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An additional classification introduced by Aldridge in 1953 is used mainly in 
toxicological literature and parallels the EC system. It is based on the' 
observation that paraoxon (an irreversible inhibitor of serine esterases) may, in 
fact, act as a substrate for others. Thus paraoxon is a substrate for A-esterases 
(arylesterases) an inhibitor of B-esterases (carboxylesterases and cholinesterase) 
and without influence on C-esterases (acetyl esterases). 
Many substrates have been used in an attempt to further classify esters which has 
resulted in a very confusing picture. This has particularly been the case with 
carboxylesterases which predominate in mammals both qualitatively and 
quantitatively, possessing a high degree of multiplicity and a large number of 
isozymes coded for by separate genetic loci (Hedrich and von Diemling, 1987). 
Heymann (1989) reasoned that carboxylesterases must be present to hydrolyse 
endogenous compounds thus attempting to simplify the nomenclature by 
identifying such substrates. He proposed that these substrates alone should form 
the basis of a new classification system, hence eliminating the present state 
whereby homologous enzymes have different names between species. 
4.2 Human Liver Esterases 
The liver of humans and other mammals contains a number of carboxylesterases 
(EC 3.1.1.1) (Williams, 1985). These are non-specific serine hydrolases with 
differing substrate and inhibitor specificities. In common with most plasma 
esterases their biological role remains unknown although a role in lipid 
metabolism has been tentatively suggested. This is due largely to their ability to 
hydrolyse medium and long chain fatty acid esters (Ketterman et al, 1989, 
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Tsujita and Okuda, 1983). They also play an important part in the hydrolysis of 
many xenobiotic esters and amides (Heymann, 1982). Most of the work to date 
has involved small mammal studies with very limited work on human livers. 
Junge et al (1974) and Tsujita and Okuda (1983) both report only one form of 
the esterase in human livers which Tsujita and Okuda (1983) propose to be 
present in the microsomal fraction. Junge et al (1974) observed some 
heterogeneity in the purified enzyme preparation when isoelectric focussing was 
carried out but further investigations were not undertaken. 
A trimeric structure was proposed by both workers with each monomer having a 
molecular weight in the region of 60,000 Daltons. 
In contrast, Ketterman et al (1989), Inoue et al (1980) and All and Kaur, (1983) 
all provide evidence of at least two human liver carboxylesterases. Most studies 
have concentrated on the microsomal fraction. Kinetic studies by Williams et al 
(1989) on microsomal and cytosolic fractions using aspirin as a substrate suggest 
carboxylesterase is present in both. Although only two livers were studied, the 
cytosolic enzyme showed a significantly higher affinity and higher predicted 
maximal activity for aspirin than did the microsomal enzyme. In a further eight 
livers, the esterase of the cytosolic fraction showed five times the activity of the 
microsomal fraction at 1mM aspirin concentration. 
White and Hope (1984a) also investigated different carboxylesterases in the 
cytosolic and microsomal fractions of guinea pig liver cells. Activity in the 
microsomes was found to be due to a carboxylesterase which is a serine 
hydrolase requiring a free thiol group for activity (White and Hope, 1984b). 
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That in the cytosol, however, has a lower molecular weight (35,000 Daltons 
compared with the usual value of 60,000 Daltons for liver carboxylesterases) and 
a different degree of sensitivity to the specific carboxylesterase inhibitor bis (4- 
nitrophenyl) phosphate (White and Hope, 1984a). 
Interestingly Ketterman (1989) claims microsomal and cytosolic esterases are 
identical and the two esterases found in purification procedures are present in 
both fractions. 
4.3 Human Blood Esterases 
Esterases constitute a significant proportion of the many protein and enzymatic 
components in blood. Esterases present in both plasma and red blood cells 
(RBC) and one or both may be involved in the elimination of an endogenous or 
foreign compound from the blood. 
A role for esterases of considerable clinical significance has been confirmed and 
this is central to the following studies. The biological role of many esterases is, 
as yet, undefined, however. 
4.3.1 Aspirin Esterase 
When aspirin is administered orally it is presystemically metabolised in the liver 
and gut wall so that only 65 % of the original dose reaches the systemic 
circulation (Rowland et al, 1972). Subsequent hydrolysis by plasma, blood 
esterases and the liver on recirculation is rapid and the biological half-life of 
aspirin in man is only about 15-20 minutes (Levy, 1965). 
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The enzyme activity referred to as 'aspirin esterase' ie the enzymes resulting in 
hydrolysis of aspirin to salicylate is contributed to by both cholinesterase and 
albumin in the plasma (Morikawa et al, 1979; Rainsford et al, ý 1980). 
Cholinesterase exhibits the greater activity at an estimated 80% and albumin 
contributes the other 20 % (Rainsford et al, 1980). Hawkins et al (1969) t 
suggested that aspirin acetylated the lysine residue of albumin thereby releasing 
salicylate and acetate. 
RBC aspirin esterase is an intracellular enzyme (Rylance and Wallace, 1981). It 
appears to be unrelated to membrane bound acetylcholinesterase (Costello and 
Green; 1983) as suggested by Harris and Riegelman (1967) and may, in fact be a 
modified arylesterase. Inhibition studies with mercury chloride and 5,5'- ", 
dithiobis - (2-nitrobenzoic acid) or DTNB (a sulphahydryl reagent) suggested 
that, unlike other arylesterases, RBC aspirin esterase requires functionally intact 
sulphahydryl groups. A greater degree of specificity is also suggested by the 
lack of inhibition by sodium fluoride which, again, inhibits many arylesterases 
(Costello and Green, 1983). 
Further work by Costello et al (1984) in which the haemocrit of dogs was 
reduced by controlled bleeding and/or removal of the spleen demonstrated a 
negative correlation between aspirin survival in the blood and haemocrit. It is 
possible that these- results could be extrapolated to humans. A similar reduction 
in erythrocyte lysate could lead to increases in aspirin survival in vivo and 
subsequently to a greater pharmacological effect. There is no evidence for this, 
however. 
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Plasma aspirin esterase has been observed to be a useful predictive tool of the 
latter's ability to hydrolyse aspirin (Williams et al, 1989). Despite two different 
enzymes being responsible in each case, Williams et al (1989) observed a 
parallel variation in plasma cholinesterases and liver carboxylesterases. 
A number of workers have demonstrated correlations between plasma aspirin 
esterase activity and the pharmacological effects of aspirin. Seymour et al 
(1984a) found a significant negative correlation between plasma aspirin esterase 
activity and the area under the pain-score-time curve in a group of 15 patients 
who receive a single dose (1.2g) of aspirin for post operative dental pain. 
Similarly Seymour et al (1984b) showed a significant negative correlation 
between plasma aspirin esterase activity and prolongation of bleeding time at 24 
hours and inhibition of platelet aggregation with collagen following a single lg 
dose of aspirin. In a study of patients with rheumatoid arthritis, plasma aspirin 
esterase activity was also negatively correlated with pain relief achieved by 
females but not by males (Rainsford, 1980). 
Therefore, despite the liver having the greater esterase capacity to hydrolysed 
aspirin, variations in the plasma enzyme appear to significantly influence the 
removal of aspirin from the blood and hence pharmacological effect. Aspirin 
esterase activity is also present in the liver (4.2) and gut wall (3.4). 
4.3.2 Cholinesterases 
The cholinesterases can be classified broadly into acetylcholinesterase (E. C. 
3.1.1.7 AChE) and cholinesterase (E. C. 3.1.1.8. ChE), formerly 
pseudocholinesterase. 
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ChE is found in almost all major systems of the mammalian body although there 
is considerable variation in the level of ChE activity between species (Silver, 
1974). Despite its widespread presence, no biological function has been . 
established to date. Several studies investigating its role have been concerned 
with the control of neurological enzyme systems (Kutty, 1980) and lipid and 
lipoprotein metabolism (Chu et al, 1978). 
ChE can be distinguished from AChE by substrate specificity and selective 
inhibitors. ChE will hydrolyse acetylcholine in vivo but benzoylcholine and 
butyrylcholine are the preferred substrates. It is inhibited specifically by 10-(1- 
diethylaminopropionyl) phenothiazine. 
The specificity of ChE is due to the active centre which consists of an anionic 
site. Once the substrate is reversibly bound, the aryl group binds to the serine 
residues of the esteratic site, and the choline is released. Next, the acetylated 
intermediate reacts with water to yield the acid and regenerate the active enzyme 
(Williams, 1985). 
Early work by Surgenor and Ellis (1954) suggested that human serum 
cholinesterase activity was due to a single protein. However, with the 
introduction of more sophisticated electrophoretic and chromatographic 
techniques, this now seems unlikely. Multiple molecular forms of cholinesterase 
have been identified using cholinesterase preparations of varying degrees of 
purity as the starting material. Various combinations of starch and 
polyacrylamide gel electrophoresis (PAGE) together with different staining 
techniques have been used to observe the different isozymes (Brown et al, 1981). 
So many different methods of study have led to conflicting conclusions. 
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However, at least five bands of different electrophoretic mobility have been 
isolated with minor additional bands sometimes found in human plasma (La 
Motta, 1968). Juul (1968) detected twelve bands of cholinesterase activity using 
a stain containing butyrylthiocholine and copper. 
The least mobile bands have the greater proportion of enzyme activity (Gaffney, 
1970). Inconsistent minor bands are most likely to be cleavage products of the 
main bands due to prolonged storage, especially when subject to intermittent 
freeze-thaw treatments (Gaffney, 1970). Such apparent quantitative changes in 
isozymes make any comparisons between individual plasmas fraught with 
difficulty. 
Cholinesterase is made up of 4 identical subunits (tetramers) and has an - 
approximate molecular weight of 342,136. It comprises of 574 amino acids with 
a molecular weight of 65,092 and 9 carbohydrate chains which vary in weight 
(Lockridge, 1987). Molecular weights have been calculated using methods such 
as ultracentrifugation (La Motta, 1970) and Sephadex gel filtration (La Du and 
Snady, 1971) but all agree quite closely with these results. 
Protease contamination can cause cleavage of the residual, dimer subunits. If 
this mixture is then subjected to SDS gel electrophoresis two bands are evident: 
one due to the monomer and the other to the unreduced dimer (Lockridge, 
1979). Proteolysis by trypsin results in disulphide-depleted tetramer, trimer, 
dimer and monomer. This disulphide bond does not appear to be essential for 
maintaining the activity (Lockridge et al, 1979) as the digestion products all 
exhibit activity (Lockridge and La Du 1982). The interchain disulphide bond is 
located only four amino acid residues from the end of the subunit 
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(Lockridge, 1987). Thus removal of the 4 amino acids does not significantly 
alter the weight, probably less than 5000 Daltons (Lockridge and La Du, 1982), 
and is imperceptable in sodium dodecyl sulphate (SDS) gels due to the high 
carbohydrate content (23.9 %) which results in broad bands (Lockridge, 1990). 
4.3.3 ', Acetylcholinesterase 
The possible existence of this enzyme was predicted by Dale in 1914, following 
work in 1899 in which he showed acetylcholine (ACh) to be naturally present in 
animal tissue (Dale, 1914). It wasn't however until 1937 that Marney and 
Nachmansohn showed that nearly all the acetylcholinesterase present in frog 
muscle was concentrated at the nerve endings (Marney and Nachmansohn, 1937) 
and that this was present in sufficient concentration to hydrolyse ACh to the 
extent predicted in theory. 
Later, the picture became more confused as acetylcholine hydrolysing enzymes 
were isolated from more tissue and organs. It appeared that they exhibited 
optimal activity at different substrate concentrations which led Alles and Hawes 
in 1940 to demonstrate the existence of two choline-esters. 
Acetylcholinesterase (AChE) is present in nerve endings, striated muscle and red 
blood cells. Sorensen (1986) detected AChE in human serum using polyclonal 
and monoclonal antibodies. Its role in limiting ACh at cholinergic synapses and 
neuro muscular junctions is well established however that in red blood cells is 
not. 
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Red blood cell acetylcholinesterase (RBC AChE) is hydrophobic and detergent 
soluble (Dudai, 1972). Partially purified membrane enzyme preparations have 
yielded multiple molecular forms with molecular weights anywhere between 
66000 and 562000 (Wright, 1973). Using immunological means to raise 
antibodies against intact human erythrocyte membrane it has been shown that 
dimeric acetylcholinesterase predominates in the native membrane (Ott, 1983). 
Purified enzyme from red blood cell membranes (RBC) is particularly useful 
model system in vitro because of its accessibility and similarities with a number 
of neural enzymes. Fritze and Beckman (1987) made use of this in a study 
investigating possible genetic differences in the RBC ACNE of psychiatric 
patients. However, no differences were found which again gave rise to the 
question of validity in using RBC activity as a marker. The effect of 
concomitant drug therapy was not investigated. 
The AChE content of the cell membrane shows a very complex profile 
dependent upon the age of the cell (Lawson and Barr, 1987). Changes in AChE 
occur in parallel with those of lipid content of the RBC (Kamber et al, 1984). 
There is a decrease in the cholesterol: phosphate ratio as the cell ages and this is 
followed by a decrease in the activities of membrane bound enzymes including 
AChE. 
4.3.4 Arvlesterases 
Arylesterases (formerly also known as 'A' esterases) are present in the plasma, 
erythrocytes and a wide variety of mammalian organs (Aldridge, 1953). 
Phenylacetate is most often used as a substrate although other substrates used 
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include alpha and beta-naphthylacetate. 
Arylesterases are dependent upon the presence of Ca2+ ions and thus are 
inhibited by calcium chelating agents eg EDTA (Erdos et al, 1959). Wilde and 
Kekwick (1964) found that 10 mM Ca2+ in the presence of enzyme seemed to 
provide optimal activity in vitro. 
Arylesterases do not appear to have a physiological role but they do have a 
major role in the metabolism of some drugs and organophosphate insecticides. It 
is the latter with which the literature on these esterases is particularly occupied. 
High levels of this esterase are an important safeguard against the toxic effects of 
such compounds. 
In 1988 the classification of 'A' esterases and arylesterases was reviewed and it 
was recommended that 'A' esterases were removed from classification EC 
3.1.1.2. (arylesterase) and together with the esterase DFPase form a new group - 
Organophosphorus Compound Hydrolase (Mackness, 1989). 
This was the result of a number of studies which provided overwhelming 
evidence to suggest that 'A' esterase and arylesterases were in fact different 
enzymes. - 
4.3.5 , Paraoxonase (A-esterase) 
Extensive studies have since shown a differential distribution of arylesterase and 
paraoxonase activities in a wide range of human population groups, other - 
mammalian species and birds. 
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Mackness and Walker (1983) carried out polyacrylamide gel electrophoresis of 
sheep serum and found that the fractions exhibiting paraoxonase and arylesterase 
activity were not coincidental. 
Several other studies have also shown that paraoxonase and arylesterase have 
different peaks of activity in Caucasian populations. Human serum paraoxonase 
activity was found to be bimodally distributed ( Eckerson et al, 1983b) and 
arylesterase activity to exhibit a unimodal distribution (Simpson, 1971; Lorentz 
et al, 1989). 
In 1987 Mackness et al looked at aryl- and A-esterase activity in the sera of 14 
species of bird. The serum arylesterase of at least ten of these birds possessed 
no measurable paraoxonase activity. 
Gel filtration of human serum in the same study produced two major peaks with 
paraoxonase activity and three with arylesterase activity, none of which 
overlapped. Erdos and Boggs (1961) showed that hydrolysis of paraoxon in 
human serum is partly inhibited by ethylene diamine tetraacetic acid (EDTA). 
The reason for this was proposed by Ortizoga-Ferado et al (1984) who resolved 
human serum paraoxonase activity into two fractions using gel-filtration 
chromatography. The first peak 'of activity (peak I) was found to be a high 
molecular weight compound which co-eluted with arylesterase. The second 
fraction was closely associated with albumin (peak II). 
The esterase activity of albumin is well known. However in purification it 
cannot be ruled out that a minor protein which cofractionates with albumin is 
responsible for the hydrolysis of paraoxon and not the albumin itself. The 
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likelihood of this was ruled out by investigating paraoxonase activity in an 
individual who was analbuminaemic. Ortizoga-Ferado et al (1984) found that, in 
this case, there was only one peak of paraoxonase activity which was completely 
inhibited by EDTA. 
Earlier experiments by the same (Mueller et al, 1983) and other workers (Eiberg 
et al, 1981) demonstrated differences in the pH profiles of the two purified 
fractions. These pH profiles were very similar to the pH profiles of individuals 
with high and low phenotypes. In Caucasians the EDTA-sensitive enzyme (peak 
I) shows a genetically determined polymorphism governed by two alleles 
(Geldmacher-von-Mallinckrodt and Diepgen, 1988). Other ethnic populations 
show different distributions of the two phenotypes (see 5.3). However, the 
EDTA-stable paraoxonase (peak II-albumin) shows unimodal distribution. The 
determination of phenotype is discussed in 5.31. These different pH profiles are 
perhaps best explained by considering the peak of activity which predominates in 
each of these phenotypes. In an individual with serum homozygous for the high 
activity. Peak I accounted for up to 75 % of the paraoxonase activity. 
Conversely Peak II is responsible for 70% of the paraoxonase activity in sera 
homozygous for the low activity allele. 
Thus, it follows that the pH profile of paraoxonase activity in the serum of an 
individual most closely resembles the pH profile of the predominating peak. In a 
serum homozygous for the high activity this is Peak I and for the low activity 
allele Peak II. (Geldmacher-von-Mallinckrodt and Diepgen, 1988). 
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4.3.6 Conclusion 
Individual variations in the level of esterase activity may determine the 
pharmacological effect of many prodrugs dependent on them for hydrolysis. 
Conversely, the therapeutic effect of an active drug may be terminated by the 
same or different esterases. 
The inter-individual variation in some esterase activity (notably paraoxonase) has 
been well documented, with less information available to date on others. 
Intra-individual variation due to seasonal, nutritional and pathological influences 
is largely circumstantial, except perhaps with regard to seasonal studies which 
are easier to control. 
All these influence blood esterase activity and the ability of an individual to 
hydrolyse ester compounds. The following chapters consider these factors 
individually. 
4'ý 
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Chapter 5 
Factors Affecting Blood Esterase Activity 
There have been several studies to investigate the intra-individual variation in 
cholinesterase, particularly in plasma, - over different time periods. Sidell and 
Kaminskis (1975a) measured cholinesterase activity twice weekly in 22 subjects 
over 1 year. In a matter of weeks they claimed the activity changed by as much 
as 25-50% in a normal healthy population. Brock and Brock (1990) used a 
much larger population of 131 individuals and found the intra-individual 
variation was anything between 3% and 42% over an 8 month period. Mason et 
al (1989), however, using a much smaller group of 9 people (7 men, 2 women 
demonstrated only a 4% variation over a 13 month period. In the latter study, it 
may have been that the proportionally smaller number of women reduced the 
well documented hormone-related changes in cholinesterase activity (Lepage et 
al, 1985). 
Brock and Brock (1990) and Mason et al (1989) both found a much smaller 
biological variation in erythrocyte AChE activity over their respective study 
periods. This may be due to the longer life span of red blood cells (120 days) 
compared with the 7 day life span of plasma ChE. 
Paraoxonase intra-individual variability measured by Mutch et al, 1991 (in press) 
was found to be more variable than plasma cholinesterase and RBC AchE in 5 
individuals measured 4 times over the span of one year. The maximum increase 
measured was obtained one week after Christmas and could be associated with 
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dietary excess, since paraoxonase activity has been linked with High Density 
Lipoprotein (HDL) (5.4). Over a period of only 35 days, Zech and Zucher 
(1974) found that paraoxonase activity was remarkably constant. 
Seasonal variations may also occur. Ratner et al (1989) measured ChE activities 
in the whole blood of an Israeli population over one year (n = 228, summer; n 
= 117, winter). He found a reduced plasma cholinesterase activity in the 
summer compared with the winter months and attributed this to an increased 
exposure of the population to organophosphate insecticides on fruit crops during 
this period. 
Plasma aspirin esterase activity is largely due to cholinesterase activity 
(Rainsford et al, 1980; Morikawa et al, 1979) and will thus follow a similar 
pattern of intra-individual variation with time. 
5.1 Age 
A number of plasma esterases have been shown to be affected by age but is not 
clear whether this occurs across the age spectrum. A reduced plasma aspirin 
esterase activity has been identified in frail elderly individuals but not in the fit 
elderly (Williams et al, 1989), when compared with fit young subjects. In the 
same study the authors identified a significant reduction in plasma arylesterase 
activity (using phenylacetate as a substrate) in the frail elderly. , 
In these observations, age per se was not an accountable factor in the reduced 
activity. Frailty, however, was, and this may be in important consideration at 
any age. 
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Mueller et al (1983) measured paraoxonase activity in 60 people aged between 3 
months and 78 years. He found no significant alteration of paraoxonase activity 
over this age range. Analysis of 31 cord blood samples in the same study 
showed that paraoxonase activity is not fully developed at birth and is still 
reduced in infants less than 1 year old (Ecobiochen and Stephens, 1973). 
Playfer (1977) found no change in paraoxonase activity with age in a cross 
section of an elderly population comprising healthy elderly, hospitalized elderly 
and nursing home residents aged 70-96 years. 
Zech and Zurcher (1974) however found that the average paraoxonase activity 
was lower in older people but since they gave no details of the population type 
these individuals were drawn from, whether this was an age-related effect is 
unclear. 
McCance et al (1949) and Lehmann et al (1957) observed serum cholinesterase 
activity to be slightly lower in the newborn than in the adult human. After 
approximately two months the activity reached adult levels and then continued to 
increase so that during childhood values were considerably higher than in adults. 
In the study by Williams et al (1989) referred to earlier, plasma cholinesterase 
activity was also measured in fit and frail elderly and compared with that in 
young volunteers. The measured activity was not significantly lower in either of 
the elderly groups although there was a trend towards a reduced activity in the 
frail hospitalized group. 
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McWilliams et al (1990) recently confirmed no significant difference between 
'normal' red blood cell AChE and that from demented or depressed elderly 
people. However, there did appear to be a reduced red blood cell AchE in 
normal women over 80 years. 
Sidell and Kaminskis (1975b) found that RBC AChE actually increases with age 
in both sexes. Those individuals aged less than 30 years appear to have the 
lowest RBC AChE as a group, and although the authors did not find statistically 
significant differences between each successive age group, there was a 
demonstrable significant increase between the younger and older age groups. 
Lawson and Barr (1987) conclude a deficiency of RBC ACNE has no pathogenic 
significance (see 6.3). 
5.2 Sex 
Some groups have reported a higher plasma aspirin esterase activity in males 
than females (Gupta and Gupta, 1977; Menguy et al, 1972a; Morikawa et al, 
1979) but other reports show no apparent sex difference (Rainsford et al, 1980, 
Williams et al, 1989). 
It has been well established over the years that plasma ChE activity is greater in 
men than women (Moses et al, 1986, Lepage et al, 1985; Sidell and Kaminskis, 
1975b). 
This has been explained by hormonal differences between women and men. 
Prior to puberty, the cholinesterase activity in males and females are similar. 
The activity decreases by about 10% after the onset of puberty and increases 
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again by about 16% in post - menopausal women reaching the same value for 
men (Lepage et al, - 1985). Sidell and Kaminskis (1975b) reported similar ChE 
activities in post-menopausal women and men over 60 years old. 
In a study looking at the possible effect of the menstrual cycle upon the inter- 
individual variation seen in females, Fairbrother et al (1989) concluded that the 
relationship between ChE activity and hormone concentration was a complex 
one. They suggested that there may be an interaction of progesterone and 
oestrogen with each other and with other hormones such as thyroxine. 
Certainly, a lower ChE activity has been demonstrated in young women (Sidell 
and Kaminskis, 1975b; Lepage et al, 1985) but this is further reduced by oral 
contraceptives (Sidell and Kaminskis, 1975b; Fairbrother et al, 1989). 
Fairbrother et al (1989) also found weekly variations in ChE activity from as 
little as 4% to as much as 32% in some women. There was no apparent pattern 
of variation and activities did not alter with hormonal treatments. In contrast, 
RBC AChE has been found to be higher in women than men and higher still in 
women taking oral contraceptives (Sidell and Kaminskis, 1975b). 
Apart from the possible hormonal effects per se, the fluctuating hydration status 
of females throughout their menstrual cycle and the dilution effect this will have 
on plasma proteins does not appear to be considered in the literature. 
Following initial studies on the paraoxonase activity in different ethnic groups, 
Geldmacher-von-Mallinckrodt et al(1983) looked for sex differences in activity 
but found none. Agarwal et al (1982) found similar results in rats. Mueller et al 
(1983b) found a slightly higher mean value in females compared with males but 
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this was not statistically significant. Mutch et al (in press) suggest that the 
absence of a high activity group in their study population may be partly due to 
the absence of females but with little direct evidence. 
5.3 Race. Genetics and Pouulation Studie 
There have been extensive studies into plasma esterase activities exhibited by 
various ethnic groups. In 1982 Kalow observed that ethnic groups afforded 
some degree of predictability with regard to intra-individual variation in the 
metabolism of some compounds. 
Different races are also exposed to different environmental pressures (eg 
nutrition and xenobiotics) which will be discussed in greater depth later. 
Williams et al (1986) measured plasma aspirin esterase activities in Caucasian 
and Ghanaian subjects and found these to be generally lower in the Ghanaian 
subjects. Interestingly, the cholinesterase activity was preserved in this group. 
The authors hence suggested other factors were more important in determining 
the rate of aspirin hydrolysis. 
Similarly lower plasma aspirin esterase activities were also found within a 
Nigerian population (Isah et al, 1988) which was not accompanied by a reduced 
plasma cholinesterase activity. 
The worldwide distribution of serum paraoxonase activity has been investigated 
(Geldmacher-von-Mallinckrodt and Diepgen, 1988). Different ethnic groups 
have been shown to exhibit different patterns of serum paraoxonase activity. Of 
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the populations studied Playfer et al (1976) found the Indians and Caucasians 
both exhibited a bimodal distribution. This, however, was not the case in 
African, Malaysian and Chinese populations where distribution was unimodal. 
Negroid and Mongoloid samples were also bimodally distributed but, compared 
with the Europeans, there was a lower percentage of the population in the low 
activity group ( Geldmacher-von- Mallinkrodt and Diepgen, 1988). 
In some of the ethnic groups studied no low activity group was detected 
(Hommel, 1978). This was particularly the case in some African, Aborigine, 
South Pacific and South American tribes. In fact the frequency of the low 
activity phenotype seems to reduce as the distance from Europe increases 
(Diepgen and Geldmacher-von-Mallinckrodt, 1986). 
Arylesterase (phenylacetate esterase) has been studied to a much lesser degree. 
Williams et al (1986) found a significantly lower activity of plasma arylesterase 
in the same group of Ghanaian individuals mentioned above. 
5.3.1 Phenotvuine A-esterase Status 
Eckerson et al (1982,1983a) postulated that human serum paraoxonase is a 
polymorphic enzyme determined by two allelic genes at one autosomal locus. 
The two isozymes are known as 'A' and 'B' and the three phenotypes as A, AB 
and B. 
Three qualitative differences in paraoxonase to arylesterase isoenzymes A and B 
are used to classify the phenotypes (arylesterase has a unimodal distribution). 
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1) 1M sodium chloride (NaCl): Isoenzyme B is stimulated 2-3 times whilst 
isoenzyme A is minimally affected (Eckerson et al, 1983a). 
2) Ratio of paraoxonase to arylesterase activity: Isoenzyme ratio of 
isoenzyme B is approximately 7 times that of isoenzyme A. (Eckerson et al, 
1983b). 
3) 0.1mM chlorpromazine: The residual arylesterase activity of isoenzyme A 
is less than that of isoenzyme B. 
5.4 Nutrition 
As previously discussed the biological function of plasma cholinesterase has been 
the subject of much speculation. It is well known that a significantly reduced 
serum cholinesterase activity may be indicative of liver damage (Brown, 1981). 
In 1950 Waterlow suggested that such damage could be the direct result of 
malnutrition when he observed an increase in the serum ChE activity of two 
malnourished infants fed on a high milk diet. This observation led to the 
suggestion that there was a relationship between ChE and food assimilation. A 
number of animal experiments have since followed. 
One early such investigation involved fasting mice for 48 hours and then 
refeeding them at time intervals with bread and water. Liver ChE was 
monitored by histochemical methods and reached its peak after four hours 
followed by a decline (Gerebtzoff, 1959). 
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Later work in rodents has added to, and in some ways confused the ever 
mounting data on ChE and energy storage. For example, Kutty et al (1981) 
demonstrated an increased liver and serum ChE activity in normal, obese and 
diabetic mice fed on a high calorie (supplied as carbohydrate) diet. 
In contrast the ChE activity in the adipose tissue of these groups was reduced. 
Hyperglycaemia was a common feature in all these animals. Kutty suggested it 
may be a cause of ChE repression in this tissue and that adipose ChE may 
actually be related to the hormone sensitive lipase which is reduced in obesity. 
Osada et al (1989) carried out similar work on male Wistar rats fed on a high fat 
diet. They found a corresponding reduced serum ChE activity in these animals 
which is in agreement with those of Kean et al, 1986. 
Most of the recent work has concentrated on circumstantial evidence involving 
the measurement of serum ChE activity in sub-populations of people with 
various genetically acquired hyperlipoproteinaemic conditions (Cucuianu et al, 
1968; Jain et at, 1983; Schouten et at, 1988). 
Kean et al (1986) attempted to elucidate exactly the optimum composition of 
food required to raise liver ChE in mice. A high protein diet enhanced the 
enzyme activity the greatest. Those mice fed high protein diets had twice the 
amount of absolute fat as those fed on a low protein diet. Obese animals show 
increased lipogenesis and hence increased by-products as the result of fatty acid 
metabolism - the significance of which is discussed below. 
In addition to these, an observation by Burch et al, 1957 confirms the link of 
serum cholinesterase with dietary protein. In patients with Kwashiorkor, serum 
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ChE activity increased two fold when treated with a high protein diet compared 
with pretreatment levels. 
A nutrition survey of elderly people in Great Britain (DHSS 1979a) found that, 
in men, serum pseudocholinesterase activity correlated significantly with arm 
circumference, skin fold thickness, protein intake and serum albumin 
concentration. This has been corroberated by Lepage et al (1985). 
These factors are closely related to protein synthesis and hence ChE, as one of 
many enzymes, reflects them. 
Chu et al (1978) correlated plasma ChE activity in whole plasma and low density 
lipoprotein fraction (LDL) with triglycerides and cholesterol levels in patients 
suffering various types of hyperlipoproteinaemias. The results of this and other 
studies led to suggestions that cholinesterase may be involved in lipid and 
lipoprotein metabolism. 
A significantly increased ChE activity is most often the consequence of an 
individual exhibiting metabolic disorders related to the storage and mobilization 
of fat. Such disorders include obesity, hyperlipidaemia (Kutty et al, 1981), 
diabetes (Antopol et al, 1937), nephrotic syndrome - especially in association 
with hyperlipoproteinaemia (Way et al, 1975) and hyperthyroidism 
(Antopol et al, 1937). These individuals usually have increased serum levels of 
very low density lipoprotein (VLDL) or pre-betalipoprotein, which is the result 
of excess fatty acids derived from carbohydrate metabolism (Kutty et al, 1981). 
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In 1963 Clitherow postulated that butyryl Co A produced during fatty acid 
metabolism may form butyrylcholine in the presence of choline. The excess of 
these metabolites produced in susceptible individuals would therefore require 
detoxification to prevent possible nicotinic side effects. These would be 
eliminated by means of a compensatory increase in cholinesterase levels. 
Serum ChE appears to form a close association with LDL by reacting with the 
phosphoryl choline site of lecithin (Kutty et al, 1973). Hence there may be two 
pools of ChE activity in serum - one is free and the other forms an integral part 
of LDL structure (Kutty et al, 1977). This may be formed via an unstable 
VLDL - ChE intermediate. 
The ultimate product however, is very stable and only ultrasonification or 
treatment with phospholipase D will release free ChE. 
Cucuianu et al (1968) proposed a link between raised serum ChE activity and 
high levels of lipoproteins. Schouten (1988) confirmed Cucuianu's proposal of 
this relationship and more particularly agreed that this relationship was strongest 
with VLDL. 
Jain in 1983 measured serum ChE and lipoproteins in a patient who accidently 
ingested parathion -a powerful organophosphate anticholinesterase. ChE 
activity was reduced as was VLDL and LDL but there was an increase in high 
density lipoprotein (HDL). During the next 72 hours following ingestion ChE 
enzyme activity increased in parallel with VLDL and LDL, and a decrease in 
HDL. 
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Schouten and Cucuianu both agree "... there is probably no cause and effect 
relationship between these two parameters... the relationship... if there is any at 
all, is certainly not a simple one" (Schouten, 1988; Cucuianu, 1988). Kutty et 
al (1976) suggested a close relationship between AChE and lipoproteins in the 
cell membranes of red blood cells. Increased fragility of red cells has been 
demonstrated when treated with physostigmine. (Milstock et al, 1972). In 
addition AChE and lipoprotein are extracted together when the erythrocyte 
ghosts are treated with hypertonic saline (Kutty et al, 1976). 
Paraoxonase, similarly, has been shown to be closely associated with lipids. 
Mackness et al (1983,1989) undertook studies to investigate this association. In 
sheep they found most of the serum paraoxonase activity was closely linked with 
HDL. Ultracentrifugation of human serum caused paraoxonase activity to 
partition in to the lipoprotein fraction at a similar rate and manner to HDL. 
Further links between HDL and paraoxonase activity have been based on 
observations in subgroups of patients with possible or real disturbances in lipid 
levels. Reduced serum paraoxonase levels were found in malnourished children 
compared with healthy children (Mackness and Clerc, unpublished). 
Fish-eye disease is a familiar condition which involves, among other symptoms, 
abnormal plasma lipoproteins. The HDL concentration was found to be reduced 
by 90 % and the paraoxonase activity by 89 % in these individuals compared to 
controls (Mackness et al, 1987b). 
Tangier disease is a condition in which levels of apolipoprotein AI and All are 
100 and 10 times respectively lower than controls. In a patient suffering from 
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this disease no paraoxonase activity could be detected (Dumon et al, 1986). 
However, as La Du (1988) suggests, paraoxonase may not be stable without the 
presence of HDL with which to form a complex. The reduced paraoxonase 
activity may therefore be a secondary effect of a clinically low HDL level. A 
primary deficiency in this enzyme would establish the clinical features associated 
with, or requiring paraoxonase. 
Although very difficult to substantiate, it is possible that the interethnic 
differences which exist in serum esterases are due to environmental factors such 
as nutrition (Kalow, 1982). Isah et al (1988) found Nigerians living in the UK 
had similar plasma aspirin esterase activity and albumin concentrations to British 
subjects, but a low cholinesterase activity. Nigerians resident in Nigeria showed 
significantly lower plasma aspirin esterase and cholinesterase activity and 
albumin concentration than British subjects. 
5.5 - The Effect of Xenobiotic Exposure on Blood Esterases 
Xenobiotics are defined as any substance which is foreign to the biologic system. 
This includes drugs and substances such as insecticides. Some substances as 
apparently innocuous as ethyl alcohol (ethanol) can thus be regarded as a 
xenobiotic since it is of minimum nutritional content. 
A reduction in serum cholinesterase activity was observed by Ward et al (1976) 
in patients suffering chronic liver disease, including alcohol related damage, and 
also by Liu and Yuan (1985). The reduction would appear to be proportional to 
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the degree of liver damage (Foldes, 1956). 
In 1980 Rainsford showed that serum aspirin esterase was severely depressed in 
patients with alcohol induced liver cirrhosis. Since aspirin esterase activity is 
due to cholinesterase and albumin, both indicators of liver function, this is 
hardly surprising. 
Builder et al (1977) also demonstrated an inhibitory effect of alcohol on aspirin 
esterase activity in the gastric mucosa. This may partly explain the reason for 
the observed increase in blood loss induced by aspirin, since a local 
concentration of unionized aspirin in the mucosal cell initiates the chain of events 
leading to breakdown of the mucosal barrier. Red blood cell 
acetylcholinesterase was suggested to have possible use as a biochemical marker 
of alcoholism when it was found to be lower in a group of alcoholics (Haboubi et 
al, 1986). Abernethy et al (1986) disputed this and it is more likely that 
inappropriate storage is to blame. 
The most extensive in vitro work on possible drug effects on serum aspirin 
esterase was carried out by Gupta et al (1979). The authors looked at a number 
of drugs chosen on the basis of most likely concurrent administration with 
aspirin. Only calcium and magnesium ions were found to be activators of this 
enzyme, the majority were inhibitory or had no effect. 
Rainsford et al (1980) found that sodium aurothiomalate and D-penicillamine 
produced higher levels of plasma aspirin esterase activity in six patients. 
Because these esterases originate in the liver it seems likely that any substance 
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capable of inducing liver enzymes may also induce esterase production. Puche 
et al (1989a) found the antiepileptic drugs sodium valproate, carbamazepine and 
phenytoin administered together raised serum aspirin esterase activity in 
epileptics when compared with normal controls. A subsequent study looked 
more particularly at serum cholinesterase in patients receiving only one of these 
drugs (Puche et al, 1989b). As expected activity increases were found with 
aspirin esterase and cholinesterase. No significant difference was seen between 
each of the individual drugs. 
Habitual aspirin intake, often without an accepted clinical indication, is 
especially prevalent amongst women. Gupta et al (1977) investigated aspirin 
esterase activities in a group of pregnant women, against a control group of 
pregnant women who were occasional users only. Unfortunately the 
physiological variability contributed to by the 'hormonal' state of pregnancy and 
the fact that there were only 12 women in the control group compared with 59 in 
the experimental group make firm conclusions difficult. Nevertheless plasma 
aspirin esterase levels were reported to be significantly lower (p < 0.05) in the 
experimental group. 
Rainsford et al (1980) found similar results in rheumatoid arthritic patients 
taking regular aspirin. 
Exogenous hormones taken in the form of oral contraceptives can have a 
profound effect on some esterases. (See 5.2). 
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5.5.1 Organophosphate Insecticides 
Organophosphate insecticides are very potent inhibitors of acetylcholinesterase 
and cholinesterase. The pharmacological effects of these substances are largely 
due to inhibition of acetylcholinesterase in the nervous system. 'Serum 
cholinesterase is the enzyme most readily inhibited (Namba, 1971) and as such is 
a very useful biochemical marker for possible exposure to such inhibitors 
(Health and Safety Executive, 1987). 
Grob et al (1947) administered 2 mg diisopropyl fluorophosphate (DFP) 
intramuscularly or intraarterially and observed a drop of cholinesterase to 5% of 
its original activity. Red blood cell AChE in contrast only dropped by 65%. 
Within one hour the serum cholinesterase had dropped to near zero but it took 24 
hours for the RBC AChE to show maximal depression. It is still not known how 
AChE differs structurally from ChE to make it more reactive than AChE to 
organophosphate esters (Lockridge, 1987). It may, in fact, be due to the 
inaccessibility of AChE to the substrate because it is membrane bound to RBC. 
Serum paraoxonase has an important role to play in protecting cholinesterase 
against the organophosphate paraoxon by hydrolysis to paranitrophenol 
(Eckerson and La Du, 1984). 
Not all xenobiotic effects are detrimental to the individual. A number of 
cholinesterase inhibitors are used clinically. Although they inhibit both 
cholinesterase and acetylcholinesterase, it is the effect on the latter which makes 
them clinically useful. Inhibitors such as physostigmine bear a close structural 
similarity to acetylcholine and they are used in conditions such as myasthenia 
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gravis and in eye drop formulations to treat glaucoma (Williams, 1985). Unlike 
the organophosphate insecticides where the effect is irreversible, the inhibition is 
terminated when the ester linkage is hydrolysed within a matter of hours. 
Certain anti-cancer drugs eg cyclophosphamide irreversibly inhibit cholinesterase 
as a side effect. In such cases it can take 2 weeks to regain 70% of normal 
activity and 6-8 weeks to regain full activity, until the liver synthesises new 
cholinesterase. 
CHAPTER 6 
The Effects of Altered Blood Esterase Activity 
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Chapter 
The Effects of Altered Blood Esterase Activity 
6.1 The Effect of Impaired Blood Esterase Activity on 
Drug Handling 
Any compromise in serum cholinesterase activity or other esterase activity will 
affect the pharmacological effects of xenobiotic compounds dependent on them 
for metabolism. If hydrolysis by esterases removes the active drug then 
impaired esterase function will result in reduced clearance and possible dose- 
dependent side effects. As an example, alcohol cirrhotics may experience 
gastrointestinal symptoms due to therapeutic doses of aspirin (Menguy 1972b). 
Alternatively if the esterase hydrolyses a prodrug, impaired esterase activity may 
mean that insufficient levels of the drug are released for pharmacological effect 
before the prodrug is cleared. Examples are shown in Tables 6.1 and 6.2. 
Menguy et al (1972b) demonstrated a significantly reduced serum aspirin 
esterase in 22 individuals with portal cirrhosis which would imply that this group 
of individuals is especially vulnerable to complications from aspirin ingestion. 
This is worsened by hypoalbuminaemia and subsequent increased fraction of 
unbound salicylate (Roberts et al, 1983). Rainsford et al (1980) confirmed this 
finding. 
Suxamethonium (succinylcholine) is a depolarizing muscle relaxant. Recovery 
of muscle control following administration is due to the rapid hydrolysis by 
plasma cholinesterase to succinylmonocholine and the slower conversion to 
succinic acid 
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Table 6.1 : 
Hydrolysis of drugs to less active drugs. 
Drug Pharmacological 
action 
Inactive /Less active 
type 
Acetylsalicylic acid analgesic salicylic acid 
Succinyl choline muscle relaxant choline 
Procaine local anaesthetic p-aminobenzoic acid 
I 
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choline (Tsuiji et al, 1955). Recovery from the effects'of suxamethonium is 
usually complete within 3 to 20 minutes (Foldes et al, 1956). Shortly after its 
introduction in the early 1950s, several cases of prolonged apnoea were reported 
(Gould 1952, Harper, 1952). These patients were found to have low serum 
cholinesterase (Evans et al, 1952). Although the atypical gene variant of low 
plasma cholinesterase activity is a very important factor, it cannot be used as a 
sole indication of increased susceptibility to prolonged drug effects (Bauld et al, 
1974): Other pathological conditions affecting cholinesterase activity have been 
discussed earlier and include liver diseases, malnutrition, 'malignancies etc 
(Brown, 1981). 
Considerable evidence does exist to support the premise that it is serum 
cholinesterase which determines the likelihood of prolonged apnoea. Goedde et 
al (1968) normalized the duration of apnoea by injecting a highly purified 
pseudocholinesterase fraction. Cholase from Behringwerke AG is only 5.5%, 
pure but is a preparation which has been used successfully by the Danish 
Cholinesterase Research Unit to reverse succinylcholine apnoea (Viby- 
Mogensen, 1981). 
6.2 Atypical Serum Cholinesterase 
Because cholinesterase has been identified using a very specific substrate, studies 
regarding its activity, mode of behaviour, inheritance pattern'etc are far more 
extensive. 
Shortly after the introduction of the muscle relaxant suxamethonium for use in 
anaesthesia in the early 1950s, there were reports of patients experiencing 
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prolonged apnoea as a result of its use (Gould, 1952; Harper, 1952). Numerous 
reasons were suggested for this phenomenon (Foldes, 1956) but since then an 
atypical cholinesterase variant has been found to be responsible. 
There is only one gene for human cholinesterase so all cholinesterase genotypes 
must arise from this locus (Lockridge, 1990). The silent allele, atypical 
cholinesterase was first proposed by Liddell et al (1962) and since then there 
have been a number of quantitative variants identified. ý When in combination 
with the 'usual' gene, although exhibiting a reduced activity, they are 
indistinguishable from usual cholinesterase. It is not until they are in 
combination with silent cholinesterase occurring as a heterozygote phenotype 
that they are detectable (Lockridge, 1990). 
Each variant appears with different frequency in sub-populations and imparts 
varying degrees of reduced activity. In addition, not all the variants have been 
positively identified as yet. 
Population studies to determine the worldwide distribution of the atypical allele 
were initiated in the late 1950s. However a limited selection of small groups led 
to similar gene frequencies being proposed in the ethnic populations studied 
(Kattamis et al, 1962; Horsfall et al, 1963)., 
Whittaker (1986) presented a comprehensive summary of ChE allele frequencies 
in various populations throughout the world. The Jews of Iraq and Iran have 
amongst the highest occurrance of the atypical allele which contrasts with other 
Jewish populations who have the much lower gene frequency of the Northern 
European populations. The Alaskan Eskimos show the highest incidence of 
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the silent allele where 1603 people were tested , 28 were found 
homozygous 
silents and 301 were heterozgotes (Lockridge, 1990). 
The C5 + variant is associated with up to a 30% increase in ChE activity 
(Robson and Harris, 1966) and is probably due to an association between ChE 
and a second unidentified protein (Scott and Powers, 1974). From the 40,000 
people tested for this variant, 9% of Europeans, 3% of Asians, 5% of Africans 
and 7% of Americans have been identified as carriers (Lockridge, 1990). 
At the molecular level, Clark et al (1968) showed that positively charged 
compounds affect the catalytic properties of normal and atypical ChE differently. 
Valentino et al (1981) predicted sensitivity to a number of drugs including 
aspirin, in individuals with usual and atypical cholinesterase. They found that 
atypical and typical cholinesterase have the same turnover number and Km 
(affinity of the enzyme) for positively charged substances and aspirin. This 
suggests that the esteratic sites are the same but the charged sites are altered in 
some way in atypical cholinesterase. Muensch et al (1978) suggested that 
atypical cholinesterase carried a positively charged residue instead of a negative 
one. In contrast, Das (1976) concluded that a mutation of a single amino acid 
residue may lead to a change in the positioning of the active centres with relation 
to one another and a modification of binding sites. 
6.3 Clinical Significance of Blood Esterases and their Pathology 
Serum cholinesterase is a direct and historically useful indicator of liver function 
since it is manufactured in the liver and immediately enters the general 
circulation (Brown, 1981). Any disease which causes reduced protein synthesis 
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therefore results in reduced serum cholinesterase activity. The usefulness of a 
single determination is limited by the occurrence of the silent gene (which is 
very rare) and variability related to sex, age, body fat etc. Its greatest value is 
as a prognostic tool when a series of measurements are made. 
A number of authors have commented on the sharp reduction in serum 
cholinesterase activity (Hunt and Lehmann, 1961; LaMotta et al, 1957) and 
phenylacetate esterase activity (Takahashi et al, 1967) shortly before an 
individual dies. This is most likely to be due to a breakdown of protein 
synthesis. In a patient who dies from acute liver failure however, serum ChE 
activity may not fall below normal baseline values. This is probably due to the 
half-life of ChE of 12-15 days. Death may therefore occur before the activity 
has fallen enough to be evident (Ward et al, ' 1976). 
Malignant disease can result in a reduced rate of protein synthesis and plasma 
cholinesterase levels always appear to fall (Brown, 1981). Whetstone et al 
(1960) observed a specific reduction in cholinesterase compared with other 
plasma esterases, albumin etc., McComb et al (1964), suggested that this may be 
due to a selective depression by the cancer cells on cholinesterase formation or 
activity. 
Burn injuries have also been show to cause a fall in plasma cholinesterase 
activity (Price et al, 1970). The initial drop in activity is probably due to loss of 
the enzyme through capillaries and intensive fluid therapy. The persisting low 
activity may be due to a reduced cholinesterase synthesis since it is known that 
skin burns cause a disturbance in liver function (Brown, 1981). ' t. 
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Deficiency of erythrocyte AChE does not appear to have pathological 
significance and there are only a few conditions in which enzymes are abnormal, 
As one might expect, these are largely manifest in cell membrane abnormalities 
(see 4.3.3) and include paroxysmal nocturnal haemoglobinuria and hereditary 
spherocytosis (Lawson and Barr, 1987). 
Attempts have been made to use plasma cholinesterase and RBC AChE as 
peripheral markers for the early diagnosis of patients with Alzheimer's disease. 
Results have been confused and often contradictory. Smith et al (1981) reported 
an apparent increase of plasma cholinesterase by as much as 101 % in patients 
with Alzheimer's disease but no significant decrease in RBC AChE in these 
patients compared with "normal" age matched controls. Atak et al (1985) 
additionally looked at activities in individuals with neurotic and endogenous 
depression. They found no difference in RBC AChE activity in any of these 
groups which was in agreement with Smith et al (1981) and also no difference in 
plasma cholinesterase which was in direct conflict with Smith's findings. 
Serum paraoxonase has been reported to be reduced after a recent myocardial 
infarction (McElveen et al, 1986) although this was not confirmed by Secchiero 
et al (1989). Premature coronary disease has been associated with low 
concentrations of HDL (Miller and Miller, 1975) which suggests that serum 
paraoxonase and HDL could be used to predict the susceptibility of an individual 
to developing atherosclerosis (Secchiero et al, 1989). 
As discussed previously, in patients suffering from Fish-Eye disease, Mackness 
et al (1987b) found that HDL was reduced by 90% and that paraoxonase 
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apparently reduced in parallel by 89 %. In Tangier disease 
(analalphaproteinaemia) no paraoxonase activity was detected (Dumon et al, 
1986). 
In 1985, Eiberg produced evidence to suggest that there was a genetic link 
between cystic fibrosis and a low paraoxonase activity. Unfortunately further 
genetic studies have resulted in no such confirmation (Tsui et al, 1985) and the 
current view is that there is no biological or physiological link between the two 
conditions. 
Plasma esterases have thus been linked on numerous occasions with a variety of 
clinical conditions. Some of these associations are somewhat tenuous. Those 
which aren't tend to be when the esterase concerned directly reflects liver 
function and hence protein synthesis. 
6.4 Pharmacological Significance of Plasma Esterases 
The pharmacological significance of plasma esterases is not in dispute. Ester 
prodrugs have extensive use in medicine and by definition are hydrolysed by 
esterases. This occurs in the intestinal mucosa, liver, serum and locally at the 
site of action following subcutaneous administration. They have been formulated 
to overcome the factors which limit the concentration of active drug available for 
pharmacological action in the body and also to maintain a more controlled 
release of active drug. Examples of the latter include oil based depot injections 
of hormones and antipsychotic drugs. The lipophilic prodrug is dissolved in the 
oil and is slowly released. The rate of release is generally dependent in the 
structure of the ester group. Hydrolysis is due initially to tissue 
58 
carboxylesterases but some of the prodrug slowly perfuses into the blood where 
the majority is acted on by serum esterases. 
Orally administered prodrugs have been formulated to overcome problems due to 
incomplete absorption. About 40% of the antibiotic ampicillin is absorbed from 
the gut due to its amphoteric nature. Esters of ampicillin such as pivampicillin 
have increased its lipophilicity and improved absorption across the gut wall 
(Williams, 1985). 
Chloramphenicol is prepared as chloramphenicol palmitate which makes the 
bitter taste of the parent drug more palatable. Steroid creams are formulated as 
the more lipophilic ester to aid transdermal absorption. Release of the active 
steroid relies on tissue esterase activity. 
Examples of such prodrugs and the corresponding active moiety are shown in 
Table 6.2. 
6.5 Summa 
As discussed above plasma esterases are of considerable clinical value in 
diagnostic, prognostic and pharmacological fields of medical research. As a 
direct product of the liver they are a valuable source of biochemical information. 
However there are still many aspects of their existence which have not yet been 
elucidated, not least of which is their physiological function. 
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Table 6.2 
Hydrolysis of less Active Prodrugs to Active Drugs 
Prodrug Pharmacological type 
Heroin analgesic 
Benorylate analgesic 
Clofibrate hyperlipidaemic 
Carbimazole hyperthyroid 
Testosterone steroid 
cyprionate 
Methylprednisolone steroid 
acetate 
Erythromycin estolate antimicrobial 
Pivampicillin antimicrobial 
Chloroamphenicol antimicrobial 
succinate 
Prochlorperazine 
valerate 
enalapril 
neuroleptrc 
angiotensin converting 
enzyme inhibitor 
Active Moiety 
6- monoacetylmorphine 
paracetamol / salicylate 
clofibric acid 
methimazole 
testosterone 
methyl prednisolone 
erythromycin 
pivampicillin 
chloramphenicol 
prochlorperazine 
enalaprilat 
CHAPTER 7 
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, ha pier 7 
Aims and Outline of the Studies Undertaken 
The studies described in this thesis were conducted in order achieve the 
following aims: 
1. To elucidate the nature of plasma aspirin esterase and determine the difference 
in activity between fit and frail elderly and the reason they exist. 
2. To investigate the effects of frailty on blood esterases in general in the fit and 
frail elderly. 
3. To investigate the effect of nutritional supplementation on blöod esterase 
activity in the malnourished frail elderly individual. 
The study in Chapter 8 was carried out in order to elucidate plasma aspirin 
esterase kinetics in the frail elderly individual and compare these with the results 
in fit elderly and young people. The work in Chapter 9 extended this 
investigation by isolating the enzymatic components and in Chapter 10 the 
kinetic analyses were repeated using the purified cholinesterase. 
In Chapter 11 the activities of several blood esterases in frail individuals, fit 
elderly and young people were determined and compared. The study discussed in 
Chapter 12 aimed to increase the activity of several plasma esterases in 
hospitalized frail elderly people (who showed a reduced activity) by means of 
improving their nutrition. In addition anthropometric measurements were 
obtained which included weight, triceps skinfold thickness and mid arm 
circumference. 
CHAPTER 8 
Determination of Plasma Aspirin Esterase Kinetics in 
Young, Fit and Frail Elderly 
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Determination of Plasma Aspirin Esterase Kinetics in Young. Fit and Frail 
Elderly - Identification of the enzymes involved 
8.1 Introduction 
Plasma aspirin esterase activity is thought to be dependent on two components, 
albumin contributing a possible 20% of the activity and cholinesterase 
contributing 80% of the remaining activity (Rainsford et al, 1980). Plasma 
aspirin esterase activity in frail elderly individuals, as defined by the criteria of 
Woodhouse et al (1988), was found to be reduced by Williams et al (1989). 
Albumin concentrations were also low in these individuals. Cholinesterase 
activity, however, was not significantly reduced at the 5% level of significance 
but did show a trend towards a reduced activity. 
It is possible therefore, that the reduced plasma aspirin esterase activity is due to 
a change in the nature of albumin or the cholinesterase enzyme (eg substrate 
affinity) or a reduction in the quantity of one or both these components. 
The aim of the following study was to identify the enzyme(s) hydrolysing aspirin 
in human plasma; to separate them using kinetic and/or physical means; and to 
analyse the kinetic parameters Km and Vmax of one/both components in the 
whole plasma of young, fit elderlyand frail elderly individuals. 
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8.2 Methods 
8.2.1 Plasma Aspirin Esterase Activity: Identification of the Enzyme 
Components. 
a) In Whole Plasma 
Physostigmine is a specific inhibitor of cholinesterase. Adding this to an 
incubation mixture of plasma and aspirin inhibits the cholinesterase so that 
remaining aspirin esterase activity is due to albumin. 
Physostigmine at concentrations between 0.05-0.4 mM was added to incubations 
of plasma and aspirin solutions between 0.4 and 3mM. The formation of 
salicylate was monitored at 300 nm on a direct reading spectrophotometer (see 
8.2.2b) 
b) Human Albumin Fraction V 
A fresh albumin solution at 40 g/l concentration was added to an incubation 
mixture containing 3mM aspirin concentration. Salicylate formation was 
monitored as before. 
8.2.2. Kinetic Analysis for Plasma Aspirin Esterase. 
a) Volunteers 
These comprised 10 (5 female) young adults with a mean age 24 years (range 
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20-31 years), 7 (6 female) fit elderly adults with a mean age of 73 years (range 
70-79 years) and 10 (7 female) frail elderly patients with a mean age of 79 years 
(range 72-86 years). The individual details are shown in Table 8.1. 
Patient Blood Samples 
All studies were approved by Newcastle Ethics Committee. All blood samples 
were taken with the individual's informed consent or the consent of a relative 
where appropriate. 
Frail elderly volunteers were recruited from long-stay geriatric units in 
Newcastle District Health Authority. Patients were selected by Dr H Wynne 
(consultant geriatrician) following the criteria of Woodhouse et al (1988). Fit 
elderly were recruited from community day centres in and around Newcastle. 
Young healthy adults were recruited from hospital staff, students and colleagues. 
All venous blood samples were collected by venepuncture by a clinician. The 
blood was dispensed into lithium heparin tubes, unless otherwise stated. Blood 
was centrifuged at 3,000g for 10 minutes and the plasma separated and stored at 
-80oC until required when it was thawed at room temperature. 
The red blood cells were also required for some assays. The buffy coat (which 
forms the interface between the plasma and red blood cells, containing white 
cells and platelets) was carefully removed. An equal volume of normal saline 
was added, mixed gently and centrifuged as before. The supernatant was 
discarded and the red cells resuspended in saline and the wash procedure 
repeated. 
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Table 8.1 
Volunteer Details 
Volunteer (sex) Age (years) Albumin 1 
/L) 
Drugs (if any) 
Frail Elderly 
1(F) 84 37 
2(F) 74 34 
3" 86 41 glibenclamide 
4(M) 80 30 thioridazine 
5(F) 75 35 terfenadine 
6(F) 79 36 dioxin, thyroxine 
7(F) 80 39 lactulose 
8(F) 81 41 
9(F) 72 34 
10(M) 80 38 
Mean ±SEM 79±0.02* 37+1.0911 
Fit Elderly 
11(F) 74 42 
12(F) 74 41 temazepam 
13(F) 71 43 
14(F) 77 41 
15(F) 73 48 
16(M) 70 45 co-codamol 
17(F) 79 41 co-codamol 
Mean + SEM 73+0.94 43+1.00 
65 
Table 8.1 continued 
Volunteer (sex) Age (years) Albumin 1 
/L) 
Drugs (if any) 
Young 
18(F) 23 50 
19(M) 24 46 
20(M) 24 47 
21(M) 20 48 
22(F) 20 43 
23(F) 22 49 
24(F) 30 45 
25(F) 31 46 
26(M) 24 47 
27(M) 26 49 
Mean +SEM 24±1.18 47±0.67 
I measured by Clinical Biochemistry Royal Victoria Infirmary, 
Newcastle Upon Tyne. 
*Significant at p <0.05; t=2.6 
#Significant at p <0.001; t=4.2 
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No subject was taking aspirin or other drugs known to affect plasma esterase 
activity. Sufficient blood was also withdrawn for haematological and 
biochemical profiles where these were deemed necessary and were not already 
available from recent investigations. 
b) Plasma Aspirin Esterase Kinetics 
Plasma aspirin esterase activity was determined by a direct reading 
spectrophotometric assay (Williams et al, 1989). 
The aspirin concentration was varied between 0.4mM and 3mM using fresh 
aspirin solutions in Tris-HCI containing 200 mM calcium chloride at pH 7.4. 
Each aspirin solution was incubated in duplicate at 370C with 300 ul plasma in a 
total volume of 3m1 Tris-HC1 buffer pH 7.4. The salicylate liberated was 
measured by monitoring at 300 nm at minute intervals over a period of five 
minutes. Spontaneously liberated salicylate was corrected for by the parallel 
incubation of aspirin solutions at each concentration in the absence of plasma. 
The results were expressed as nmol salicylate produced/ml plasma/min. 
The lower limit of detection was 4.1 nmol salicylate produced/ml plasma/min. 
The interassay coefficient of variation (CV) was 4.7% (at a plasma aspirin 
esterase activity of 182 nmol salicylate/ml plasma/min at 3mM aspirin 
concentration; S. D. = 8.6; n= 5). 
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c) Plasma Cholinesterase Activity 
This was measured by the method of Kalow and Lindsay (1955). 
1.5m1 0.133 M phosphate buffer pH 7.4,0.75 ml water, 15 pl plasma were 
incubated at 37oC until equilibration. The reaction was started by the additiion 
of 0.75m1 of 0.2 mM benzoylcholine chloride (final concentration 0.05 mM). 
The final incubation volume was 3m1 and each measurement was carried out in 
duplicate. The rate of benzoylcholine disappearance was monitored at 240 nm 
for a period of 2.5 min during which time the reaction was linear. 
The results were expressed as nmol benzoylcholine chloride hydrolysed/ml 
plasma/min. The interassay variability CV was 2.7% (at a plasma cholinesterase 
activity of 1277 nmol benzoylcholine chloride hydrolysed/ml plasma/min; 
S. D. = 35.6; n=3). 
8.2.3 Linearity of the Enzyme Activity with Time 
Most of the enzyme measurements made in this thesis, unless otherwise stated 
involved continual monitoring of product formation at intervals over a certain 
time period. Conditions were selected to give linearity with time. 
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a) Linearity with Protein 
Plasma Aspirin Esterase Activity 
This was confirmed by incubating 100 pl, 200pl and 300pl of plasma with the 
lowest (0.4 mM) and highest aspirin concentration (3mM) used in the kinetic 
study. (Fig 8.1 and 8.2). 
Plasma Cholinesterase Activity 
2.5 Nl, 5 pl, 10 p1,15 p1, and 20 p1 of plasma was incubated with a final 
concentration of 0.05 mM benzoylcholine chloride as described in 8.2.2 . 
Confirmation of linearity was thus established (Fig 8.3). 
b) Substrate Curves 
Single measurements of enzyme activity are usually carried out at a substrate 
concentration in excess of that producing maximal enzyme activity. Thus one is 
able to assume this remains constant because the enzyme - substrate complex 
present at any one time is so small by comparison to substrate. A discussion of 
Michaelis-Menten enzyme kinetics is included in Appendix II. 
Aspirin Esterase Measurements 
Williams et at (1989) used a 1mM aspirin concentration in order to compare 
plasma aspirin esterase activities. This was below Vmax chosen because at 
higher aspirin concentrations show proportionately greater spontaneous 
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hydrolysis than enzyme mediated hydrolysis was observed. It is desirable to 
minimise this in order to avoid erroneous results. I used concentrations of 
aspirin up to 3mM. Spontaneous hydrolysis reached a maximum of 17% of total 
enzyme hydrolysis in the plasma of lowest activity. 
Cholinesterase Measurements 
Benzoylcholine chloride does not degrade spontaneously and single enzyme 
measurements can be made at saturating substrate concentration (0.05 mM 
benzoylcholine chloride). Measurements below 0.03 mM substrate 
concentration were not possible due to non-linearity over a 2.5 minute time 
period . Figure 8.4 shows the effect of varying substrate concentration. There 
is 
a maximal activity of 1300mnol benzoylcholine chloride hydrolysed /mlplasma 
/min at 0.05mM substrate. 
The methods used for enzyme kinetic and statistical analyses are described in 
Appendices II and III. 
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8.3 Results 
8.3.1 Aspirin Esterase Activity due to Albumin 
From Table 8.2, it can be seen that aspirin esterase activity in plasma was 
completely inhibited by physostigmine (0.05-0.4mM). When albumin fraction 
V, at a concentration similar to that found in plasma was incubated with aspirin, 
there was a small proportion of enzyme hydrolysis of 20.8 nmol salicylate/ml 
albumin/min, in addition to spontaneous hydrolysis (Table 8.3 ). However, this 
was completely inhibited by the addition of 0.2 mM physostigmine. 
8.3.2. Kinetic Analysis 
The frail elderly individuals were significantly older (79 ± 0.4 years; 
p<0.05). The frail elderly had a significantly lower albumin concentration (37 
± 1.09 g11) than the fit elderly (43: 1.00 g/1) (Table 8.1). 
Aspirin esterase activity increased with substrate concentration (after adjustment 
for spontaneous hydrolysis) to a maximum. Eadie-Hofstee analysis of the data 
indicated only one significant enzyme component. The Vmax and Km values 
were calculated from the Y-intercept and slope of the line respectively as shown 
in Fig 8.5. Vmax was reduced in the frail elderly (448 ± 40.2) compared to the 
fit elderly (694 ± 65.2; p<0.01; F=5.71). There were no significant 
differences between the fit elderly and fit young (598 ± 50.6), Table 8.4 and 
Fig. 8.6. 
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Table 8.2 : 
Plasma Aspirin Esterase Activity in the Presence 
of Varying Concentrations of Physostigmine (inhibitor) and Aspirin 
(substrate). 
Aspirin concentration 
(mM) 
Physostigmine 
concentration 
(mom 
nmol salicylate 
/ ml plasma /min 
0.5 0 41.6 
0.05 <4 
0.2 <4 
0.4 <4 
1.0 0 93.7 
0.05 <4 
0.2 <4 
0.4 <4 
3.0 0 179 
0.05 <4 
0.2 <4 
0.4 <4 
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Table 8.3: 
Asprin Esterase Activity due to Albumin Fraction V (40g/1) 
When Incubated with Aspirin (3mM) 
Incubation contents 
Albumin (fraction V) 
40g/1 
nmol salicylate/ml albumin / min 
Physostigmine 
(0.2mM) 
25.0 
no Physostigmine 
45.8 
Blank (no protein) 25.0 25.0 
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Table 8.4 
Kinetic Analysis of Plasma Aspirin Esterase 
Frail Elderly 
Vmax 
Plasma 
cholinesterase 
(nmol benzoyl- 
choline 
hydrolysed'min 
Vmax 
Plasma aspirin 
esterase 
(nmol 
salicylate/ml 
plasma /min 
Km Aspirin 
(mM) 
1 550 4.1 
2 395 4.6 
3 1570 648 5.5 
4 1015 240 2.6 
5 - 455 3.1 
6 1090 608 5.1 
7 480 433 6.3 
8 1500 424 3.5 
9 1490 298 2.6 
10 1135 431 3.5 
Mean + SEM 01183± 145 *448 ± 40.2 4.1 +0.4 
Fit Elderl 
11 1680 541 4.6 
12 1840 966 5.7 
13 1410 541 4.6 
14 1345 621 5.0 
is 1515 559 4.7 
16 1920 773 6.1 
17 2410 861 3.9 
Mean +SEM 1731+ 139 694± 65.4 +0-. 3--] 0.3 
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Table 8.4 continued 
Young 
Vmax 
Plasma 
cholinesterase 
(nmol benzoyl- 
choline 
h drol sed'min 
Vmax 
Plasma aspirin 
esterase 
(nmol 
salicylate/ml 
plasma /min 
Km Aspirin 
(mM) 
18 1600 576 4.6 
19 1800 670 4.5 
20 - 509 4.2 
21 2065 503 2.8 
22 1495 438 3.1 
23 990 533 4.5 
24 1375 419 3.6 
25 1795 682 5.5 
26 2435 961 6.3 
27 1440 690 5.5 
Mean + SEM 1666 + 140 598+50.6 4.5 ± 0.3 
0p<0.01 ;F=5.7 , compared with 
fit elderly volunteers (ANOVA 
followed by the Scheffe test ) 
*p<0.05 ;F=4.17, compared with young and fit elderly volunteers 
( ANOVA followed by the Scheffe test ) 
Correlation coefficient between V max for plasma aspirin esterase and 
cholinesterase is r= 0.77. This is significant at p<0.001 
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Title : Plasma aspirin esterase activity in young " fit and frail elderly 
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The Km values did not differ significantly in any of the three groups (frail: 4.1 ± 
0.4mM; fit: 4.9± 0.3mM; young: 4.5± 0.3mM) as shown in Table 8.4 and 
Fig. 8.7 (F =1.26). 
The Vmax for plasma cholinesterase was also lower in the frail elderly 
individuals (1183 ± 145; p< 0.05; F=4.17) as shown in Table 8.4. and 
Fig. 8.8. 
Regression analysis of the Vmax values for plasma aspirin esterase and 
cholinesterase showed that the two are significantly correlated (r = 0.77; 
n= 23; p<0.001) and this is shown in Fig 8.9 . 
8.4 Discussion 
The frail elderly volunteers were significantly older that the fit elderly at 
p<0.05. As people age they become increasingly frail, thus finding suitable 
fit age matched controls was difficult. Plasma albumin concentration was 
significantly reduced in the frail group which is one of the characteristics of this 
population. (Woodhouse et al, 1988). 
No plasma aspirin esterase activity was attributable to albumin. This was 
confirmed by incubating plasma with the specific cholinesterase inhibitor 
physostigmine and aspirin, and also incubating the purified preparation albumin 
fraction V with aspirin. 
Kinetic analysis of plasma aspirin esterase by Eadie- Hostee revealed only one 
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major enzyme component in all the plasma samples analyzed. These findings 
suggested that cholinesterase alone contributed to plasma aspirin esterase 
measurements using this spectrophotometric technique. 
The reduced Vmax for plasma aspirin esterase and cholinesterase observed in the 
frail elderly group is in agreement with the results of Williams et al (1989) who 
measured plasma aspirin esterase at a 1mM aspirin concentration. They found a 
significantly reduced plasma aspirin esterase activity (p < 0.01) and although 
cholinesterase was not statistically significant at the 5% level there was a trend 
towards a reduced activity. 
Production of abnormal proteins has been postulated as one of the fundamental 
mechanisms of ageing (Goldstein, 1977). However the Km values for plasma 
aspirin esterase measured here shows no significant change with age or frailty 
and were in good agreement with that obtained by Valentino et al (1981) who 
gave the value as 4.2 mM. 
The reduced Vmax for aspirin esterase in the frail elderly group however 
compared with the fit elderly group strongly suggests that impaired aspirin 
esterase activity is due to a decrease in the total plasma content of cholinesterase 
rather than a detrimental change in enzyme protein contributing to a change in 
affinity of the active site. 
CHAPTER 9 
Semi-purification of Aspirin Esterase (Cholinesterase) 
from Whole Plasma Using Ion-Exchange Gel 
Chromatography 
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Chapter 
Semi-purification of Aspirin Esterase (cholinesterase) from Whole Plasma 
using Ion-Exchange Gel Chromatography. 
9.1 Introduction 
Although there did not appear to be a significant contribution by albumin to 
plasma aspirin esterase activity (Chapter 8), it cannot be assumed to be absent. 
The calculated Km value may be a composite of two very similar values, one for 
albumin and one for cholinesterase or another protein. Only separation of 
albumin and other proteins by a semi-purification technique would allow the 
calculation of a Km value for the "pure" cholinesterase contribution to plasma 
aspirin esterase. 
The following chapter details ion exchange gel chromatography which was used 
to separate the enzyme components and SDS polyacrylamide gel chromatography 
which was used to visualize proteins and esterase activity. The preliminary 
studies sought to confirm the later methods. 
These methods were used in order to achieve the aim of the following work 
which was to remove the albumin component and repeat kinetic studies on the 
plasma aspirin esterase in young, fit and frail elderly. 
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9.2 Purification of Cholinesterase (ChE). 
Purification of ChE has been carried out over many years, using various 
combinations of the same techniques. Early experiments used mainly horse 
plasma which has slightly different stability properties to human plasma. The 
purification procedure is difficult mainly due to the complexity of the ChE 
structure, the minute quantities present in plasma, and the poor yield. 
In most of the purifications from horse plasma the initial step was to precipitate 
proteins using 33 % saturation with ammonium sulphate. The ChE remained in 
solution and this gave a two fold purification. Strelitz (1944) perfected this 
technique using acidified 33 % saturated serum which resulted in a reported 40- 
fold purification and 58 % yield. This method was used as the basis of 
preparation commercially throughout the 1960s, giving approximately 100-fold 
purification, However, few workers were able to obtain the same degree of 
purification claimed by Strelitz (Jansz and Cohen, 1962; Heilbronn, 1962). 
Later work also indicated that the harsh acid conditions used by Strelitz were 
actually be destroying one or more of the active sites of ChE. (Main 1987). 
After 1970, methods were still using commercially available horse serum BuchE 
purified by the Strelitz method. Two methods notably used the same starting 
material and the same techniques but to different effect. Lee and Harpst (1971) 
used differential sedimentation, zone electrophoresis (Jansz and Cohen, 1962), 
ion-exhange chromatography eluting with a linear sodium chloride gradient and 
then gel filtration on sephadex G. 200. The overall yield was reported to be 10% 
and no isoenzymes were found to be present. This was possibly due to the initial 
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Strelitz step. 
Main et al (1972) used preparative PAGE on commercially available ChE which 
had been purified 8-fold by filtering through Sephadex G. 200 and then 
Sepharose 6B. This process was time consuming and involved three runs before 
finally removing gel contaminant by passing down Sepharose 6B. It did, 
however, successfully remove the remaining contaminants and several bands 
(isoenzymes) of activity were evident. 
A method by Main et al (1974) aimed to reduce the large losses of cholinesterase 
activity in the Strelitz method. Particular attention was paid to the stability of 
ChE at pH 3.0 was found that ChE lost 50% of its activity in about 25 minutes 
at 24oC. This loss was reduced dramatically in 33 % saturated ammonium 
sulphate. During the Strelitz method ChE is exposed to a more dilute 
ammonium sulphate at pH 3. This procedure may well have destroyed the ChE 
and Main et al (1974) overcame this by adjusting the pH of acidified ammonium 
sulphate solutions to pH 7 before ChE was exposed to more dilute concentration 
of ammonium sulphate. The procedure then followed an adaptation of Yoshida 
(1970) using ion exchange gel chromatography on three successive DEAE- 
Sephadex A 50 columns and eluting with linear gradients of choline chloride, 
sodium chloride and choline chloride respectively. The product was 
concentrated by precipitation with 70% saturated ammonium sulphate and 
subjected to preparative PAGE (Main et al, 1972). The gel contaminants were 
removed as before. The results were impressive: - cholinesterase was purified 
19,000-fold and 15-18 mg product was obtained from 20 1 serum. 
The difficulties in purifying horse cholinesterase, although significant, are less 
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than those encountered by workers interested in human ChE, of which smaller 
quantities of plasma are available. 
The Strelitz method has not been widely applied to the purification of human 
plasma because human ChE is less stable than horse ChE at low pH. The 
protective effect of ammonium sulphate on the stability of human ChE is less 
than one-tenth that of horse ChE (Main, 1987). 
Interest in the isoenzymes of cholinesterase, the desire to characterize these 
multiple molecular forms and relate them to the atypical genetic cholinesterase 
variant has been the stimulus for most of the work on human serum.. Gaffney 
(1970) and Das and Liddell (1970) were among the first to work on the human 
enzyme. They both used various combinations of the methods mentioned above 
with considerable success. Das and Liddell avoided using the Strelitz method 
and the high loss of activity associated with it. They achieved a 13,000-fold 
purification and a yield of 54%. No contaminating proteins were discovered but 
the authors did not claim the product was 100% pure. 
The most exciting development in recent years has been the use of affinity gels. 
These have resulted in purification methods with the capacity and efficiency to 
supply the quality of pure enzyme needed for structural studies. 
Lockridge and La Du (1978) used only a two step procedure - ion exchange gel 
as described by Das and Liddell and modified by Muensch (1976) and 
procainamide affinity gel to obtain an yield of 70% pure enzyme. 
Ralston et al (1983) also used procainamide affinity gels as a second step. 
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Ammonium sulphate precipitation was deemed more suitable for an initial 
'clean-up' method prior to large scale preparation of pure human ChE. 
La Du and Choi (1975) used the apparent lower affinity of the atypical ChE for 
choline ester substrates to advantage when separating a mixture of atypical and 
typical ChE. A different affinity gel was used in this case (N (6-aminocaproyl - 
6' - aminocaproyl) -p- aminophenyl - trimethylammonium bromide 
hydrobromide). As predicted the atypical cholinesterase eluted before the usual 
form due to the lower affinity for the gel. 
Despite the advent of much more sophisticated analytical and preparative 
techniques, most methods used today still use those procedures first introduced 
when enzyme purification was in its formative years. 
Lockridge (1990) details routine preparation of purified cholinesterase, the yield 
being 8-12 mg from 10 1 serum. He uses two ion-exchange columns and an , 
affinity column to obtain enzyme of electrophoretically pure quality from which 
the amino acid sequence has been elucidated (Lockridge et al, 1987). 
9.2.1 Ion-Exchange Gel Chromatography 
DEAE - Sephacel is an ion-exhange gel consisting of microcrystalline cellulose 
reformed into beads (40-160 um). The small particle size ensures minimal flow 
disturbance and good resolution (James and Stanworth, 1964). The gel like 
structure of the beads is strengthened by cross-linking with epichlorohydrin but 
the main-structure forming bonds are hydrogen bonds. During ion-exchange, 
depending on conditions such as ionic strength and pH, it is possible to bind the 
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substance of interest and elute the contaminants or 'vice versa'. In the method 
detailed below it is the former property which was used. The chloride ions in 
equilibrium with the sephacel gel initially are replaced with acetate ions from the 
sodium acetate buffer. At this point the eluting buffer exhibits the same pH and 
conductivity as the applied buffer. 
The iso electric point of cholinesterase has been estimated at 3.99 (Das and 
Liddell, 1970) and the optimal pH of the buffer for anion-exchange gels such as 
DEAE - Sephacel is one pH unit above the isoelectric point (anonymous, 1987). 
This means at pH 5.5 cholinesterase carries a net negative charge and replaces 
the acetate ions on the gel. Other proteins may also be negatively charged at this 
pH and are similarly attracted to the anion exchange gel. 
Chloride ions in the form of increasing concentrations of sodium chloride are 
introduced in a stepwise fashion at this point. Proteins which are less strongly 
attracted to the gel are eluted at lower concentrations of chloride ions. As the 
concentration increases, proteins which are more firmly attached are replaced by 
chloride ions. This results in an elution profile of the various proteins from the 
crude sample. Eventually the DEAE - Sephacel is regenerated when all the 
remaining protein and acetate ions are replaced by chloride ions. The gel can be 
re-equilibrated with acetate ions and re-used. 
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9.3 Method 
9.3.1, Preparation of Ion-Exchange Gel 
DEAE - Sephacel was allowed to equilibrate with 50 mM sodium acetate buffer 
pH 5.5 containing 5 mM calcium chloride and 0.1 mM EDTA. The mixture was 
stirred gently, and the buffer decanted off and replaced with new at intervals. 
When the supernatant attained a pH of 5.5, the Sephacel was ready for. use. 
This was degassed under vacuum. 
A glass column of dimensions 26 mm x 4000 mm was positioned vertically using 
a plumb line. The Sephacel slurry was stirred gently and a small quantity 
(approximately, 1 cm depth) was allowed to settle at the base of the column. 
This prevents small cellulose beads forcing their way into the fine mesh of the 
net base and impeding the flow. 
The remaining slurry was poured slowly and carefully down a glass rod to 
prevent trapping any air bubbles. At this point a flow of buffer through the 
column was initiated by releasing the outlet pipe. A bed volume of 
approxmately 80 ml was poured into the column. 
Four or five bed volumes of degassed buffer were passed through the bed until 
the pH and conductivity of the buffer eluting from the base of the column was 
the same as that entering the column. The flow rate was kept at 1 ml/min. 
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9.3.2 Plasma Application to Column 
Plasma was thawed at room temperature and centrifuged at 3,000 g for 5 
minutes to remove the fibrin. 
An accurate volume of plasma between 4 and 5 ml was applied to the top of the 
column. Sodium acetate buffer containing 5 mM calcium chloride, 0.1 mM 
EDTA and 50 mM sodium chloride was used to elute those contaminating 
proteins less strongly bound to the gel. 5 ml fractions were collected until the 
eluting proteins became minimal (low absorbance at 280 nm on a direct reading 
spectrophotometer ie less than 0.01 abs units). When this occurred the sodium 
chloride was increased to 100 mM and the process repeated. Finally buffer 
containing 200 mM sodium chloride was used to elute the most strongly bound 
proteins and clean the column. 
Once the eluting buffer no longer contained proteinous matter (ie absorbance at 
280 nm was zero) buffer containing no sodium chloride was used to regenerate 
the column. 
When pure human albumin was applied to the column, the technique was 
identical to that for plasma. 
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9.4 SDS - Polyacrylamide Gel Electrophoresis (SDS - PAGE) 
9.4.1 Theory of SDS - PAGE 
Proteins carry a net charge when at any pH other than their isoelectric point and 
will migrate in an electric field. Viscous drag which is dependent on the size 
and shape of the protein impedes this movement (Hayes and Stockman, 1989a). 
The support matrix provides a porous media in which the pore size is in the 
same order as the size of the proteins to be separated. This minimises the free 
diffusion of components. They also dissipate some of the heat generated by the 
electric current. 
I chose polyacrylamide which is a synthetic polymer of the acrylamide 
monomer. It consists of long chains with a cross linking of free functional 
groups by bifunctional compounds such as N Ni - methylene bisacrylamide. 
The relative proportions of these determine the pore size of the matrix (Names, 
1985). 
Discontinuous Buffer System 
This uses a stacking gel which is a polyacrylamide gel of low ionic strength and 
pore size to concentrate the sample (Hayes and Stockman, 1989b). 
. ,, 
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Reservoir Buffer 
The gel is submerged in a buffer which interacts with the gel to create a voltage 
gradient. This occurs as the result of pH differences in the stacking and 
resolving gels. The proteins become unstacked and separate according to 
intrinsic charge and the size of the protein subunits. 
9.5 Method of SDS - PAGE (High pH Discontinuous System) 
9.5.1 Preparation of Gels 
i) Resolving Gel 
Reagents - all filtered through Whatman no. 1 filter paper as appropriate. 
1 30M Tris-HCI (pH 8.8) - Resolving gel buffer stock 
2 Acrylamide - bisacrylamide in proportions 30: 0.8 
3 Ammonium persulphate 1.5 % w/v 
4 Sodium Dodecylsulphate (SDS) 10% w/v 
5 (N N N' N' - Tetramethylethylene diamine) TEMED 
In order to prepare a 7.5 % gel :-7.5 ml acrylamide - bisacrylamide (30 : 0.8); 
3.75 ml resolving gel buffer stock; 0.3 ml 10% SDS; 1.5 ml 15% ammonium 
persulphate; 16.95 ml water and 15 '1 TEMED. 
The reagents were mixed thoroughly. TEMED was added last since this is the 
polymerization catalyst and the gel requires immediate pouring after this is 
added. 
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F*gure 9.1 Discontinuous PAGE Apparatus 
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ii) Stacking Gel 
Reagents 
1 0.5 M Tris - HCI (pH 6.8) Stacking gel buffer stock. 
It is then made by the same method as the resolving gel. 
9.5.2 Apparatus 
The equipment used was a cooled vertical slab gel apparatus called the Protean 
Cell (Hoefer Scientific Instruments). A diagrammatical representation is shown 
in Fig 9.1. Each gel was formed between two glass plates which were separated 
by two PVC spacers. This was held together by two clamps on either side of the 
plates. The upper most edge of the plates was left open for the pouring of the 
gel and sample application. - The box was sealed using polycarbonate cams which 
pressed the base against a silicone rubber gasket in a casting stand. 
Once the gel had set and the samples been applied, the upper reservoir was 
attached by locking against another silicone rubber gasket using the same cam 
system. The plates were simultaneously released from the casting stand and 
fitted into the filled reservoir tank. The upper reservoir was filled to the 
appropriate level also. 
The electrical connections were completed and the power applied. Cold water 
from the tap was used as the coolant and circulated constantly through the 
perspex tube heat exchanger. The reservoir buffer was stirred continuously to 
98 
dissipate heat. A current of 50 mA was applied initially until the resolving gel 
was reached then it was increased to 100 mA. Too small a current would allow 
diffusion of the proteins to occur resulting in band spreading. Too large a 
current can result in poor resolution. This was run until the dye front was about 
2cm from the base of the gel plate. 
2.5 ml acrylamide: bisacrylamide (30 : 0.8); 5 ml stacking gel buffer stock; 0.2 
ml 40% SDS, 1 ml 1.5% ammonium persulphate and 0.015 ml TEMED were 
mixed thoroughly and poured immediately. 
9.5.3 Pouring the gel 
The glass surfaces of the plates were thoroughly cleaned with ethanol. A 30 ml 
syringe with a silicone tubing attachment was filled with the freshly prepared gel 
solution. The solution was carefully dispensed through the nozzle between the 
glass plate sandwich. Care was taken not to generate too many air bubbles. The 
gel plates were filled to about 8 cm from the top. Any air bubbles were 
removed by careful aspiration using an IV cannula 12 G needle. 
The surface was carefully covered with water saturated butanol and left to set for 
at least half an hour. 
When the gel had set the butanol was poured off and the surface washed with 
water two or three times. This removed any unpolymerized acrylamide. The 
stacking gel solution was carefully syringed, in a similar manner as before, onto 
the surface of the resolving gel to about 0.5 cm from the top of the plates. The 
comb which forms the sample wells was carefully positioned to avoid trapping 
any air bubbles which distorts the sample wells. 
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The space between the plates was overfilled with stacking gel. As the stacking 
gel sets it contracts which reduces the sample well size. The stacking gel took 
about 20 minutes to set. The comb was carefully removed and the wells filled 
with reservoir buffer stock. 
9.5.4 Sample preparation 
a) Sample buffer 
Reagents 
1 0.0625 M Tris - HCl pH 6.8 
2 10 % v/v glycerol 
3 2% w/v SDS 
4 5% v/v Mercaptoethanol 
5 0.02% v/v Bromophenol blue 
The above were prepared. The reconstituted sample containing cholinesterase 
activity was mixed with an equal volume of sample buffer. This was boiled for 
5 minutes. 
Molecular weight markers were also applied to the gel. The prepared standards 
were reconstituted with 2 ml of sample buffer, and boiled as with the samples. 
Those chosen had molecular weights ranging from 12,300 - 78,000. The 
commercial cholinesterase was reconstituted with water to a concentration of, 
approximately 1 mg protein/ml. An equal volume of this and sample buffer was 
mixed and treated as before. 
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b) Sample Application 
A microliter syringe was found to be the easiest way of placing the prepared 
samples into the wells. 100 pl of the sample was carefully dispensed into the 
base of alternative sample wells taking care not to contaminate adjacent wells. 
Blank sample buffer was placed in the wells between samples. 
9.5.5 - Reservoir Buffer Stock 
0.25 M Tris 
1.92 M glycine - 
1% SDS (pH 8.3) 
These were dissolved in'and made up to 11 with water. This was diluted 1 in 10 
prior to use and a 51 volume was required each time. 
The apparatus was transferred into the tank containing reservoir buffer as 
described in 9.3.3. 
9.5.6 Removal of the gel 
The current was turned off and the gel plates removed from the reservoir buffer 
tank intact. The side clamps were removed leaving the gel sandwiched between 
the two glass plates supported by the spacers. One spacer was removed and was 
used to carefully lower the top glass plate away from the gel which bonds very 
tightly with the glass. The stacking gel was cut away using the edge of the 
spacer and disgarded in most cases. A small cut was made in one corner of the 
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gel to identify its position. 
The gel was now ready for staining. 
9.6 Non-SDS Gels For Native Proteins 
These were used when esterase activity was monitored. In such cases the basic 
method and reagents are identical to those above except SDS was excluded in all 
reagents and the sample buffer not boiled. 
During the electrophoresis of native proteins separation occurs due to size "n 
charge differences of the molecules. 
9.7 Staining the Gels 
9.7.1 Protein Stain 
Reagents 
1 0.1 % Coomassie Blue R250 
2 Water : methanol: glacial acetic acid 
552 by volume 
The above stain filtered through a Whatman no. 1 filter paper to remove any 
insoluble material. 
The gel was submerged in approximately 500 ml stain overnight. 
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Destaining was carried out using a large vessel (41 volume). The gel was 
wrapped in netting and protected in a cylindrical perspex tube through which 
destain can freely pass. This was placed in the vessel on a special support 
beneath which a magnetic stirring rod was used to continually agitate the destain 
solution. 
This was left for approximately four hours until dark blue spots were visible and 
the gel had changed to a much paler blue background colour. 
9.7.2 Staining Native Proteins 
In order to stain for esterase activity, the temperatures used during the process 
must be optimal for enzyme activity. Samples were kept on ice until application 
to the gel. Incubations with substrate were carried out at room temperature or 
37oC. 
a) Napthylacetate Esterase Activity 
This involved coupling of the napthol produced by hydrolysis of the naphthyl 
ester with the diazo salt Fast Blue 2R to form an azodye. It is a general esterase 
dye. 
Reagents 
Substrate 
alpha napthylacetate 1g 
acetone 50 ml 
water 50 ml .I 
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Stain 
Fast Blue 2R 100 mg 
Tris - HC1 pH 7.0 (100 mM) 10 ml 
alpha-napthylacetate 1%3 ml 
water 87 ml 
The method is a modification of that by Hopkinson et al, 1973. The gel was 
incubated in the above stain for approximately half an hour or until the bands of 
esterase activity appeared. The gel was then removed to avoid overstaining and 
placed in water. 
b) Butyrylthiocholine Esterase Activity 
The method used to detect cholinesterase activity was that used by Coates et al 
(1975). 
Reagents 
1 Butyrylthiocholine 100 mg 
2,0.07 M phosphate buffer pH 6.1 containing 2 mM 20% copper 
sulphate, 10mM glycine and 30mM sodium sulphate 
3 30 mM sodium sulphate 
4 0.01 % dithioxamide solution in 0.02 M sodium acetate 
Butyrylthiocholine (100 mg) was dissolved in Reagent (2) and the gel was 
incubated in this solution at 370C for 3 hours with gently shaking. The gel was 
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washed with water and then transferred to a solution of 20% sodium sulphate for 
overnight incubation. The bands of cholinesterase activity were evident as a 
dark green colour due to dithio-oxamide complexing with the copper. (Chubb 
and Smith, 1975). 
The protein content of the fractions was analyzed using the method outlined 
below. This enabled the calculation of the appropriate volume of sample to 
apply to the polyacrylamide gel. In Chapter 10 it was used to the calculate 
Vmax which was expressed per mg protein in whole plasma and purified 
fraction, and the purification factors. 
9.8 Protein Assay 
9.8.1 Introduction 
The method used was a modification of that developed by Lowry et al (1951) as 
suggested by Peterson (1977). 
The basic reaction is the formation of a coloured complex when the 
phosphomolybdic-tungsten mixed acid in Folin and Coicalteu's phenol reagent 
reacts with the amino acids (Peterson, 1979). 
Peterson consolidated several methods to remove interfering salts and optimise 
assay conditions. This resulted in a rapid, consistent protein assay for dilute 
samples. 
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9.8.2 Method 
Dilute Fractions from Ion-Exchange Column 
The initial concern was that the concentration of EDTA (approximately 0.7 mM) 
may interfere with the assay (Peterson, 1979). In order to test this, a known 
amount of protein was added to blank buffer, taken through the assay and read 
against a standard curve made up in water. This sample did not differ by more 
than 6% from the actual value and so the precipitation step was considered 
unnecessary in this case. The standard curves produced using water and buffer 
solvents were also comparable (Fig 9.2 ). 
Plasma 
This required a1 in 100 dilution prior to analysis. 
Stock Reagents 
1 Copper-tartrate-carbonate (CTC) 
20% sodium carbonate, copper sulphate to a final concentration of 0.1 %, 0.2% 
potassium tartrate and 10% sodium carbonate. 
2 10% SDS 
3 0.8 M sodium hydroxide 
4 Folin-Ciocalteu's phenol reagent 
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Working Solutions 
Reagent A 
Equal proportions of CTC, NaOH, SDS and water. 
Reagent B 
One volume of Folin-Ciocalteu's phenol reagent mixed with five volumes of 
distilled water. 
A protein standard solution was prepared containing 600 ng/ I Bovine Serum 
Albumin (BSA) in reconstituted freeze dried buffer. A serial dilution of stock 
solution was made from 0 to 60 pg/ml protein in 1.0 ml water. 15 PI of each 
fraction or 15 pl of 1 in 100 dilution of plasma was made up to 1.0 ml with 
water. 1.0 ml of reagent A was added to each tube, mixed and left for exactly 
10 minutes. 0.5 ml reagent B was added, mixed and left for at least 30 minutes. 
Each sample was repeated in triplicate. 
The resulting blue complex was read at 750 nm on a uv spectrophotometer 
within two hours. 
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9.9 - Preliminary Background Studies 
This work involved confirming the removal of albumin from the purified 
cholinesterase fractions and identifying the peaks of protein content using various 
esterase substrates and the cholinesterase inhibitor, physostigmine. 
9.9.1 Methods 
Removal of Albumin Component 
Human albumin solution 4.5% was used. 5.0 ml of albumin solution was 
applied to the top of the column and eluted as described in 9.3.2. This was 
compared with that for plasma. 
Identification of Peaks 
Peaks were located by monitoring for protein at 280 nm. They were identified 
by the methods described below. 
a) Phenylacetate Esterase Activity (Arylesterase) 
This was measured by a modification of the method of Kitchen et al (1973). 200 
pl fraction, 795 p1 Tris-HC1 buffer pH 8.0 and 3mM phenylacetate (final 
concentration) were mixed and incubated at 37oC. 
The formation of phenol was monitored at 272 nm by uv spectrophotometry. 
Physostigmine (0.2 mM) was included as a specific inhibitor of cholinesterase 
activity. I 
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b) Cholinesterase Activity 
This was measured as previously described. The plasma was replaced with 100 
pl fraction. Physostigmine (0.2 mM) was included in parallel incubations in 
order to confirm activity was due to cholinesterase. 
c) Aspirin Esterase Activity 
This was measured using a modification of the method in Chapter 8.200 pl of 
fraction, 1.0 ml Tris-HC1 buffer containing 200 mM calcium chloride pH 7.4 
and aspirin at a final concentration of 2 mM, to a final volume of 1.5 ml were 
incubated at 37°C. Physostigmine was included at a final concentration of 0.2 
mM to confirm aspirin esterase activity due to cholinesterase. 
9.9.2 Results 
The elution profile obtained for the purification of whole plasma on DEAE- 
Sephacel is shown in Fig 9.3. Table 9.1 shows the activity of peaks 1 and 2 (Fig 
9.3) to three esterase substrates - aspirin, benzoylcholine chloride and 
phenylacetate. The specific cholinesterase inhibitor physostigmine inhibited all 
the aspirin esterase and cholinesterase activity in peak 1. Phenylacetate 
hydrolysis in peak 1 was also inhibited by physostigmine. This showed that 
esterase activity in peak 1 was due to cholinesterase. 
Peak 2 contained no aspirin esterase or cholinesterase activity. It did, however, 
contain arylesterase activity which was unaffected by physostigmine. These 
results are shown in Table 9.1. 
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Title : The elution profile of whole plasma after passage down a DEAF- Sephacel 
ion exchange column 
Ordinate : Protein content of each 5ml fraction : absorbance at 280 nm 
Abscissa : Number of 5m1 fractions collected 
A 50mM sodium chloride 
100mM sodium chloride 
200mM sodium chloride 
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Table 9.1 
Peak Identification : Peaks 1 and 2 showing Esterase Activity 
Aspirin* Benzoylcholine Phenylacetate@ 
chlorides 
2mM + 0.05 + 3mM + 
0.2mM mm 0.2mM 0.2mM 
physos- PhYsos- PhYsos- 
timine ti mine ti mine 
1 2517 0 800 0 11.14 0 
2 0 0 0 0 1.6 1.14 
*nmol salicylate produced /ml fraction /min 
#nmol benzoylcholine chloride hydrolysed / ml fraction / min 
@nmol phenol produced/ ml fraction / min 
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Peak A was identified as albumin as shown in Fig 9.4. The fraction numbers do 
not correspond exactly which is probably due to slight variations in flow rate. A 
small percentage of albumin showed the same retention time as peak 1. This 
was quantified by plotting the two peak profiles on graph paper, cutting them out 
and weighing them on a microbalance. In this way the percentage of albumin 
not removed by the first increment of 50 mM sodium chloride could be 
calculated. 
The cholinesterase activity in peak 1 expressed as activity per ml fraction closely 
followed the protein content outline of the peak (Fig 9.5). Cholinesterase 
activity with benzoylcholine as substrate was used instead of aspirin esterase as 
an indication of enzyme activity in the peak because it was much more sensitive. 
The activity in peak 1 was sensitive to inhibition by 0.2 mM physostigmine 
(Table 9.1) confirming the results of Rainsford et al (1980) and Wilde and 
Kekwick (1964), thus the activity was indeed due to the cholinesterase enzyme. 
The activity in peak 2 was insensitive to physostigmine and was thus identified 
as arylesterase. Despite concentrating the fraction and substrate as much as 
possible an accurate outline of the enzyme activity in this peak was not possible 
due to a lack of sensitivity. 
X 
It was found that 97% of albumin was removed from the plasma by 50 mM 
sodium chloride. 
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9.9.3 Discussion 
The elution profile obtained in this method was very similar to that described by 
Rainsford et at (1980) and Wilde and Kekwick (1964). Das and Liddell (1970) 
also used a similar technique but instead employed a sodium chloride gradient 
following the initial elution with sodium acetate buffer alone. 
Rainsford et al (1980) identified the albumin fraction as having 20% of the 
aspirin esterase activity of plasma, using a fluorimetic assay which involved 
incubation of the enzyme source with aspirin followed by extraction of salicylate 
with ether. 
Although no aspirin esterase activity was found attributable to albumin using the 
spectrophotometric assay, it was possible to demonstrate the removal of 97% of 
the albumin content. Thus 3% or less remained in the protein fraction 
containing cholinesterase activity (Fig 9.4). 
Both Rainsford et al (1980) and Wilde and Kekwick (1964) claimed that the 
albumin peak contained naphthylacetate esterase activity when separated on a 
non-SDS gel. Incubation of the albumin fraction separated in this study with 
phenylacetate showed no arylesterase activity. 
By applying the separation technique described above I could separate purified 
enzyme from a series of plasmas to determine the kinetics of aspirin esterase. 
CHAPTER 10 
Determination of Aspirin Esterase Kinetics(Km) using 
the Cholinesterase Fraction Recovered from DEAE- 
Sephacel in Young; Fit and Frail Elderly 
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Chapter 10 
Determination of Aspirin Esterase Kinetics (Km) using the Cholinesterase 
Fraction Recovered from DEAE-Sephacel in Young. Fit and Frail Elderly. 
10.1 Introduction 
In order to determine the Km values of plasma aspirin esterase activity, due to 
the cholinesterase enzyme, it was necessary to remove the albumin component. 
This study involved the use of purified cholinesterase fractions prepared from 
young, fit and frail elderly individuals by ion-exchange gel chromatography as 
previously described. Determination of Km values would indicate whether the 
lower Vmax of plasma aspirin esterase (Chapter 8) exhibited by the frail elderly 
was due to a reduced affinity of the enzyme. 
10.2 Method 
Patients 
Frail elderly, fit elderly and young individuals were recruited into the study as 
discussed in Appendix I by Dr H Wynne. Table 10.1 shows individual patient 
details. 8 frail elderly individuals (mean age 822.5) with a low plasma aspirin 
esterase activity [< 100 nmol salicylate/ml plasma/min (Williams et al, 1989)] 
were selected; 8 fit elderly individuals (mean age 73±2.6 ) and 9 young 
individuals (mean age 25. ±. 4.0)were also chosen. 
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Table 10.1 
Volunteer Details 
Volunteer 
(sex) 
Frail Elderly 
Age 
( years) 
Plasma 
aspirin 
esterase 
(nmol 
salicylate/ml 
plasma/min 
Albumin 
(g11) 
Drug 
(if any) 
1(F) 88 61.8 30 chlorpheniramine, 
docusate 
2(F) 85 44.2 32 
digoxin 
frusemide 
3(F) 71 44.2 31 
4(M) 70 35.5 38 
5(F) 84 53.0 28 
6(F) 89 39.7 38 
7(F) 83 48.6 24 
bendrofluazide 
8(F) 87 48.6 29 
terodiline, amiloride 
frusemide 
Mean +SEM 82±2.5 48.6+0.0* 31±1.6 
Fit Elderl 
9 69 88.3 43 
10 88 97.2 48 
11 66 110.4 43 
12 71 106.0 41 
13 70 - 41 
14 67 110.4 41 
15 83 101.6 - 
16 71 123.6 37 
Mean ± 
SEM 
73±2.6 106.0±0.0 42±1.2 
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Table 10.1 continued 
Volunteer 
(sex) 
Young 
Age 
( years) 
Plasma 
aspirin 
esterase 
(nmol 
salicylate/ml 
plasma/min 
Albumin 
(g11) 
Drug 
(if any) 
17 (F) 29 136.9 41 
18 (F) 27 101.6 42 
19 (F) 28 97.2 42 
20 (V) 25 - 43 
21 (F) 24 79.5 43 
22 (F) 20 97.2 48 
23 (F) 25 66.2 48 
24 (M) 21 97.2 44 
25 (F) 25 88.3 50 
Mean +SEM 25±4 93±0.0 45±1.0 
*p <0.005 therefore plasma aspirin esterase significantly lower 
in the frail elderly 
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Aspirin Esterase Assay as applied to Purified Cholinesterase 
The outline of the procedure followed for each sample is shown in the flow chart 
(Fig 10.1). 
The protein fraction was separated as described in Chapter 9. A modified 
aspirin esterase assay was then applied to the purified protein fraction. 200 pl of 
the freshly reconstituted fraction (kept on ice) was incubated with a freshly 
prepared aspirin solution. This was made up to a final volume of 1.5 ml with 
Tris-HC1 buffer as before. 
The incubation mixture was prewarmed to 37oC for one minute, aspirin 
substrate was added and the salicylate formation was monitored continuously for 
1.5 min at 340 nm on a uv spectrophotometer. The aspirin concentrations used 
were 1 to 4 mM. The maximum concentration was limited by the degree of 
spontaneous bydrolysis. Corrections were made for spontaneous hydrolysis by 
the parallel incubation of blank buffer containing aspirin. 
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Figure 10.1 Summary of Method for Determining the Kinetics 
of Aspirin Esterase from a purified fraction 
collect plasma 
select frail elderly on the basis of 
a low plasma aspirin esterase 
(< 100 nmol salicylate /ml plasma /min) 
DEAE- Sephacel ion exchange column 
fractions at 5min 
intervals 
UV spectrophotometry at 280nm 
determine cholinesterase activity acr. -Wý oss peak I. UV spectrophotometry 240nm. 
freeze dry pooled fractions 
determine recovery of 
cholinesterase 
pool fractions exhibiting cholinesterase 
and aspirin esterase activity 
activity to an accurate volume 
of approximately 50ml 
-ated for <2 days 
aspirin esterase kinetics reconstitute with 7. Om1 purified water 
application to SDS 
and non-SDS native 
PAGE 
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10.2.1 Linearity of the Reaction 
The assay involved a continual monitoring of salicylate formation so linearity 
with time can by visually judged. The linearity at high substrate concentration 
had to be assumed due to a shortage of protein material. Linearity with protein 
was tested for by incubating 50 - 300 pl fraction with low substrate 
concentration (0.25mM) over 1.5 min (Fig 10.2). 
10.2.2 Commercial Cholinesterase 
An analysis of commercial cholinesterase was made in order to compare the Km 
value and purification factor obtained with that from purified fraction. 
The freeze-dried powder was reconstituted to 2 mg protein/ml in water. A final 
incubation volume of 1.5 ml Tris-HC1 buffer contained 40 jil protein 
preparations and aspirin solution ranging from 1 to 4 mM. This was incubated 
and monitored as before. Figures 10.3 and 10.4 show linearity of the reaction 
with protein at low (0.5mM) and high (8mM) aspirin concentrations 
respectively. 
The following parameters were calculated: 
1. Recovery of activity- the total number of units of cholinesterase activity 
recovered as a percentage of that applied . 
2. Purification factor- the activity of plasma aspirin esterase and cholinesterase 
expressed per mg protein/min in purified fraction divided by that in whole 
plasma. 
3. Protein content (mg/ml) 
4. Plasma aspirin esterase Km and Vmax- both calculated using the direct-linear 
plot method (Appendix II). Vmax was expressed as nmol salicylate formed/ mg 
protein/min 
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10.3 Results 
10.3.1 Purification 
The plasma aspirin esterase activity in the frail elderly (mean 48.6 ± 0.0) was 
significantly lower than the mean value in the fit elderly (106.0 ± 0) and the 
young (93 ± 0) at the 0.5% significance level (Table 10.1). 
The percentage recovery of cholinesterase and aspirin esterase activity was not 
significantly different in any of the three groups as shown in Table 10.2 (frail 
elderly: 58.5 ± 3.3 and 55.7 ± 5.6; fit elderly: 66.3 ± 3.3 and 59.6 ± 4.0; 
young 59.5. ± 2.4 and 49.8 ± 3.0) at the 5% significance level. There was a 
significant correlation between aspirin esterase and cholinesterase recovery 
(r=0.606; p<0.005; t=3.57; Fig 10.5). 
The mean purification factors for aspirin esterase (frail: 29 ± 2; fit: 30 ± 2; 
young: 26 ± 3) and cholinesterase activity (frail: 20. ± 3; fit: 23 ± 3; young: 30 
± 4) are shown in Table 10.3 and summarized in Table 10.6. They were not 
significantly different. 
The correlation between the albumin content of plasma and purification factor 
was tested for in order to determine whether this had any bearing on a successful 
separation. No correlation was found in either case (aspirin esterase: r=0.04; 
t=0.19 and cholinesterase: r=0.316; t=1.6). 
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Table 10.2 
Recovery of Esterase Activity 
Volunteer % Aspirin esterase 
recovery 
% Cholinesterase 
recovery 
Frail Elderly 
1 45 44 
2 - 63 
3 76 70 
4 51 71 
5 41 53 
6 81 76 
7 45 52 
8 51 58 
Mean + SEM 55.7± 5.6 58.5±3.3 
Fit Elderly 
9 70 61 
10 51 63 
11 50 71 
12 53 61 
13 48 53 
14 - 86 
15 70 72 
16 75 63 
Mean +SEM 59.6+4.0 66.3+3.3 
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Table 10.2 continued 
Volunteer % Aspirin esterase 
recovery 
% Cholinesterase 
recovery 
Young 
17 40 72 
18 41 60 
19 54 64 
20 - 63 
21 61 65 
22 36 40 
23 38 53 
24 64 66 
25a 54 56 
25b 53 57 
25c 47 58 
Mean + SEM 49.8 ±3.0 59.5+2.4 
No significant difference between the three groups at p <0.05 
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Table 10.3 
Purification Results from Plasma Cholinesterase 
subject 1Aspirin Esterase Activity 
(1mM) 
2 Cholinesterase Activity 
Vmax 
Plasma purified 
fraction 
purification 
factor 
plasma Purified 
fraction 
purification 
factor 
Frail 
Elderly 
1 0.54 18.81 35 13.5 317 24 
2 0.92 27.2 30 15.3 365 24 
3 - 33.4 - - 158 - 
4 0.45 12.5 28 6.99 47 7 
5 0.70 14.6 21 13.8 444 33 
6 0.54 21 39 13.3 283 16 
7 0.58 14.6 25 11.7 141 12 
8 0.74 16.7 23 13.8 374 27 
Mean 
+SEM 
29.2 20±3 
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Table 10.3 continued 
subject 1Aspirin Esterase Activity 
(1mM) 
2Vmax (Cholinesterase) 
Plasma purified 
fraction 
purification 
factor 
plasma Purified 
fraction 
purification 
factor 
Young 
17 1.42 35.5 25 22.5 491 22 
18 1.32 27.2 21 25.1 606 24 
19 1.20 35.5 29 20.5 630 31 
20 1.02 25.1 25 15.5 436 28 
21 - 22.9 - - 344 - 
22 0.81 23 28 21.3 1310 62 
23 0.64 17.1 27 12.6 520 42 
24 1.34 41.8 31 27 1010 37 
*25a 1.32 31.4 23 24 455 19 
25b 1.35 31.4 23 24 505 22 
25c 1.28 33.4 26 24 398 17 
Mean ± 
SEM 
26±3 30±4 
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Table 10.3 continued 
subject Aspirin Esterase Activity 
(1m1Vn 
Vmax (Cholinesterase) 
Fit 
Elderly 
Plasma purified 
fraction 
Purification 
factor 
plasma Purified 
fraction 
purification 
factor 
9 1.22 39.7 33 21.8 44.6 20 
10 1.56 33.4 21 27 482 19 
11 1.32 31.4 24 21.4 508 26 
12 1.38 51.6 37 25.9 1026 40 
13 - 1.28 35.5 28 26.6 398 15, 
14 1.85 48.1 26 23.0 503 22 
15 1.42 48.1 34 21 508 24 
16 1.44 48.1 33 25.7 493 18 
Mean 
+ SEM 
30±2 23±3 
I nmol salicylate formed / mg protein /min at 370C 
2 nmol benzoylcholine chloride hydrolysed/mg protein/ min at 370C 
*CV=6% (n=3; x=3.6; SD=0.24 ) 
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10.3.2 Kinetics 
The protein content of the plasma and purified fractions is shown in Table 10.4. 
These were used in order to establish the Vmax values for the enzymes which 
were expressed as units of enzyme activity per mg protein. Vmax for aspirin 
esterase and cholinesterase were significantly -different for the three groups at 
p<0.05 (F = 3.9 and F=5.2 respectively) as shown in Table 10.5 (frail: 80 
± 17 and 266 ± 45; fit: 124 ± 17 and 546 ± 65; young: 183 ± 30 and 645 ± 
105 respectively). This is to be expected since the frail elderly were selected on 
the basis of a low plasma aspirin esterase. There was a significant correlation 
between Vmax for aspirin esterase and Vmax for cholinesterase (p < 0.001; 
t= 34.4) as shown in Fig 10.6 and Table 10.5. 
The Km values were calculated using the direct linear plot method (Fig 10.7). 
This is explained in Appendix II. The calculated values are shown in Table 
10.5. The mean value for the young individuals was 4.7 ± 0.4; for the fit 
elderly: 3.6 ± 0.2 and for the frail elderly: 4.3 ± 0.5 (mean in mM ±SEM), 
shown in Fig 10.8. 
There were no significant differences between the three groups at p<0.05, 
Table 10.6 summarizes this data. 
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Table 10.4 
Protein Content of Plasma and of Purified Fraction 
volunteer protein concentration mg/ml 
Frail Elderly plasma purified fraction 
1 69.5 0.86 
2 77.4 1.41 
3 - 2.1 
4 65.0 4.5 
5 66.0 0.75 
6 65.8 1.71 
7 - 1.93 
61.2 0.89 
Fit Elderly 
9 82.0 1.63 
10 63.9 1.51 
11 85.0 1.37 
12 65.5 0.65 
13 75.2 1.75 
14 76.5 2.05 
15 79.6 1.61 
16 81.2 1.72 
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Table 10.4 continued 
volunteer protein concentration mg/ml 
Young plasma purified fraction 
17 69.9 1.48 
18 66.3 1.05 
19 72.3 1.01 
20 74.2 1.25 
21 - 1.32 
22 82.5 - 0.37 
23 71.8 0.63 
24 77.2 0.75 
25a 68.1 1.40 
25b 68.1 1.17 
25c 68.1 1.61 
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Table 10.5 
Kinetic Results from Purified Cholinesterase 
_- 
Subject Vmar Purified Enzyme Km(mM) 
Aspirin 
Esterasei 
Cholinesterase2 Aspirin Esterase 
Frail Elderly 
1 109 317 4.2 
2 116 365 4.5 
3 44 158 3.2 
4 135 47 3.9 
5 92 " 444 3.4 
6s 46 283 2.7 
7 52 141 5.9 
8 170, 374 6.9 
Mean + SEM 80±17* 266±45* 4.3±0.5 
Fit Elderly 
9 111.4 446- 3.3 
10 53 482 3.8 
11 108 508 2.5 
12 233 1026 3.5 
13 109 398 4.0 
14 129 503 4.7 
15 113 508 3.0 
16 134 493 3.6 
Mean +SEM 124±17 546±65 3.6+0.2 
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Table 10.5 continued 
Subject Vmax Purified Enzyme Km(mM) 
Aspirin 
Esterasel 
Cholinesterase2 Aspirin Esterase 
Young 
17 107 491 3.8 
18 179 606 6.3 
19 155 630 3.3 
20 107 436 4.0 
21 125 34.4 6.0 
22 370 1310 4.2 
23 190 520 5.9 
24 305 1010 4.6 
25a 110+ 455++ 3.8 
25b 132 505 3.8 
25c 88 398 3.3 
Mean +SEM 183+30 645+105 4.7+0.4 
Key " 
1. nmol salicylate/mg protein /min. Calculated from the direct- 
linear plot. 
2. nmo1 benzoylcholine chloride hydrolysed/mg protein/min 
+ CV=16% 
+ +CV =11 % only the first value is used in the calculation of the 
means. 
* Significantly different from the young group p<0.05; F=4.85 
(aspirin esterase) ; F=3.87 (cholinesterase) 
Regression analysis between aspirin esterase and cholinesterase: 
r=0.93; t=34.4; p<0.0001 
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Table 10.6 
Summary of Data from Tables 10.3 and 10.5 
Frail Elderly Fit Eldgrly Young 
Aspirin Esterase Mean + SEM 
*Vmar 
purified enzyme 
+80±0.17 124±17 183±30 
pur cation 
factor 
29±2 30±2 26±3 
Km 4.3+0.5 3.6±0.2 4.7+0.4 
Cholinesterase 
**Vmax 
purified enzyme 
±266±45 564±16 645±105 
purification 
factor 
20±3 23±3 30±4 
* nmol salicylate produced/mg protein/min 
**nmol benzoylcholine chloride hydrolysed/mg protein/min 
+p < 0.05 compared with the young 
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10.3.3 Polvacrvlamide Gels 
The SDS gels, when stained for protein, (Plate 10a) showed the bands of protein 
present in pooled fractions of purified plasma with cholinesterase activity. These 
showed a very similar profile to the Sigma preparation of cholinesterase (gel 2; 
tracks 2 and 4). Comparison with molecular weight markers (12,300 - 78,000) 
indicated a band which had a similar Rf value to ovalbumin (Rf = 0.32). This 
protein also appeared to be present in a higher concentration in the Sigma 
preparation than purified plasma enzymes. Using the Sigma cholinesterase 
preparation as standard it was not possible to distinguish a protein band due to 
cholinesterase. However albumin (Rf = 0.54) was evident in each sample. 
The general esterase stain using naphthylacetate substrate is shown with a 5% 
non SDS gel (Plate 10b; gel 4). The general esterase activity is expressed as the 
nmol phenol produced per mg protein following incubation of an aliquot of 
purified fraction with phenylacetate, another general esterase substrate. 
The more specific cholinesterase stain is shown on a 7.5 % gel and there is only 
one band of activity (Plate 10b; gel3) 
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Plate 10a 
Purified Fractions Separated on SDS gels and stained for Protein. (7.5% gel) 
Gel 1. From left to right 
Track 1: Volunteer no 11 protein on gel: 68 pg 
Track 2: Volunteer no 24 protein on gel: 37 Vg 
Track 3: Volunteer no 6 protein on gel: 87 pg 
Track 4: Volunteer no 13 protein on gel: 88 pg 
Track 5: molecular weight markers range 12, 300-78,000 
Gel 2. From left to right 
Tracks 2 and 4: Sigma cholinesterase preparation 
Protein on gel: 35 pg 
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Plate 10b 
Purified Fractions Separated on Non-SDS Gel for Native Proteins 
Gel 3. Stained for Cholinesterase Activity (7.5% gel) 
Track 1: Volunteer no 20,15.2 u* of cholinesterase activity on 
gel. 
Track 2: Sigma cholinesterase preparation, 42 u of 
cholinesterase activity on gel. 
Track 3: Volunteer no 12,23 u of cholinesterase activity on 
gel. 
Track 4: Same as track 2. 
*u= Nmol benzylcholine chloride hydrolysed/min at 37°C. 
Gel 4. Stained for Naphthylacetate Esterase Activity (5 % gel). 
Tracks 1 and 4: Volunteer no 20,12.5 u ** of phenylacetate 
esterase activity on gel. 
Tracks 2 and 3: Sigma cholinesterase preparation, 32 u of 
phenylacetate esterase activity on gel. 
Tracks 5 and 6: Volunteer no 12,11.1 u of phenylacetate 
esterase activity on gel. 
** u= nmol phenol produced/min at 37oC. 
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10.3.4 Commercial Cholinesterase 
The Km and Vmax values for the cholinesterase preparation from human plasma 
produced by Sigma Chemical Co. were also calculated (Fig 10.9). The Km 
value was 5.0. mM and the Vmax was250nmol salicylate/ mg protein/min. The 
purification factor for this preparation was approximately 50 - fold (Table 10.7) 
when compared with a representative plasma. 
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Table 10.7 
Purification Factor of Sigma Chemical Co Preparation 
of Human Plasma Cholinesterase. 
Preparation units of Protein Specific activity Purification 
activity mg / ml U/ mg factor 
(U)* 
commercial 864 0.73 1183 50 
cholinesterase 
plasma 1606 68.1 21 - 
(volunteer 25 
*nmol benzoylcholine chloride hydrolyzed per ml per minute at 370C and 
0.05mM substrate 
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10.4 Discussion 
10.4.1 Kinetics 
The frail elderly were selected on the basis of a low aspirin esterase activity 
which enabled me to determine whether the Km values in the fit and frail elderly 
and young individuals altered as a consequence. The Km values obtained for 
three groups were not significantly different and were similar to those obtained 
in whole plasma in Chapter 8 and also to that of Valentino et al (1981) who 
calculated the Km value as 4.2 mM. 
If albumin contributed a significant degree of activity to aspirin esterase, 
removal of this protein would alter the affinity of cholinesterase enzyme for 
aspirin substrate. An increase in affinity would be apparent as a reduced Km 
value. This Km value would therefore be a measurement of the affinity of 
cholinesterase only for aspirin. 
The calculated Vmax values were expressed as nmol salicylate/mg protein/min. 
Because of the selection process the Vmax value of the purified fraction was 
significantly lower in the frail elderly (p < 0.05), as was the Vmax of plasma 
cholinesterase. These values were also dependent on the recovery of enzyme 
activity after purification. The mean recovery of activity for both enzymes 
between the three groups was not significantly different. The two Vmax values 
were also significantly correlated, again confirming the relationship between the 
two enzymes. 
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10.4.2 Purification Procedure 
Lockridge and La Du (1982) used 10 1 of human plasma in order to obtain 12 
mg yield of electrophoretically pure cholinesterase. This had a specific activity 
of 200 pmol benzoylcholine chloride hydrolysed/mg/min at 25°C. This was 
determined using the same assay as I used (Kalow and Lindsay, 1955). Thus, 
these results can be related to my results and used in order to obtain an 
approximation of the amount of cholinesterase in my purified protein fractions. 
If we consider the results from subject 13 whose purified cholinesterase fraction 
had a specific activity of 398 nmol/mg/ml at 37°C. This is equivalent to 217 
nmol/mg/min at 250C using the temperature correction factors supplied by King 
(1965). It is therefore approximately 900 times less pure than the samples 
obtained by using affinity chromatography (200,000: 217 nmol/mg/ml). 
Lack of protein material from clinical sample restricted subsequent analytical 
procedures. SDS-PAGE was useful in order to show other proteins present, 
however. Using a coomassie blue stain for protein it was possible to detect 0.2 - 
0.5 pg protein in each band (Hames, 1985). 50 ul of sample was the maximum 
volume which could be applied to each sample well of the gel. In the case of 
volunteer 13 this volume would obtain 87.5 ug total protein (1.75 mg/ml; Table 
10.4) of which 97.2 ng would be pure cholinesterase (87.5 pg = 900). This was 
insufficient to be detectable with coomassie blue stain on this gel. 
Using Electron molecular weight markers, the albumin band was indicated (Plate 
10a; gel 1). Even though approximately 97% of the albumin is removed, 
about 1.2 g/1(ie 3%x 40 g/l) remains. Again, considering volunteer 13, if 3% 
of the fraction protein content was albumin, then this was equivalent to 
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52 pg/ml (ie 1.75 mg/ml x3 %). In a sample volume of 50 pl this would mean 
that approximately 2.6 ug albumin may be present which will be strongly 
evident stained on an SDS gel, but as a proportion of the original concentration 
is very small. 
Non-SDS native gels were a sensitive visual means of showing esterase activity 
(Plate 10b, gels 3 and 4). Unfortunately, because the cholinesterase enzyme is a 
tetramic structure of molecular weight 340,000, it remains as a very large 
molecular form which does not resolve successfully even on a5% 
polyacrylamide gel (Plate 10b; gel 4). This was also confirmed by Lockridge et 
al (1979). 
Lockridge et al (1987) proposed that serum cholinesterase consisted of four 
identical subunits held together by covalent bonds. On SDS gels the resultant 
bands from pure cholinesterase appeared to be due to monomers and dimers. 
This degree of analytical process would require amounts of plasma vastly in 
excess of that available in a clinical situation. 
The small amount of cholinesterase in human plasma may also be one of the 
reasons for the unsuccessful attempts by other workers in this laboratory to stain 
for aspirin esterase activity (Wood and Williams, personal communication) using 
thioaspirin substrate (White and Hope, 1981). 
The purified human cholinesterase from Sigma Chemical Co had a purification 
factor of approximately 50-fold based on a plasma protein content of 68 mg/ml. 
This was almost twice the value I achieved (Table 10.3), although not nearly as 
pure as that acheived by affinity chromatography (Lockridge and La Du, 1978). 
CHAPTER 11 
Blood Esterase Activity Measurements in Young; Fit and 
Frail Elderly 
152 
Chapter 11 
Blood Esterase Activity Measurements in Young. Fit and Frail Elderly 
11.1 Introduction 
The aim of this section of work was to establish normal ranges of several blood 
esterase activities in the young; fit and frail elderly. The esterases of interest 
included: red blood cell acetylcholinesterase and arylesterase and the plasma 
esterases: aspirin esterase, cholinesterase, phenylacetate esterase and 
paraoxonase. There are existing literature levels for aspirin esterase and 
cholinesterase (Williams et al, 1989) but other established ranges using the same 
methods have been only in fit, young people (Mutch et al, in press). 
11.1.1 Plasma Aspirin Esterase and Cholinesterase Activity 
The range of activity in young; fit and frail elderly has already been established 
earlier in this thesis. The fit elderly had a range of plasma aspirin esterase 
activity (nmol salicylate/ml plasma/min): 93.7 - 172.8, mean ± SEM 119.2. ± 
10.3, n=7; frail elderly: 66.6 - 112.4, mean ±SEM 88.3. ± 5.5, n= 10 and 
young: 93.7 - 193.8, mean f SEM 114.5 ± 9.2, n= 10. Williams et al (1989) 
also established ranges using larger numbers of individuals and these results are 
summarized in Table 11.4. 
The assay for cholinesterase activity described in Chapter 8 of this thesis was 
carried out at 37°C, that by Williams et al (1989) at 25oC and the measurements 
in this section at 300C. For this reason it was necessary to use the temperature 
correction factor advocated by King (1965) in order to allow a direct comparison 
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of all three groups of data. The results I obtained for all three groups at 370C 
are as follows: (nmol benzoylcholine chloride/ml plasma/min. fit elderly) 1345 - 
2410, mean ± SEM 1731 ± 139, n=7; frail elderly: 480 - 1570, mean 1183 
± 145, n=7 and young: 990 - 2435, mean ± SEM 1666 ± 140, n=9. 
11.2 General Meth 
11.2.1 Selection of Subjects 
These were recruited by Dr H Wynne (Consultant in Geriatric Medicine). Frail 
elderly were selected from local long-stay geriatric hospitals, the fit elderly from 
local social clubs and the young from hospital and University colleagues, as 
described in Chapter 8. 
All the samples were treated as soon as possible after collection as described in 
Chapter 8. In addition, for these series of experiments, the red blood cells were 
also used. This is described in 11.3.1 
11.2.2 Storage of Sam 
The samples required storage for a reasonably short period of time (maximum of 
two months). During this time it is essential that the original esterase activity 
was maintained. Turner et al (1984) found plasma cholinesterase was retained 
for more than twelve months when stored at -200C, and thus plasma aspirin 
esterase activity will also be stable for this period. 
Mueller et at (1983) found plasma paraoxonase activity was retained for up to 
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one year at -700C. Reiner et al (1989) showed plasma phenylacetate activity 
was stable at -15oC for at least seven weeks. 
The stability of the red blood cell esterases needed to be established and this was 
done by comparing the activity of fresh cell preparation with aliquots stored at 
-800C over a few days. 
11.2.3 Linearity of the Reactions 
For enzyme mediated reactions it is necessary to confirm that optimal conditions 
are maintained throughout the time period of product formation and correlation 
of the regression line is continually monitored. 
Linearity with time could be visually judged in those assays which involved the 
continual monitoring of product formation. Red blood cell esterase activity was 
measured by an end point method and thus a time curve was necessary to 
confirm linearity. 
Protein concentration in the incubation was varied as indicated in the 
corresponding graphs and all other conditions were kept constant. 
Substrate activity curves were also executed. These confirmed that activity 
measurements were taking place at the maximal enzyme rate. Thus product 
formation would minimally reduce substrate concentration. 
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11.3 Red Blood Cell Acetvlcholinesterase 
The method used is a modification of the Ellman reaction (Ellman et al, 1961) 
by Kaplan (1964). 
The technique uses the specificity of acetylcholinesterase for acetylthiocholine 
which is an analogue of the natural substrate. Thiocholine is released when 
acetylthiocholine is hydrolysed. This continually reacts with the colour reagent 
5: 5-dithobis-2-nitrobenzoate. The yellow colour is due to the action 5-thio-2- 
nitrobenzoic acid, the rate of formation of which is measured at 412 nm on a uv 
spectrophotometer. 
11.3.1 Treatment of Blood Sample 
The blood was collected and treated as usual. 
The washed red cells were resuspended in an equal volume of saline. This was 
mixed well and a small sample removed for determination of the red cell count 
and haemoglobin concentration (Department of Haematology, Royal Victoria 
Infirmary, Newcastle Upon Tyne). From the remainder, 20 pl was removed 
using a positive displacement pipette and added to 4.98 ml distilled water. This 
was vortexed and frozen at -80°C until solid. On removal it was allowed to 
thaw at room temperature and then 5.0 ml of 0.2 M phosphate buffer pH 8.0 
was added. This was vortexed again and stored at -800C until analysis within 24 
hours. (Mutch et al, in press). 
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11.3.2 w. Metho 
Reagents 
0.2 M phosphate buffer pH 8.0 
0.1 M phosphate buffer pH 8.0 
0.1 M phosphate buffer pH 7.0 
6.5 mg/10 ml physostigmine sulphate 
Colour Reagents 
5: 5-dithiobis-2-nitrobenzoic acid (DTNB) 
DTNB 39.6 mg } 
} 10 ml phosphate buffer pH 7.0 
NaHCO3 15 mg } 
Substrate: 
Acetylthiocholine iodide 130.2 mg in 6 ml water containing 60 1 HC1 
(ACTH) 
Plasma esterase inhibitor: 
Quinidine sulphate 1 mg/ml 
Combined Reagent: 
ACTH 6 ml 
DTNB 7.5 ml 
Quinidine Sulphate 3.0 ml 
Mixed well, aliquoted and stored at -20oC 
Assay 
The blood preparation was allowed to thaw at room temperature. The incubation 
mixture in the spectrophotometer cuvette consisted of 1.95 ml 0.1 M phosphate 
buffer pH 8.0 and 1 ml of lyzed, diluted red blood cells. A parallel blank 
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consisted of 1.85 ml buffer, 1 ml lyzed, diluted red blood cells and 100 ju 
1 of 
physostigmine sulphate solution. 50 ul of combined reagent was added to each 
cuvette which were inverted to mix. 
The rate of formation of 5-thio-2-nitrobenzoic acid was measured at 412 nm on a 
uv spectrophotometer at 300C. The results were expressed as nmol 
thiocholine/mg haemoglobin /min. The reaction was shown to be linear with 
protein (Fig 11.1) and the activity is measured at maximum enzyme activity (Fig 
11.2). 
11.4 Plasma Paraoxonase 
Paraoxonase, which hydrolyses the organophosphate paraoxon and has been 
thought to be the cysteine containing A esterase which hydrolyses phenylacetate 
and similar aromatic esters (Eckerson et al, 1983b). However Mackness et al 
(1987a) maintain that paraoxonase and arylesterase activities can be separated 
and have done so using avian plasma. 
11.4.1 Amy 
The substrate is paraoxon which, as an organophosphate requires very careful 
handling. It was essential to wear gloves at all times. The reagent was prepared 
for use by aliquoting an appropriate amount into dry acetone to a final 
concentration of 103 pmol/ml. 2.92 ml 50 mM glycine buffer containing 1 
mM calcium chloride, 50 p1 plasma and 30 pl of stock paraoxon was added. 
This was incubated at 300C and the rate of formation of yellow paranitrophenol 
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was continually monitored for a 2.5 minute period at 412 nm on a uv 
spectrophotometer. This was carried out in duplicate and a blank was incubated 
in parallel to correct for the spontaneous hydrolysis of paraoxon. This did not 
exceed 20% of enzymatic hydrolysis. The results were expressed as nmol 
paranitrophenol produced/ml plasma/min: 
The reaction was shown to be linear with protein (Fig 11.3) and the activity was 
measured at maximum enzyme activity (Fig 11.4). 
The interassay CV was 1% (n = 3; at a plasma paraoxonase activity of 97.4 
nmol paranitrophenol produced/ml plasma/min). 
11.5 Plasma Phenylacetate Esterase 
Phenylacetate is a substrate for plasma arylesterase activity in human plasma. 
The method used is a modification of that described by Williams et al (1986) and 
involves the continuous monitoring of phenol formation. 
11.5.1 Assay 
3.0 ml of Tris - HC1 buffer pH 8.0 containing 10 mM Calcium chloride, 5 }i1 
plasma and 10 p10.2 mM physostigmine were mixed and incubated in triplicate 
at 3000 in a spectrophotometer cuvette. 15 pl of phenylacetate (600 mM) in 
dimethylsulphoxide was added to start the reaction. The formation of phenol 
was monitored at 272 nm on a uv spectrophotometer over a one minute time 
period. 
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Physostigmine was added in order to inhibit any hydrolysis of phenylacetate by 
cholinesterase which I found occured in purified plasma fractions. In fact there 
was no convincing measurable decline in activity. 
The presence of calcium ions ensures maximal activity of the esterase (La Du 
and Snady, 1971). The reaction was linear with protein (Fig 11.5) and was 
measured at maximum enzyme activity (Fig 11.6). The results were expressed as 
nmol phenol produced/ml plasma/min. The interassay CV was 2.2% (n = 4; at 
a plasma phenylacetate esterase activity of 106.8 nmol phenol produced/ml 
plasma/min). 
11.6 Red Blood Cell Esterase Activity 
Unlike acetylcholinesterase, red blood cell aspirin esterase is an intracellular 
enzyme. Rylance and Wallace (1981) demonstrated the high aspirin esterase 
activity of intact red blood cells with red cell stroma. 
Costello and Green (1983) identified a RBC hydrolase as the major determinant 
of in vitro aspirin survival in human blood and postulated that it was a non- 
specific arylesterase. Later work involving the correlation of in vivo aspirin 
survival with haemocrit in dogs confirmed the in vitro work (Costello and 
Green, 1984). 
The method employed in this study uses phenylvalerate as substrate for the red 
blood cell hydrolase. Costello and Green (1983), using various inhibitors 
(sodium fluoride) and activators (metal ions), suggested that this arylesterase 
actually had some properties which belonged more to carboxylesterases. Thus it 
is highly probable that esterase activity measured by the hydrolysis 
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hydrolysis of phenylvalerate is an indirect measure of intracellular red blood 
cell aspirin esterase. 
The assay uses the observation by Emerson (1943) that 4-aminoantipyrine 
condenses with aromatic aminos in the presence of acid oxidizing agents and 
with phenols (Gottlieb and Marsh, 1946). Thus a colour test for phenols was 
developed. The proposed structure of the dye formed during this reaction is 
shown in Fig 11.7. Substitution is thought to occur in the para-position to the 
phenolic - OH group (Emerson, 1943). 
In this assay acetylcholinesterase activity was inhibited with physostigmine. 
Attempts were made to measure aspirin esterase activity directly using aspirin 
substrate and analysis of the supernatant following incubation, precipitation of 
the protein and High Perfomance Liquid Chromatography of the sample. 
However this proved unsuccessful due to poor duplication. 
11.6.1 Method 
Preparation of Patient Samples 
The red cells were prepared and washed as in the method for Red Blood Cell 
Acetylcholinesterase (see 11.3). The washed red cells were aliquoted and frozen 
at -800C until analysis within 24 hours. An aliquot was also sent to The 
Department of Haematology, RVI to obtain the red cell count. 
Freezing lyzes the cells and releases the intracellular esterase. 
167 
Figure 11.7 Formation of the Red Antipyrine Dye 
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Reagents 
Phenylvalerate 15 mg/ml in redistilled dimethylformamide 
0.3 % Triton X-100 in water 
50 mM Tris-HC1 with 0.2 mM EDTA buffer pH 8.0 
1.05% sodium dodecylsulphate (SDS) in the above 
0.5 % 4-aminoantipyrine (AAP) in 0.5 M Tris buffer pH 9.0 
0.4% Potassium ferricyanide (K3 Fe (CN)6) 
Working Solutions 
(Freshly prepared for each assay). 
Substrate 
2 ml of phenylvalerate (PhV) is added to 29 ml triton stock solution. Final 
concentration is 1 mg in 3.5 ml incubation volume. 
Reaction Inhibitor 
2 ml AAP is added to 18 ml Tris-SDS buffer. 
Colour Developer 
1 ml of 0.4% K3 Fe (CN)6 is added to 9 ml H20. 
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Assay 
The red cell aliquot was diluted 1 in 2 with 50 mM Tris-HC1 containing 0.2 mM 
EDTA pH 8.0.25 pl of this preparation was dispensed into a tube using a 
positive displacement pipette, 10 pl of physostigmine in saline to give a final 
concentration of -2 mM was also added and the volume made up to 1 ml with 
Tris-HC1 and EDTA buffer. This was repeated in duplicate (A). In a second 
pair of tubes all but the red cell aliquot was added (B), and the third pair of 
tubes (the blanks) contained the same as the first two at this stage (C). These 
six tubes were all required for measuring enzyme activity in one blood sample 
only. 
These tubes were vortexed and preincubated at 370C for 5 minutes with gentle 
shaking. 1.0 ml of 30% Triton-X was added to the blank tubes (C). 1.0 ml of 
substrate was added to tubes (A) and (B), these were vortexed and returned to 
the water bath at 370C for gently shaking for 25 minutes. 
After 25 minutes, the tubes were removed and placed on ice. The reaction was 
stopped by adding 1.0 ml reaction inhibitor. The 25 pl of 1 in 2 red cell 
preparation was added to tube (B). This measured the spontaneous hydrolysis of 
phenylvalerate at 37oC for 25 minutes and the addition of the red cell aliquot at 
this stage ensured the reaction had stopped before enzyme in the red cells was 
added. This was vortexed thoroughly. 
The colour developer was added as a 0.5 ml aliquot and the tubes were vortexed 
a final time. 
The colour change was measured in a direct reading uv spectrophotometer at 
170 
510 nm against the blank tubes. A QC for enzyme activity is not possible in this 
particular assay because the enzyme activity appears to deteriorate with time. 
A typical standard curve is shown in Fig 11.8. The results were expressed as 
nmol phenol produced/106 RBC/min. 
The reaction was shown to be linear with time at the lowest substrate 
concentration (Fig 11.9) and linear with protein at phenylvalerate concentrations 
of 0.05 mg (Fig 11.10), 1 mg (Fig 11.11) and 2 mg (Fig 11.12). A typical 
substrate curve is shown in Fig 11.13. 
Standard Curve 
A stock solution of 1 mM phenol in water was prepared. 125 pl, 250 pl, 500 
pl of phenol stock solution was pipetted into a series of tubes to contain 125,250 
and 500 nmol of phenol respectively. This was made up to volume with water 
1.5 ml 50 mM Tris-HC1 with EDTA was added to each tube and mixed, then 
1.0 ml of reaction inhibitor was added and mixed. Finally 0.5 ml colour 
developer was added and mixed. The colour intensity was measured against a 
blank containing no phenol at 510 nm in a uv spectrophotometer. 
11.7 Results 
The patient details are summarized in Table 11.1. The frail elderly were 
receiving more regular medication than the fit elderly or young. 
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Table 11.1 
Volunteer Details 
Volunteer 
(sex) 
Frail Elderly 
Age 
( years) 
Albumin 
(g11) 
Drugs (if any) 
1(F) 93 34 doch; in codeine phosphate, 
2(M) 88 34 
3(F) 84 35 rnvem; de, salbutamoº, tmoxicen, "ºose. 
haºoperidol, ehºormc hiazoºe, 
carbamaz ine thioridaz; ne 
4(F) 81 33 
5(F) 85 39 
6(F) 88 29 docuaate. bendroauaz; de. chlormethiazoºe, 
morphine sulphate 
7(F) 88 33 
8(F) 86 37 ehºom, ethiazoºe 
9(F) 81 35 
10(F) 88 30 paracetamol, codeine phimphate 
11(F) 85 33 dothi in diazepam 
12(F) 86 29 
codeine phosphate mknºax enema 
13(M) 70 36 
14(M) 86 41 halo r; doº ranitidine, paracetamol, send 
15(M) 90 38 mod ma, senne 
16(F) 91 37 doch; in mcetamo,, em., 
17(F) 94 35 d; oxin cline chºormethiazole 
18(F) 95 36 ranitidine nwetamo,. em,. 
19(F) 85 38 ranitidine paracetamol, send 
20(F) 96 37 
-I 
i 
Mean 
.: 
L SEM 87± 1.3 35.0±0.7 
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Table 11.1 continued 
Volunteer 
(sex) 
Fit Elderl 
Age 
( years) 
Albumin 
(g/l ) 
Drugs (if any) 
21(M) 65 45 warfarin 
22 (F) 91 35 
23M 86 - dioxin, thyroxine 
24(M) 73 - 
25(F) 68 - 
26(F) 74 39 
27(F) 80 44 
28(F) 71 38 
29(F) 84 44 
30(M) 60 44 amilodi ine 
31(F) 87 44 
32(F) 81 42 
33(F) 73 40 
34(F) 79 39 
35(F) 72 39 
36(F) 78 47 
37(M) 79 41 
38 (F) 84 43 
39(M) 70 46 
40(F) 75 40 
Mean ± SEM 76.5. ±1.7 41.8±0.8 
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Table 11.1 continued 
Volunteer 
(sex) 
Young 
Age 
( years ) 
41(M) 23 
42(F) 22 
43(F) 22 
44 (F) 23 
45(F) 25 
46(F) 21 
47(F) 21 
48(M) 21 
49(M) 22 
50(F) 24 
51(M) 24 
52(F) 22 
53(F) 29 
54(F) 28 
55(F) 22 
56(F) 28 
57(F) 28 
58(F) 27 
59(F) 24 
60(F) 26 
61(F) 26 
62(F) 28 
Mean ±SEM 24.2. ±0.6 
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Table 11.2 and 11.3 show individual esterase activities in detail and Table 11.4 
is a summary of these results. The final column in Table 11.4 shows a 
comparison of the results I obtained for plasma aspirin esterase and 
cholinesterase in young and fit elderly and in frail elderly (Chapter 8) and the 
results of Williams et al (1989) using the temperature correction factors of King 
et al (1965) as appropriate. I obtained a much greater range of activities in a 
smaller group for both these enzymes than Williams et al (1989). My range of 
activity for plasma aspirin esterase in the frail elderly was 27.1 - 97.9 (mean = 
64 nmol salicylate/ml plasma/min, n= 20) compared with 75.1 - 83.0 (mean = 
78.9 nmol salicylate/ml plasma/min, n= 43; Williams et al, 1989). The 
cholinesterase activities showed a similar profile where my range was 609-1863 
nmol benzoylcholine chloride hydrolysed/ml plasma/min ( mean= 1174, n=20) 
compared with that of Williams et al: 1523 - 1940 nmol benzoylcholine chloride 
hydrolysed/ml plasma/min (mean: 1731, n= 43). The lower mean value had 
major implications which will be discussed in Chapter 12. The plasma aspirin 
esterase and cholinesterase activities showed a significant correlation at 
p<0.001 (t = 6.8) as shown in Table 11.3 and Fig 11.14 . 
The paraoxonase and phenylacetate esterase activities in the frail elderly were 
significantly reduced at the 5% significance level (mean: 100. --E 7 and 65 ±4 
respectively) compared with the fit elderly (mean: 146 ±9 and 83 ±6 
respectively) and the young (mean: 144 ± 10 and 99 ±4 respectively). 
Phenylacetate hydrolysis was significantly lower in the frail elderly compared 
with the young at p<0.001 and at p<0.01 paraoxonase activity in the frail 
elderly was significantly lower than that in that in the young and fit elderly 
subject groups. Esterase activities in the three groups is shown in Fig 11.15 . 
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Table 11.2 
Normal Ranges for Blood Esterases in Young: Fit and Frail 
Elderly 
Volunteer 1Paraoxonase 
* 
2PhAc 
* 
RBC x 
1012/1 
3RBC 
Esterase+ 
4RBC 
Ache+ 
Frail 
1 152.0 95.7 4.26 189 42.9 
2 47.2 56.8 3.22 103 42.6 
3 106.9 73.7 4.29 138 56.3 
4 50.1 53.7 4.72 105 38.9 
5 138.3 85.4 3.83 119 44.7 
6 121.1 80.6 4.14 110 34.2 
7 61.1 43.5 3.75 134 31.0 
8 160.5 98.8 4.43 214 34.7 
9 93.6 76.7 4.10 134 35.8 
10 86.9 74.1 3.84 122 38.2 
11 107.0 69.6 3.15 82 42.6 
12 66.8 37.3 4.07 119 34.9 
13 109.0 58.4 4.90 156 - 
14 137.0 75.9 3.5 134 - 
15 98.6 52.8 4.43 92 - 
16 106 53.9 4.64 89 - 
17 96.9 78.9 4.22 170 - 
18 113.6 54.6 3.63 122 - 
19 66.8 57.9 3.25 109 - 
20 71.8 35.9 3.63 - - 
Mean +SEM 100+7 65±4 4.0±0.1 128±8 40±2 
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Table 11.2 continued 
Volunteer 1Paraoxonase 
** 
2PhAc 
** 
3RBC 
Esterase+ 
4RBC Ache 
++ 
Fit Elderly 
21 191.2 85.9 130 - 
22 92.5 55.7 128 - 
23 190.2 107.1 124 - 
24 113.1 66.6 99 - 
25 137.0 84.7 140 - 
26 135.4 92.9 132 - 
27 170.3 110.6 115 - 
28 97.6 54.3 138 - 
29 145.1 95.7 137 - 
30 117.1 68.0 131 - 
31 243.8 136.7 116 - 
32 107.2 88.2 140 - 
33 97.0 54.9 128 - 
34 114.8 65.4 133 - 
35 110.5 29.5 98 - 
36 200.6 116.8 108 40.2 
37 195.1 84.2 139 42.7 
38 166.3 108.2 144 38.1 
39 124.9 68.9 103 33.9 
40 160.3 93.2 144 38.3 
Mean+SEM 146±9 83±6 126±3 39±1 
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Table 11.2 continued 
Volunteer 1Paraoxonase 
*** 
2PhAc 
*** 
3RBC 
+++ 
Esterase 
4RBC Ache 
+++ 
Young 
41 116.4 86.8 94 36.6 
42 134.0 117.1 135 34.3 
43 178.9 118.1 116 36.2 
44 138.7 94.0 152 35.5 
45 167.7 131.1 108 32.8 
46 131.8 108.2 115 32.4 
47 142.3 116.2 92 31.8 
48 131.5 71.4 132 42.8 
49 127.0 102.8 97 39.2 
50 90.0 98.5 145 42.1 
51 167.1 85.5 94 38.3 
52 113.8 85.3 - - 
53 78.5 79.0 119 51.6 
54 194.5 117.5 136 39.5 
55 129.0 96.1 131 38.9 
56 106.9 68.3 85 - 
57 167.6 104.5 131 - 
58 223.3 107.8 82 - 
59 265.7 87.2 - 31.2 
60 164.0 120.9 143 38.3 
61 93.6 76.6 126 - 
62 96.9 111.6 - - 
Mean+SEM 144±10 99±4 117+5 38±1 
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Key for Table 11.2 
* r= 0.77; t=5.1 Significant correlation at p <0.001 
+r=-0.08; t=-0.25 
**r=0.83; t=6.3 Significant correlation at p <0.001 
++r=0.45; t=0.87 
***r=0.34; t=1.6 
+++r=0.23; t=0.88 
1 nmol pnp/ml plasma /min 
2Nmol phenol/ml plasma/min 
3nmol phenol/106 RBC/min 
4nmol thiocholine /mg haemoglobin/min 
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Table 11.3 
Plasma Aspirin Esterase and Cholinesterase Activities 
in the Frail Elderly Subjects 
Frail Volunteer Aspirin Esterase 
nmolsalicylate 
/ml plasma/min 
Cholinesterase 
nmol benzoylcholine chloride 
hydrolyzed/ml lasma/min 
1 60.4 788 1119 * 
2 27.1 429 609 
3 70.8 620 880 
4 74.9 933 1325 
5 75.0 1030 1463 
0 Jv. L 00. ) 711 
7 56.2 588 835 
8 87.4 1227 1742 
9 75.0 832 1181 
10 85.4 865 1228 
11 35.2 538 764 
12 45.6 636 903 
13 87.4 1135 1612 
14 68.7 1061 1507 
15 66.6 923 1311 
16 97.9 1312 1865 
17 77.0 1106 1571 
18 50.0 780 1108 
19 37.5 445 632 
20 43.7 602 855 
Mean ±SEM 64±4 827±57 1174±80 
r= 0.84 ; t= 6.8. Significant correlation at p<0.001. * corrected to an 
assay temperature of 370C from 300C using the correction factor 1.42 
( King et al, 1965) 
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Figure 11.14 
Title : The correlation between plasma aspirin esterase activity 
and cholinesterase activity in 20 frail elderly volunteers. 
Ordinate : Aspirin esterase activity at 1 Mm aspirin concentration and at 37°C 
Abscissa : Cholinesterase activity at 37°C 
p< 0.001 correlation significantly different from zero 
188 
300 Mean : young = 138 
fit =146 
a frail =100 ". 5 n 
0 
200 
a aaD 
p. a 
Gomm aaa a 
ctS Q $p 
naaa 
aa 
0 
as 
100 aaa 
öga =ooý 
r oaa Goa 
oo a 
_ a' a 
a 
Sao 
as 
0 
young fit elderly frail elderly 
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Abscissa : Values in young; fit and frail elderly 
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and 11.16. In addition the frequency distributions for paraoxonase activity is 
plotted in Fig 11.17,11.18 and 11.19. There is no evidence of bimodality in 
any of the three groups. 
There was also a significant correlation between paraoxonase and phenylacetate 
esterase activity in the frail and fit elderly at p<0.001 (t = 5.1 and t=6.3 
respectively) as shown in Table 11.2 and Figs 11.20 and 11.21, but not in the 
young (r=0.34, t=1.6) 
Red Blood Cell Esterases 
Figures 11.22 and 11.23 show the distribution of RBC esterase activity and RBC 
acetylcholinesterase activity in the three groups. There was no significant 
correlation between the intracellular RBC esterase and membrane bound 
acetylcholinesterase (Table 11.2). The mean number of red blood cells in the 
frail elderly individuals is 4.0 X1012. ± 0.1/1 (Table 11.2). Unfortunately, these 
were only obtained for the frail elderly subjects and so these values were 
compared with the usual reference values. The mean value for females was 
3.95x1012 ± 0.1/1 which was at the lower end of the normal range (3.9 - 5.6 x 
1012/1). The mean value for the four male subjects was 4.0 x 1012. ± 0.3/1 
which is below the normal range for men (4.5 - 6.5 x 1012/1). 
Figures 11.24 and 11.25 show a decline in red blood cell acetylcholinesterase 
and intracellular esterase activities with increased storage time, respectively. As 
a result both these assays were carried out within 24 hours of blood sample 
collection. 
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Figure 11.17 
Title: The distribution of paraoxonase activity 
in frail elderly individuals (n=20) 
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Figure 11.18 
Title: The distribution of paraoxonase activity in 
fit elderly individuals (n=20) 
Ordinate: number of individuals 
Abscissa: plasma paraoxonase activity 
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Figure 11.19 
Title: The distribution of paraoxonase activity in 
young individuals (n=20) 
Ordinate: number of individuals 
Abscissa: plasma paraoxonase activity 
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Figure 11.20 
tween plasma phenylacetate esterase activity 
and naraoxonase activity in 20 frail eld erly volunteers. 
Ordinate : Plasma phenylacetate esterase activity at 30°C 
Abscissa : Plasma paraoxonase activity at 30°C 
p< 0.001 correlation significantly different from zero 
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Title : The correlation between plasma phenvlacetate esterase activity 
and paraoxonase activity in 20 fit elderly volunteers 
Ordinate : Plasma phenylacetate esterase activity at 30°C 
Abscissa : Plasma paraoxonase activity at 30°C 
p<0.001 correlation significantly different from zero 
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Figure 11.22 
Title: Red blood cell esterase (RBC) activity in young: fit 
and frail elderly. 
Ordinate : RBC esterase activity, nmol phenol produced by 
106 RBC in a1 min. time period at 37°C 
Abscissa : Values in young; fit and frail elderly 
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Ordinate: nmol of thiocholine produced per mg of haemoglobin 
over a1 min. time period at 30°C. 
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The values are the mean of two determinations. 
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11.8 Discussion 
Plasma aspirin esterase, cholinesterase, paraoxonase and phenylacetate esterase 
(arylesterase) activities were all significantly reduced in the frail elderly. 
Williams et al (1989) also found this to be the case with plasma aspirin esterase, 
cholinesterase and phenylacetate esterase. 
Playfer et al (1977) investigated plasma paraoxonase activities in old age and 
found no reduced activity. However the elderly population he used was a cross- 
sectional sample of people from nursing homes, long-stay geriatric hospitals and 
healthy elderly living independent lives at home. 
Zech and Zurcher (1974) state that the average phosphoryl phophatase activity of 
older persons is lower but give no details of patient type, age etc. 
My sample of frail elderly people had a mean age almost ten years above that of 
the fit elderly. This highlights the constant problem of finding suitable age- 
matched controls for studies involving frail elderly subjects. 
Phenotyping of paraoxonase activity is carried out by means of frequency 
distributions resulting from qualitative properties of the enzyme such as 
stimulation by 1M sodium chloride (Eckerson et al, 1983a). Using small 
populations it isn't possible to identify the presence or absence of bimodality 
with certainty (Jackson et al, 1989). Since my samples were randomly selected 
on this basis, I assumed they were unimodally distributed. There was no 
evidence of bimodality when the activities were plotted as frequency 
distributions (Fig 11.17,11.18,11.19). The assay I used measured paraoxonase 
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activity in an alkaline medium, thus both the activities of EDTA-sensitive 
enzyme and EDTA-insensitive albumin are determined. The reduced 
paraoxonase activity in the frail elderly may, in part, be due to a reduced 
albumin content of the plasma. 
Plasma paraoxonase and phenylacetate esterase activities were highly correlated 
in the fit and frail elderly individuals. La Du and Eckerson (1984) also found a 
high correlation between the activity of the two esterases and concluded that this 
would be expected if the two enzymes were identical. They explained the 
bimodality of paraoxonase and unimodality of arylesterase activity by suggesting 
that paraoxon was a 'discriminating' substrate and phenylacetate a 
'nondiscriminating' substrate (Eckerson et al, 1983b). 
However, this correlation was not repeated in the fit young, which, together with 
results in Chapter 12 suggests that the relationship between the two esterases 
may not be quite so simple. Mackness et al (1987a) differentiated between 'A'- 
esterase (paraoxonase) and arylesterase (phenylacetate esterase) activity in avian 
plasma. As a result the two enzymes are now classified separately (Mackness, 
1989). 
I obtained lower limits of activity for cholinesterase (480 - 1570) and aspirin 
esterase (66.6 - 112.4) than Williams et al (1989) (1523 - 1940 and 75.1 - 83.0 
respectively), using similar methods, although I did have similar upper limits. 
These esterases, together with phenylacetate esterase (Takahashi et al, 1967) and 
paraoxonase (Playfer et al, 1977) are produced in the liver and are good 
peripheral markers of protein synthesis. Low activities may be due to reduced 
protein synthesis (Brown et at, 1981). This resulted in unforeseen problems 
202 
retaining patients recruited in the following study (Chapter 12). 
There was no correlation between intracellular RBC esterase and AChE. 
Neither of these showed a reduced activity when expressed per 106 RBC. 
However the mean RBC number in the frail elderly was lower than the normal 
range which suggests that these enzyme activities may be reduced due to the 
increased tendency of these individuals to suffer from chronic anaemias 
(Weatherall, 1987). 
CHAPTER 12 
The Effect of Improved Nutrition on Plasma Esterase 
Activity in a Hospitalized Frail Elderly Population 
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Chapter 12 
The Effect of Improved Nutrition in Plasma Esterase Activity in a 
Hospitalized Frail Elderly Population. 
12.1 » Introduction 
The reasons for the reduced plasma esterase activities demonstrated in the frail 
elderly individual are probably multi-fold (Williams et al, 1989; Summerbell et 
al, 1990). They may be a general marker of declining protein synthesis in these 
individuals. Low activities of cholinesterase have been noted in individuals 
preceding death (Brown et al, 1981). Serum cholinesterase activity has been 
found to correlate significantly with mid-arm circumference (MAC) and triceps 
skinfold thickness (TSF) in men but its use for assessment of nutritional status 
remains speculative (DHSS 1979a). Some workers have observed increases in 
plasma esterase activities in humans as the result of improved diet (Waterlow, 
1950; Burch et al, 1957). Others have noted diet-modifying effects on 
cholinesterase activities in the liver and plasma of rats (Kean et al, 1986; Osada 
et al, 1989). These have been discussed in greater depth in the General 
Introduction. 
In studies of a similar population of frail elderly patients to those used in these 
studies, Lipski et al (in press) noted the energy intake of these individuals was 
only 65 % of calculated daily requirements. This results in the predisposition of 
such a group to subclinical malnutrition. This may become evident as an 
increased tendency to suffer from infections, fracture events, cognitive 
impairment etc (Beaumont and James, 1985). 
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Background 
Malnutrition occurs when an individual's average dietary intake falls below that 
required to maintain a positive energy balance (ie energy intake is equal to or 
exceeds energy expenditure); and to maintain tissue and organ integrity and 
function. Individuals vary in their requirements depending on their sex, age, 
stature and daily expenditure (ie occupation). 
Malnourishment amongst elderly people in institutional care has been widely 
reported. (Exton-Smith et al, 1965; Davies, 1984). People suffering from 
severe mental or physical incapacity are most at risk since both affect the ability 
to obtain and prepare food. Table 12.1 shows the recommended daily intake of 
the major nutrients in the elderly . These are the results 
from a 1979 survey 
which have been superceded by a more recent report published in 1991 (DHSS, 
1991). Nevertheless it is still useful as a summary and guideline of nutrient 
needs since the 1991 report is less general concerning the specific nutrient 
requirements of adults above 59 years old. 
Poor nutrition is associated with general weakness and disability and may be a 
factor in the aetiology of dementia (Goodwin et al, 1983). Attempts have been 
made to improve the prognosis of dementia by dietary means. Lecithin in the 
diet is a source of choline, a precursor of brain acetylcholine. White et al (1977) 
showed a selective loss of cholinergic neurones in Alzheimer's disease. Etienne 
et al (1978) demonstrated significant increases in plasma choline in a group of 
seven elderly patients following a four week dietary regime supplemented with 
lecithin powder. There were no improvements in memory function or 
constructional ability in the treated group, however. 
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In addition to cognitive impairment, there is evidence that poor nutrition may 
contribute to some of the alterations in drug metabolism in old age. Chronic 
vitamin C deficiency in the elderly is associated with impaired clearance by 
oxidation of the model drug antipyrine. Supplementation of the diet with vitamin 
C restored drug elimination rates to normal levels (Smithard and Langman, 
1978; Ginter and Vejmolova, 1981) 
Wynne et al (in press) showed a reduced elimination of conjugated paracetamol 
in institutionalized frail elderly. The formation of the glucuronide conjugate was 
particularly impaired and this may be due to a reduced carbohydrate and protein 
intake resulting in reduced availability of glucuronic acid (Sonne et al, 1989). 
Pantuck et al (1984) enhanced glucuronidation in humans by feeding volunteers 
on a diet rich in cruciferous vegetables for ten days. This was demonstrated by 
a reduction of paracetamol half-life from 2.5 hours to 2.4 hours which was 
significant at the 5% level, and an increased ratio in the plasma concentration of 
paracetamol glucuronide to paracetamol from one hour through to eleven hours. 
These vegetables are rich in indoles which have induced glucuronidation. 
Primary causes of malnutrition in the elderly population include factors such as 
poverty, physical and mental disabilities and ignorance concerning adequate 
nutritional intake. Secondary factors are more exclusive to this group. They are 
also more diverse and difficult to quantitate and include oral problems, 
malabsorption, alcoholism and drug therapy (Lehmann, 1989). 
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12.1.2 Nutritional Status in the Institutionalized Elderly 
This group of elderly people includes the 'frail' group of individuals referred to 
earlier. Any assessment of nutritional status in the elderly, and in subgroups of 
this population is very difficult due to a lack of anthropometric and biochemical 
reference limits. 
As an individual ages he is increasingly susceptible to acute and chronic illness 
which can affect the appetite (both by psychological and physical means) and 
also the nitrogen balance (if calorie intake is too low protein is broken down for 
its calorific value). In the elderly a common psychological cause of a reduced 
appetite is endogenous depression (Lipschitz and Mitchell, 1984) and a multitude 
of other psychiatric disorders including paranoia may occur (Morley, 1990). 
Physical loss of appetite can be due to oral or dental problems, oesophageal 
strictures and loss of of factory sense (Cain and Stevens, 1989). 
Less well defined is the effect of cognitive dysfunction in nutritional status. 
There is some controversy surrounding the cause/effect relationship between the 
two (Morgan et al, 1986; Goodwin, 1989). Kay et al (1980) found 22% of the 
80+ years age group were moderately or severely demented. Some authors 
have suggested that dementia is associated with metabolic changes resulting in 
weight loss (Morgan and Hullin, 1982; Asplund et al, 1982; Abalan, 1984) or 
malabsorption (Burns et al, 1986). 
Vir and Love (1979) found that the nutritional intake of institutionalized elderly 
in Belfast hospitals was poor compared with those in residential care. 
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Lipski et al (in press) compared the dietary intake and nutritional status of fit 
young and fit old (community based) and elderly hospitalized patients. This 
study was carried out in Newcastle District Hospitals and on similar groups of 
people as in this thesis and is therefore especially relevant. They found that the 
elderly long-stay patients were clinically malnourished and did not consume 
sufficient nutrients to meet basic metabolic needs. The energy intake for men 
and women was only 68 % and 63 % of daily requirements respectively. 
Morgan et al (1986) compared calorie intake of fit active elderly with that of a 
group of women suffering from senile dementia in a long-stay geriatric hospital. 
Despite similar energy intakes the hospitalized elderly weighed, on average, 15 
kg less as a group. However, the methods used for assessing dietary intake were 
different in hospital and community elderly (who assessed their own intake) and 
no data is published to substantiate these claims. 
Burns et al (1989) carried out a six month study which compared the weights of 
hospitalized demented patients with community based demented patients and 
found that the former group suffered a continued weight loss over this period 
over this period of time whilst the latter did not, despite comparable diets. 
These are in contrast to the findings of Lipski et al (in press) and Vir and Love 
(1979) discussed earlier. The discrepancies may occur in the way in which 
dietary intake was assessed. Lipski et al (in press) used the validated diet history 
method in a structured interview with the elderly living at home. In order to 
assess the dietary intake of the hospitalized elderly a nurse completed a daily 
record of weighed food intake for seven days. Burns et al (1989) and Morgan et 
al (1986) used the weighed dietary intake on randomly selected individuals from 
each group for a period of 3 days and 5 days respectively as a means of 
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assessing food consumed over the whole period. Vir and Love (1979) also 
weighed the food intake for three days but on all the subjects under study. The 
number of individuals in each study was also quite variable. Burns et al (1989) 
concluded that it was not dementia per se which caused weight loss but "some 
factor associated with hospitalization". The valid comparability of hospitalized 
with community based subjects must be questioned, however. The authors do 
concede that the hospitalized group were more cognitively impaired,, had a 
longer mean duration of illness and were receiving more intensive drug therapy. 
Singh et al (1988) suggested the weight loss may be due to the aimless repetitive 
movements many Alzheimer's patients carry out. However this would not 
explain the results of Burns et al (1989) since as the disease progresses the 
patient usually becomes less mobile. Thus a parallel increase in weight would be 
expected. 
The heterogeneity of the elderly population cannot be emphasized enough. 
Consequently each patient should be treated as an individual. A detailed dietary 
assessment is really the only means of ensuring an adequate nutritional intake. 
This must include careful assessment of the possible effects on concurrent illness 
and drug therapy. 
Some of the clinical signs of malnutrition are very similar to those associated 
with 'normal' ageing eg hair and skin changes, muscle wasting and mental 
confusion. For a patient who is in long-term care, therefore, serial assessments 
are a useful adjunct to the monitoring of nutritional status (Bowman and 
Rosenberg, 1982). 
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12.1.3 The Effect of Drug Therapy on Nutrition 
The frail elderly population are often on more regular medication than the fit 
elderly which can be seen in Table 12.4. The elderly as a whole form the 
largest group of prescription and self-administered drug users. In 1985 the 
proportion of elderly people in the population was 18 % and they received 39 % 
of the prescription items dispensed (Cartwright, 1988). 
Drugs can affect nutritional status in a variety of ways. Whether or not clinical 
malnutrition manifests depends largely on pre-existing deficiencies, doseage and 
duration of drug treatment. 
Anorexia may be caused by drugs such as the phenothiazines which can cause 
somnelance and hence a disinterest in food. Digoxin has a low therapeutic index 
and toxicity is particularly a problem in the elderly who have a reduced renal 
clearance (Baskin and Kendrick, 1978). 
Some drugs cause nutritional side effects which may go unnoticed in younger 
people. For example corticosteroids inhibit bone formation which may 
exacerbate pre-existing oste-oporosis. 
Hypokalaemia is associated with diuretic use resulting in muscle weakness and 
cardiac arrhythmias. Again, though common to all age groups, the elderly are 
most vulnerable (Rikans, 1986). This is related to a reduced potassium intake 
and diminished homeostatic control of blood pressure (Vestal, 1978). 
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Other nutritional effects include the magnesium deficiency related to diuretic and 
digoxin use (Roe, 1984) and salicylate inhibition of folate uptake by red cells 
(Munro et al; 1987). 
12.1.4 Dietary Assessment 
Biochemical Markers of Nutritional Status 
Nitrogen Balance 
Measuring nitrogen balance is a method whereby nitrogen (protein) intake is 
compared with nitrogen excretion. When the body is in a state of negative 
nitrogen balance there is a loss of nitrogen due to its use as an energy source 
instead of fat or glycogen whose supplies have been exhausted. This process 
cannot continue indefinitely. Eventually the formation of body tissue, enzymes 
and cellular components suffers and the organism dies. 
Albumin Measurement 
The usefulness of albumin measurements as a marker of nutritional state remains 
controversial. Lipschitz and Mitchell (1984) claimed that hypoalbuminaemia 
was an excellent indicator of protein - energy malnutrition (PEM) in the elderly. 
However, other authors (Friedman et al, 1985) and more recently O'Keefe and 
Dicker (1988) challenged this claim. They qualified their doubts by observing 
fluid retention and hence dilution of plasma albumin in patients with cardiac, 
renal or liver failure. In their studies they observed rises in albumin 
concentration in the absence of significant changes in dietary intake. 
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Albumin synthesis is sensitive to protein intake. This is based on the observation 
that prolonged starvation is associated with a gradual reduction in plasma 
albumin concentration (O'Keefe and Dicker, 1988). The decline is not large 
because skeletal muscle is used as a store to replace such visceral proteins in 
order to maintain oncotic pressure (Munro, 1964). However the elderly do 
appear to be more vulnerable to the immediate effects of a negative nitrogen 
balance due to a lack of adequate hormone response (namely increase cortisol 
and insulin ratio) which protects younger people (Lehmann, 1989). 
Albumin is probably a useful screening test or a quantitative measure when used 
to monitor a treatment (Lehmann, 1989). However it is insufficiently specific 
since albumin levels are also affected by a number of other conditions such as 
oedema, infection, inflammation and open wounds (Friedman et al, 1985). 
An acute fall in albumin concentration, especially in the elderly is often a sign of 
sudden clinical deterioration such as sepsis (O'Keefe, 1988; Kemm and Allcock, 
1984). 
Serum Transferrin 
Serum transferrin (the major iron transport protein) is also used as a measure of 
protein visceral stores. However tissue iron stores increase with age and 
consequently serum transferrin levels are reduced. This means some healthy and 
adequately nourished elderly will have transferrin levels in the range that would 
normally indicate poor nutritional status (Lipschitz et al, 1981). 
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Haemoglobin Concentration 
Anaemia was found in 98 % of elderly undernourished patients in one study 
(Mitchell and Lipschitz, 1982a) but as a general rule it is non-specific and more 
likely to be due to a blood loss. 
Immune Function 
Changes also occur in immune function with age which bear a close resemblance 
to those seen in malnutrition, but, it is difficult to ascribe host defence 
abnormalities to the ageing process or nutritional status (Lipschitz and Mitchell, 
1984). Lymphopaenia has been used as a useful but non-specific tool which to 
monitor the treatment progress (Lehmann, 1989). 
Creatinine 
The Creatinine - Height Index (CHI) is calculated by relating the 24 hour 
excretion of creatinine to height. This combines biochemical with 
anthropometric measurements and hence the drawbacks of both. There is an 
increased variability to both with increasing age (Mitchell and Lipschitz, 1982a). 
In addition, the accurate measurement of height in bed-ridden, stooped patients 
can be very difficult. Current reference ranges were obtained from a relatively 
small number of young males which means they are inappropriate for use in 
older subjects (Bristian et al, 1975). 
Mitchell and Lipschitz (1982b) related creatinine excretion to total arm length 
(TAL) in an attempt to partly overcome this problem. This was found to be a 
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better indication of malnourishment in males and younger females. However, 
neither CHI nor TAL could distinguish between well and poorly nourished 
groups of elderly females. This was attributed to a possible exhaustive depletion 
of lean body mass in old females or it may relate to a lower creatinine output in 
response to protein deprivation by inactive elderly compared with physically 
active more muscular individuals (Uauy, 1978). 
Ideally a protein marker of malnutrition should have a small body pool size, a 
rapid rate of synthesis, a reasonable distribution in the intravascular space and a 
short biologic half-life (Long, 1984). These optimal criteria ensure the protein is 
maximally responsive. Unfortunately it also means it is reponsive to other 
stimuli and does not only reflect changes in nutritional status. 
12.1.5 AnthronometricMeasuremen 
Anthropometric measurements are carried out in order to quantify the amount, 
composition or rate of tissue change which occurs when a person gains or loses 
weight (Heymsfield et al, 1984). Muscle and fat are usually of most interest. 
From these two measurements fat free mass (FFM) or lean body mass can be 
calculated. 
The instruments used have changed little over the years and include scales, tape 
measures and hand held calipers. All these are non-invasive. Ideal weight 
measurements for height and frame size have been defined over the years, 
usually as the result of mortality statistics (Metropolitan Life Assurance 
Company of New York). 
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The first comprehensive data on upper arm tissue distribution over various age 
ranges (to74 years) is based on the Health and Nutrition Survey (HANES II, 
1971-1974) reported by Bishop et al (1981). A set of reference values based on 
various individual studies is issued by British Indicators, the manufacturers of 
Harpenden calipers 
Obviously calibration of any instruments used with appropriate standards is 
imperative. Just as important is skill and technique in order to achieve 
meaningful and repeatable results. 
Hall et al (1989) issue guidelines for the correct measurement of height, weight 
and limb measurements. Adherence to these standards ensures comparable 
results between centres. 
Skinfold Calipers 
These are instruments which measure skin fold thickness by applying a pressure 
to the skin surface between two jaws. The applied pressure is important since it 
must remain constant throughout the range of measured skinfolds. This has been 
standardized at 10 gmm-2 (Brozek, 1951). The contact surface area has not 
been standardized in the same way but within a reasonable range of surface 
areas, it seems there is little influence on the skinfold thickness (Heymsfield et al 
1984). 
a) Errors in Measurement 
These are due mainly to difficulties with technique and anatomical differences 
between individuals especially due to age. 
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b) Errors in Technique 
It can be difficult to distinguish between fat and muscle. British Indicators issue 
guidelines as to the correct use of Harpenden Calipers. Measurements should be 
made at consistent 'anatomical landmarks' and the observer should be practised 
at finding these (Plate 12). A tape measure is often useful. Muscles should be 
relaxed and the calipers placed perpendicular to the fold. A minimum of two 
measurements should be taken, however too many repeated measurments at the 
same site can result in leakage of water from compressed fat cells and 
consecutive measurements becoming smaller. 
c) Errors due to Anatomic Anomalies associated with Age 
Skinfold calipers only measure subcutaneous fat. However, total body fat is 
distributed between subcutaneous and internal sites which do not change in 
proportion to one another (Allen et al, 1956). The relative distribution varies 
between individuals depending on sex, race and age (Heymsfield et al, 1984) and 
this must be taken into account when interpreting results. 
.ý -. ý 
Biceps 
5 
l 
Suprailiac 
Plate 12: The Four Anatomical Sites of TSF Measurement 
0 
Triceps Subscapular 
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General Problems associated with Anthropometric Measurements in the 
elderly. 
Height measurements are of limited use since there is a well recognized loss of 
stature with increasing age. This appears to be due to, amongst other things, 
shrinkage of the vertebrae and postural changes due to diseases such as 
osteoporosis resulting in increased fracture events and subsequent malformation. 
Limb measurement would appear to be a good alternative provided no gross 
abnormalities exist. Measurement includes knee height (Chumlea et al, 1985) 
and arm length (Mitchell and Lipschitz, 1982b). Making circumference and skin 
fold measurements is difficult in demented patients who possess a limited ability 
to cooperate. Weight measurements can also vary due to hydration status. 
New Developments 
Recently there has been concern about the need for reliable body compostition 
data in the elderly population over 75 years old (Kuczmarski, 1989; Chumlea 
and Baumgartner, 1989). Too often sudden weight losses are ignored, not even 
noticed, or regarded. as the part of the normal ageing process. In fact they may 
be indicative of a protein-energy malnutrition. 
The National Health and Nutrition Survey (NHANES III) presently underway 
will attempt to obtain accurate measurement data using trained personnel and 
calibrated equipment from approximately 5180 persons over 60 years old. These 
will be a representative sample of healthy community dwelling elderly people in 
the USA (Kuczmarski, 1989). 
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The data will not be available until 1994, when it is hoped it will serve as the 
baseline for longitudinal studies of diet and health (Woteld, 1988). 
12.1.6 Nutritional Supplementation 
Nutritional support may be offered to an elderly person as a highly concentrated 
food additive or substitute. There are a large number of products available 
including soluble powders which are mixed with foods, milky and fruit flavour 
drinks and savoury soups. The supplements vary in their composition, calories, 
protein, minerals and trace elements. 
Ideally supplements should not suppress the appetite for the normal meals 
offered. For this reason, especially in hospital, they are probably best given at 
night-time when there is a longer meal-free period. A high nutrient density is 
preferable so the maximum energy content can be given in the minimum volume 
or mass (Elmstahl and Steen, 1987). A number of alternatives or flavours 
should also be offered. A study by Bolton et al (1990) compared short and long- 
term palatability of six commercial supplements in cancer patients. In general 
the milk-based products proved to be the most sustainable. 'Flavour fatigue' 
was recognized by Saukop and Calman (1979). This can by a very real problem 
especially in elderly patients. 
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12.2 Aims 
The aim of this section work was to investigate the effect of improved nutrition 
on the activity of various blood esterases in hospitalized frail elderly individuals 
who exhibited a low body mass index (ratio of weight to height) and/or a poor 
nutritional intake (as determined from a record of food intake supervised by a 
state registered dietician). Anthropometric , physical and mental assessments 
were also made to determine those useful for monitoring changes in nutritional 
status. 
12.3 Method 
Frail elderly patients over 65 years old receiving long-term hospital care were 
recruited for the study by Dr H Wynne (Consultant Geriatrician). These patients 
had all been identified as having a reduced plasma esterase activity (one or more 
esterase measurement below the lowest value measured for the fit elderly group) 
in Chapter 11. Advice on the suitability of a patient regarding their dietary 
habits was sought from Catherine Hankey, a state registered hospital dietician. 
The patients were selected on the basis of a low body mass index which had to 
be visually judged due to the difficulty in obtaining an accurate measurement of 
stature (Chumlea and Baumgartner, 1989). They also exhibited a low Triceps 
Skinfold Thickness (TSF) as defined by McEvoy and James (1982). They used a 
fit elderly population in Newcastle upon Tyne as their reference range drawn 
from a similar socio-economic group as my subjects. In addition the subjects 
also showed a tendency towards a reduced plasma albumin concentration. 
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A single random number scale was used, allocating suitable individuals to the 
feed or control group on the basis of an odd or even number. A non-involved 
individual organized this procedure so that anyone involved in the selection 
process (myself, Dr Wynne and Miss Hankey) did not introduce bias. 
A 'variety of supplements was offered to the feed group depending on individual 
preference, the details of which are shown in Table 12.2. The control group 
continued to receive a hospital diet with no intervention. 
Before the study period, a three day assessment was carried out for each patient. 
Anthropometric measurements were made which included weight on calibrated 
hospital scales in light indoor clothing. The scales were calibrated using 3x10 
kg lead weight. TSF measurements were made in triplicate using Harpenden 
calipers on the right arm unless this was deformed in some way, in which case 
the left one was used. Readings were made at the mid-point between the 
acromion process and the olecranon process. Mid arm circumference was 
measured using a flexible tape measure at the same point. 
A mental test score (Crichton Index) and physical assessment was also made (an 
example of some of the questions asked is shown in Fig. 12.1) . 
Blood for esterase analysis was collected and treated as before (Chapter 11). A 
full biochemical and haematological profile was also obtained . 
These measurements were all repeated at 4 weeks and 8 weeks. 
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Table 12.2 
A Summary of the Composition of Supplements used 
Supplement Presentation Constituents 
Maxijul Dry soluble powder. glucose polymer 
no flavour K+, Na+ 
mix in with food 100g=360Cals 
Buildup Dry powder, mix with fat, carbohydrate, 
whole or skimmed protein, vitamins and 
milk, variety of sweet minerals. 325Cals/ 
flavours serving (whole milk) 
Fortisip liquid milk based drink, carbohydrate, fat 
variety of sweet and protein 3000al/ serving 
savoury flavours 
Provide liquid water-based high protein, low fat, 
drink. Tropical fruit carbohydrate, 
drink Na+, K+. 150 
Cal/serving 
Ensure milk based drink. Carbohydrate, fat, 
Sweet and savoury protein, minerals, and 
flavours vitamins. 253 
Cals/serving 
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Figure 12.1 
An Example of the Questions asked in the Crichton Royal 
Behavioural Scale 
Questions answered by a nurse or careworker: 
DATE 
Communication 
Always clear, retains information 0 0 0 0 
Can indicate needs, understands simple 
verbal directions, can deal with simple information 1 1 1 1 
Understands simple verbal and nonverbal 
information, cannot indicate needs 2 2 2 2 
Cannot understand verbal or nonverbal, 
cannot indicate needs information 3 3 3 3 
No effective contact 4 4 4 4 
Orientation 
Complete 0000 
Orientated in ward, identifies persons 
correctly 1 1 1 1 
Misidentifies people and suuruondings 
but can find way around 2 2 2 2 
Cannot find own bed or toilet unassisted 3 3 3 3 
Lost 4 4 4 4 
Abbreviated Mental Test Score ( answered by patie nt: maximum score is 10) 
Age 1 1 1 1 
Time (nearest hr 1 1 1 1 
Year 1 1 1 1 
Name of Place 1 1 1 1 
Recognition of 2 persons 1 1 1 1 
Birthday (date and month) 1 1 1 1 
Date of World War 1 1 1 1 1 
Queen's name 1 1 1 1 
Counting backwards 20-1 1 1 1 1 
Address (42, West Street) 1 1 1 1 
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12.3.1 Provision of Supplements 
Maxijul was supplied as individual named and dated bags which contained 140 g 
of dry powder equivalent to 500 calories. Each bag contained the maximum 
amount of powder to be included in one days calorific intake. Unused powder 
was weighed and the amount included in the patient's food could be calculated. 
Other supplements were offered twice daily. Most patients tolerated Build-up. 
Those who didn't were offered one of the alternatives until a preference was 
found. 
12.3.2 Intra-Individual Variation in Plasma Esterase Activity 
This study took place over a nine month time period. During this time there 
may be an intra-individual variation of plasma esterase activities due to 
environmental and biological factors other than dietary. The patient group 
which did not receive dietary supplementation during this time controlled for 
these factors. In addition, blood samples were taken from a young volunteer 
throughout the nine-month period and an infra-individual coefficient of variation 
was obtained, shown in Table 12.3. 
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Table 12.3 
The Intra-individual Variation of Blood Esterases During a Nine 
Month Time Period 
Assay RBC Plasma Cholin- Phenyl- Paraoxon- RBC 
Esterase Aspirin esterase acetate ase acetyl- 
Esterase Esterase cholin- 
esteras 
CV% 9.6 (4) 8(4) 8(5) 3(4) 11(4) 6(4) 
(n) 
n= number of samples taken over a nine month period 
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12.3.3 Collation of Dietary Data 
When collecting a three day food intake record, it is necessary to standardize the 
food portion size. This was validated by weighing food portions in the main 
kitchen of the hospital. When the details, including food type (eg yoghurt, 
mashed potato, glass of lemonade) and portion size (weight, volume) are entered 
onto the computer a comprehensive estimation of the amount of macro - and 
micro - nutrients in the food is provided. These are summarized for a whole 
days' intake when the entry is complete. 
The software package used was Salford University's Microdiet system. This 
uses 'The Composition of Foods' (McCance and Widdowson, 1960) as the basis 
of the nutritional data. 
12.3.4 Statistics 
ANOVA was used to compare the means of the three groups. For repeated 
measures on the same group, ANOVA for repeated measures was used (an 
equivalent of the paired t-test). An unpaired t-test was used to compare the 
mean value of the feed groups with the equivalent value in the control group (see 
Appendix III) 
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12.4 Results 
Dietary 
The clinical details of those patients who entered the study are shown in Table 
12.4. They are the same patients recruited in Chapter 11. Table 12.5 shows 
the average daily intake of all major nutrients in the feed group (normal daily 
intake as hospital meals plus supplemental feeding) compared with the 'control' 
group (normal daily intake as hospital meals only). These amounts however are 
only an indication of the nutrients offered to the patients since unconsumed food 
was not collected. Figures 12.2 and 12.3 show a comparison of the nutrient 
values before and after supplementation in the 'feed' and control groups. 
Anthropometric 
There was a trend towards a weight gain in the feed group (mean weight ± SEM 
increased from 45.8 ± 3.5 kg to 47.1 ± 3.5 kg) whilst the 'control' group 
remained constant (38.0 ± 2.6 kg to 37.8 f 3.0 kg. See Fig 12.4). This was 
not matched by a similar trend in TSF ('feed' mean ± SEM: 8.2 ± 1mm to 7.6 
± 1mm Fig 12.5) or MAC ('feed' mean .f 
SEM: 19.5 
,f1.2cm 
to 19.3 ± 
1.3cm Fig 12.6)and consequently AMC. The TSF values are much lower than 
those obtained by McEvoy and James (1982) (Table 12.6). This emphasizes the 
importance of using a single trained observer. All the anthropometric data is 
summarized in Table 12.7. 
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Table 12.4 
Volunteer Details 
Volunteer (sex) Age (years) Drugs (if any) 
Feed 
6(F) 88 docusate, bendrofluazide, chlormethiazole, 
morphine 
8(F) 86 chlormethiazole 
10(F) 88 paracetamol, codeine 
11(F) 85 dothiepin, diazepam 
14 (M) 86 haloperidol, ranitidine, paracetamol. senna 
15(M) 90 paracetamol, senna 
16(F) 91 dothiepin, paracetamol, temazepam 
Control 
1(F) 93 dothiepin, codeine 
5(F) 85 
7(F) 88 
12(F) 86 codeine, micralax enema 
13(M) 70 
17(F) 94 digoxin, pericyclazine, chlormethiazole 
20(F) 96 
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Table 12.5 
Comparison of Average Daily Intake 
between Frail Elderly Patients 
Receiving Supplements and a Control Group 
Average Daily Intake±SEM 
Nutrient Feed group Control group 
(after supplements at (no supplements at 
8 weeks) 8 weeks) 
carbohydrate 164.7_±14.4g* 105.9±6.8g 
fat 67.2±6.7g 59.3±6.2g 
protein 58.4-+-6. Ig* 40.2±4.5g 
fibre 11±1.4g 7.9±1.1g 
calcium 1210±168.7mg* 612±59.7mg 
vitamin D 4.5, f0.9mg* 1.4±0.3mg 
vitamin B12 3.8+0.6mg 2.5+0.3mg 
vitamin B6 6.1 ± 1.4pg 0.5±0.1 pg 
vitamin E 6.3-+-0.6pg* 2.9±1.3pg 
iron 10.1±1.2pg 7.9±1. lpg 
riboflavin 2.9±0.8pg 1.1 +0.1 pg 
nicotinic acid 16.7-+-5.6pg* 6.3±0.3}ßg 
retinol 289.6±31.3mg 311.1±37.8mg 
biotin 43.7_6.4mg* 25.3±4.0mg 
carotene 1456±24.6mg 973±380 mg 
* significant at 95 % level 
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Table 12.6 
Anthropometric Standards from a Fit Elderly Population 
iMt. Evoy and Tames. 1982 ) 
E FEMALE 
mm S. D. Mean S. D. 
TSF 13.38 5.0 19.8 5.0 
(MM) 
MAC 29.1 2.7 27.7 2.7 
(CM) 
*AMC 24.9 2.2 21.5 2.6 
(cm) 
* AMC = Arm Muscle Circumference 
where 
AMC = MAC - (TSFxO. 314) 
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Plasma Proteins 
There was no significant change in albumin concentrations (mean albumin conc. 
g11 of feed group .± 
SEM: 33.7 ± 1.3 to 34.9 ± 2.4. Fig 12.7). The detailed 
esterase activities are shown in Table 12.8 and summarized in Table 12.9. There 
was a significant (p < 0.05; F=6.9) increase in plasma cholinesterase activity 
in the feed group after 4 weeks (mean activity ± SEM for 'feed' increased from 
944. ± 106 nmol benzoylcholine chloride hydrolysed/ml plasma/min to 1158. ± 
140 nmol benzoylcholine chloride hydrolysed/ml plasma/min) but this decreased 
again after 8 weeks to 988 ± 140 nmol benzoylcholine chloride hydrolysed/ml 
plasma/min (Fig 12.8). Plasma aspirin esterase activity followed a similar 
profile of activity ('feed' mean plasma aspirin esterase activity ± SEM in nmol 
salicylate produced/ml plasma/min baseline value was 71.0 ± 8; at 4 weeks was 
80 ±7 and at 8 weeks was 71.9 ± 9. Fig 12.9) but did not show such a marked 
spread of activity. 
Paraoxonase activity showed a trend towards increased activity at 8 weeks in the 
'feed' group (mean paraoxonase activity± SEM changed from 116.9 ± 9.5 
nmol pnp/ml plasma/min at 0 weeks to 126.5 ± 5.3 at 4 weeks and 129.9 ± 
10.5 at 8 weeks) and a decreased activity in the control group (99.4 ± 13.5 
nmol pnp/ml plasma/min at 0 weeks to 106 ± 11.6 at 4 weeks and 94.2 ± 12.6 
at 8 weeks. Fig 12.10). These two values were significantly different at 8 weeks 
(p<0.05; t=2.3). 
Phenylacetate esterase activity showed a different pattern of activity, tending 
towards a reduced activity in both groups at 8 weeks. (In feed group mean value 
reduced by 3.1 nmol phenol/ml plasma/min and in control group it reduced by 
5.9 nmol phenol/ml plasma/min. Fig 12.11). 
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.a 
10 
8 week study period 
Title : Albumin concentration in frail elderly patients 
before and after dietary supplements. 
Ordinate: Mean albumin concentration of group (n=7) 
±SEM 
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control 
Abscissa: 0,4,8 weeks of study period 
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Table 12.8 
Es teras e Measu rements at 0. 4 and 8 weeks 
of Stud y period in Fe ed and Control Groups 
Volunteer Albumin Aspirin esterase Cholinesterase 
g/L nmol salicylate nmol benzoyl 
/ml plasma /min choline chloride 
/ml plasma/min 
FEED pre mid post pre mid post pre mid post 
6 29 28 24 56 50 31 685 654 485 
8 37 42 39 87 104 85 1227 1480 1285 
10 30 34 34 85 87 87 865 1373 1103 
11 
14 
33 
38 
29 
41 
30 
43 
35 
69 
58 
87 
42 
85 
538 
1061 
606 529 
1204 1150 
15 34 38 37 67 87 75 923 1415 1120 
16 35 37 37 98 87 93 1312 1373 1247 
CONTROL 
1 
5 
34 
39 
33 
39 
33 
27 
60 
75 
63 
63 
56 
25 
788 
1030 
868 879 
879 458 
7 33 29 32 56 60 54 588 705 758 
12 29 31 27 46 62 33 636 879 485 
13 37 36 37 87 71 83 1135 986 1079 
17 35 35 36 77 67 60 916 980 905 
20 31 37 38 44 56 65 602 879 876 
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Table 12.9 
A Summary of the Results in Table 12.8 Showing 
the Mean Values of Esterase Measurements. 
Esterase Feed Group 
Mean ±SEM 
Control Group 
Mean ±SEM 
pre- mid- post- pre- mid- post- 
IAspirin 71±8 80+7 71±9 64±6 63±2 53±7 
Esterase 
2Cholin- 944±10 1158± 988±14 841±92 882±35 777±87 
esterase 6 140 0 
3PhAc 73±7.2 79.7.1 70±5.6 62±9.3 62±7.8 56.3±6. 
Esterase 8 
4Paraox- 117±9.5 127±5.3 130. ±10. 99. ±13.5 106±11. 94±12.6 
onase 5 6 
5RBC AChE 37±2.1 42±2.0 38±2.1 39+3.3 40.2.5 40+1.6 
24+2.3 24±1.2 24+1.5 24±1.7 25±0.6 24±3.4 
RBC 120± 17 134± 12 128 + 17 146±10 137±10 130±9 
Esterase 
6Albumin 34±1.3 36±2.1 35±2.4 34±1.3 34±1.3 33±1.6 
conc. 
1 nmol salicylate/ ml plasma /min 
2 nmol benzoylcholine chloride hydrolysed /ml plasma /min 
3pmol phenol /ml plasma /min 
4nmol thiocholine/mg haemoglobin/min (two values due to non- 
comparable substrate) 
5nmol phenol/106 RBC /min 
6 gß, 
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U 
0 0 
2000- 
---. o- Feed 
-- ý--" Control 
p<0.05 compared 
with pre- study value 
t 1000 
ä0 
00 
UV 
CI 
= ä 
0 
N 
0 
.G 
pre- mid- post- 
8 week study period 
Title : Plasma cholinesterase activity in frail elderly patients 
before and after dietary supplements. 
Ordinate : Mean plasma cholinesterase activity of group (n=7 ) 
± SEM (30° C) 
Abscissa : 0,4,8 weeks of study period 
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Figure 12.10 
Title : Plasma paraoxonase activity in frail elderly patients before and after dietary supplements. 
Orcjnate : Mean plasma paraoxonase activity of group (n =7) ± SEM (30 C) 
Abscissa : 0,4,8 weeks of study period 
pre- mid- post- 
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Figure 12.11 
Title : Plasma phenylacetate esterase activity in frail elderly ad=Ls 
before and after dietary supplements 
Ordinate : Mean phenylacetate esterase activity of group (n a7t SEM 
(300 C) 
Abscissa : 0,4,8 weeks of study period 
pre- mid- post- 
247 
Red Blood Cells 
These results are shown in Fig 12.12,12.13 and Table 12.8. There was no 
significant change in red blood cell esterase activity expressed as nmol 
phenol/106 RBC/min in the feed or control groups. The feed group did show a 
trend towards improved esterase activity (mean activity ± SEM at 0 weeks 120 
± 17; at 4 weeks 134 ± 12; at 8 weeks 128 ± 17) which was not apparent in 
the control group (146 ± 10 at 0 weeks; 137 .f 
10 at 4 weeks; 130 ±9 at 8 
weeks). The number of red cells, however did not change, over this pcriod 
(Table 12.10). 
Due to two batches of non-comparable substrate, numbers were reduced in the 
measurement of RBC acetylcholinesterase. Nevertheless, no change in activity 
was apparent over the eight week period ( Fig. 12.12 ). 
Table 12.11 shows that there was no improvement in physical or mental 
functioning after 8 weeks. 
Although randomly selected, the control group showed reduced anthropometric 
and esterase levels compared with the group selected for feeding. These 
differences were not statistically significant at week 0, although TSF and weight 
values did become statistically significant at p<0.05 at weeks 8 (t = 2.3 and t 
= 2.3 respectively). 
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Table 12.10 
RBC Numbers before and after Study Period 
in 'Feed' and 'Control' Groups 
Volunteer RBC x 1012 /1 
week of study 
Feed 0 8 
6 4.14 4.17 
8 4.43 4.71 
10 3.84 2.88 
11 3.15 3.15 
14 3.50 3.22 
15 4.43 4.32 
16 4.64 4.69 
Mean+ SEM 4.0±0.2 3.9±0.3 
Control 
1 4.26 4.33 
5 3.83 4.81 
7 3.75 4.25 
12 4.07 4.07 
13 4.9 4.79 
17 3.50 3.69 
20 3.63 4.25 
Mean +SEM 4.5±0.2 4.3: 0.1 
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Table 12.11 
Mental and Physical Assessment Results of Frail Elderly 
Patients. 
A comparison of results before and after dietary supplements 
Volunteer Pre-study value Post-study value 
Control Mental Physical Mental Physical 
1 0 26 0 26 
5 2 27 2 25 
rr w A ON . 
34 V All? 
12 0 29 0 32 
13 0 14 0 15 
17 1 24 0 22 
20 3 9 6 8 
Mean +SEM 1±0.5 23±2.9 1+0.8 22 2.8 
Feed 
6 7 20 8 19 
8 4 29 4 25 
10 4 21 8 19 
11 4 19 4 21 
14 4 28 5 8 
15 0 20 0 17 
16 4 11 2 13 
Mean +SEM 4+0.7 20±2.1 4+1.0 17±1.9 
Mental : maximum / minimum proficiency = 10/0 
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Intra-individual Variation of Blood Esterases 
Over a nine month period there was considerable infra-individual variation in 
blood esterases measured (Table 12.3). The calculated coefficient of variation is 
a composite of intra-individual variation and interassay variation. The 'non- 
feed' group is used to control for the former. The latter is controlled for by 
using an interassay quality control which is plasma of a known activity. The CV 
for each assay is given in the methods. 
12.5 Discussion 
It was only possible to obtain an estimate of increased nutrient intake in the feed 
group based on the quantity of Maxijul used and drug record charts of Build-up 
accepted (but not necessarily all consumed by the patient). Using the mean 
weight gain of 1.3 kg; the value Of 37 KJ/g fat (DHSS, 1979b) and the study 
period in days (56 days) it is possible to estimate the mean increase in KJ 
consumed per day. In this case the value is 859 KJ/day. 
Banerjee et al (1978) found that supplemented patients in their study using 
Complan (a similar supplemental drink) were selectively reducing their intake of 
fat and carbohydrate. 
McEvoy and James (1982a; also used Build-up in order to determine the 
feasibility of supplementation on an acute geriatric unit. They recorded a 
significant weight increase over a four week period which was due to an increase 
in fat rather than muscle mass. I observed a trend towards an increased weight 
gain over the 8 weeks but no similar trend in TSF or MAC. (In old age, fat is 
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centrally rather than peripherally sited (12.1.5). This discrepancy may be due to 
the difference in the elderly population I used compared with McEvoy and James 
(1982a) They used a population which may not have been clinically stable since 
they were in an acute rather than long-stay geriatric ward. 
The frail elderly people in my study were taking more prescribed medication 
than the fit elderly and younger people. The effect of drugs on plasma esterase 
activities is largely unknown. Gupta et al (1979) investigated the effect of a 
limited range of drugs commonly ingested with aspirin including codeine, 
dextropropoxyphene, propranolol and cimetidine which all inhibited plasma 
aspirin esterase, and many others which had no effect. This is discussed in 
greater detail in Chapter 2. 
Drugs may also result in malabsorption of nutrients (eg folate by sulphasalazinc 
or calcium by tetracycline), utilization (eg folate uptake into red cells is inhibited 
by salicylates) or increased vitamin catabolism (eg of vitamin D by 
anticonvulsants). In addition microbial overgrowth of the bowel (McEvoy et al, 
1983) and disease state (from overt malabsorption syndromes to diabetes) are 
more common in the elderly. 
Albumin concentrations did not change. The relative merits of this protein as an 
indication of poor nutritional status has been discussed in 12.1.4. 
No significant changes were seen in any of the blood esterase activities except 
for a rise in plasma cholinesterase activity at 4 weeks (p < 0.05). This esterase 
may be the most sensitive to changes in nutrient status since it has been closely 
related to lipid metabolism (5.4) and has an estimated half-life of 12 days. The 
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substrate is also very specific which may improve the sensitivity of the assay to 
dietary changes. 
Paraoxonase activity is also measured using a specific substrate and again 
showed a trend towards increased activity in the 'feed' group. This profile was 
not followed by the arylesterase activity suggesting that the two esterases are not 
the same enzyme. 
The RBC have a much longer life span (approximately 120 days) thus it was 
very unlikely any change in enzyme activities would occur over this time period. 
As discussed earlier, reduced RBC esterase activities may be a symptom of 
chronic subclinical anaemias rather than a reduced esterase level per se. 
Mental and Physical Assessments. 
Many of the people in the study were mentally and/or physically restricted. No 
significant change, as measured by the Crichton Index was detected after 8 
weeks of supplemental feeding. Goodwin et al (1983) found a significant 
association between low blood levels of vitamin C, B12, folate and riboflavin 
and poor scores of cognitive function in a group of healthy elderly. Other 
authors have also found links between vitamin depletion and mental functioning 
(Strachen and Henderson, 1965,1967) but these do not appear to be reversible 
with vitamin supplementation. (Beaumont and James, 1985). Tucker et al 
(1990) correlated electroencephalographic (EEG) indices with cognitive 
performance and nutrient status. It is not possible to decide whether these 
relationships reflect cause or effect. 
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12.5.1 Problems Encountered During the Study. 
As with many clinical studies there were a number of problems due to the 
numbers of people involved. 
Nursing Staff 
This study depended quite heavily on the goodwill of nursing staff at a long stay 
geriatric hospital. A constant presence was not maintained at the hospital, 
although regular visits were made by clinicians and the dietician. I also made 
daily visits during this period to renew supplies and give encouragement. It was 
emphasized to staff during this time of the importance of maintained use of the 
supplements. Despite this, use of the Maxijul was especially sparodic depending 
on the duty staff. Initial problems centred around the practice of mixing the 
Maxijul powder with food or drink in front of the patient with subsequent refusal 
of both. This made the nurses reluctant to use it. 
Patients 
Maxijul was well tolerated by most patients when it was included in their diet. 
Some more cognitively astute patients claimed they could taste it, which was 
particularly a problem if they saw the nurse mix it with their food. 
Build-up was also very well tolerated. Finding a supplement for those who 
didn't like it was difficult for two reasons. Firstly, most supplements are milk 
based so the choice was restricted. Secondly these people tended to be naturally 
more wary of 'new' foodstuffs. 
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Patient Failure to Complete Study 
This occurred for two reasons. Either the patient was discharged to a nursing 
home (although remaining clinically stable) or there was a rapid deterioration in 
their health and they died suddenly. This study took place over the winter 
months which may have augmented this problem. 
Some of the patients who entered this study had very low plasma esterase 
activities. As discussed in Chapter 12, some of these were below the range of 
Williams et al (1989). This may have been an indication of declining protein 
synthesis and hence liver function since some of the patients with the lowest 
values failed to complete the study (compare Tables 11.2 and 11.3 with Table 
12.4). 
Anthropometric Measurements 
Some of the problems encountered were purely of a practical nature. The 
calibration of hospital scales was imperative, as, they varied as much as ±1 kg 
from day to day. 
Use of the Harpenden calipers was restricted by the inability of most people to 
cooperate due to physical or mental impairment. Repeated measurements were 
not possible because of a tendency for the reading to reduce as water is squeezed 
from the cells. 
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12.5.2 The Power of the Study 
The power of 'a study is the chance of detecting a difference between samples. 
This depends on the difference between the sample means and on art/n. 
Obviously, these aren't known before a study has been performed. The 
investigator must therefore decide on a threshold value of jil - p2 / v; such 
that if two groups of patients (in my case 'feed' and 'control') differed by at least 
this value then this would represent an important clinical finding. 
eg Consider Table 12.3 where the combined intra-and inter assay coefficient of 
variation for the cholinesterase assay is approximately 8% and consider the mean 
8 week cholinesterase activity level in the 'feed' group from Table 12.9. (988 ± 
104 (SEM) nmol benzoylcholine chloride hydrolysed/ml plasma/min). 
Sample size n 
n= 2S2 D-2 (E B+1.96)2 
where, for a chosen power of 80 % and 5% significance level 
S= estimate of population standard deviation 
D= difference between the means 
EB = 0.84 
Thus: estimated S= 300 
I would like to detect aD= 200 
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estimated n in this case would be: 
n= 2x 3002 x1 (0.84 + 1.96)2 
2002 
= 35.28 = 35 
I would require two sample sizes of 35 individuals in order to achieve 80% 
power to detect a change of 200 nmol benzoylcholine chloride hydrolysed/ml 
plasma/min at the 5% level of significance. 
In order to achieve these numbers the study would have to extend over a longer 
period of time, probably in more than one geriatric unit and using more 
resources. I believe that if suitable elderly people were identified on admission 
to such units and special attention was paid at the outset to their dietary needs, 
significant improvements and sustenance in enzyme activities and anthropometric 
measurements would be seen. 
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h rl 
General Discus ion and Summary 
The first section of work deals with the enzyme kinetics governing aspirin 
(acetylsalicylic acid) hydrolysis in the plasma which is thought to be due to 
cholinesterase and albumin. It was postulated that the lower plasma aspirin 
esterase demonstrated in the frail elderly by Williams et al (1989) was due to 
either a reduced cholinesterase activity or a reduced albumin concentration. I 
postulated that if the former were true it could be due to one or both of the 
following reasons: the cholinesterase enzyme may be present in a reduced 
quantity in the frail elderly , or the active sites of the enzyme may 
be altered in 
some way so as to reduce the affinity of the enzyme for substrate molecules. 
Kinetic analysis using whole plasma as the source of enzyme suggested that the 
first hypothesis appeared to be the case . However , the 
Km value obtained was 
probably a composite of that for cholinesterase and albumin which was not 
evident as a bi- exponential Eadie Hofstee plot. 
iýý, 
Thus in Chapter 10 , purification of whole plasma 
in DEAE Sephacel ion 
exchange gel was used to remove the albumin component so that a true Km 
value for the cholinesterase contribution towards aspirin esterase could be 
obtained. These values were very similar to those obtained using plasma, and 
there was no significant difference between the young; fit and frail elderly. In 
addition the Km value for commercial cholinesterase (as a standard) was very 
similar and comparable with that obtained by Valentino et al (1981). 
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Plasma aspirin esterase, cholinesterase and phenylacetate esterase have already 
been demonstrated to exhibit a reduced activity in the frail elderly (Williams et 
al, 1989). 
In Chapter 11 I confirmed these findings and extended the hypothesis to 
paraoxonase and the red blood cell intracellular esterase and 
acetylcholinesterase. Other workers investigating the effect of age on 
paraoxonase activity had produced conflicting results (Zech and Zurcher , 1974; 
Playfer et a1,1977) but neither had considered the effect of frailty and age. I 
found that paraoxonase activity was significantly reduced in the frail elderly. 
This may be expected by virtue of the fact that phenylacetate esterase was also 
significantly reduced and the two are thought to be the same enzyme by some 
workers (Eckerson et al, 1983b). 
The red blood cell esterases were not significantly reduced per se but the elderly 
(and especially the frail elderly) showed an increased tendency towards 
anaemias and thus also have lowered red blood cell esterase activities. 
It is interesting, in the light of work using rodents (Kutty et al, 1981; Osada et 
al, 1989) to consider the influence of diet on esterase acitvity in humans. 
Waterlow ( 1950) showed that the plasma cholinesterase activity in malnourished 
infants could be improved by increasing their nutritional intake. In Chapter 12 1 
postulated that the same may be true in the frail elderly who are often demented 
and show early signs of malnourishment which may become more acute during 
illness ( Chandra, 1990). 
I offered supplemental feeding to randomly selected group of frail elderly 
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individuals who had demonstrated a trend towards low blood esterase activity 
and poor nutritional status. Because of the small groups ( due to a high 
proportion of individuals who failed to complete the study) it was not possible to 
make firm conclusions. A small increase in weight and a tendency towards 
improvement in some esterases was demonstrated. This led me to conclude that a 
larger study in which such frail elderly patients are identified on admission to 
hospital, and dietary intervention is given a high priority would be worth 
considering. 
Unfortunately, due the nature of the individuals I dealt with in this thesis ie frail 
elderly, studies with large numbers were difficult to achieve. This was 
particularly the case with the last study which extended over several months 
from the moment of recruitment to final completion. Any future follow-up work 
would have to be extended over a longer period of time in order to achieve 
significant results. 
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Appendix I 
Materials 
All the general reagents used in the following experiments were of analytical 
grade or better. Those used for gel electrophoresis were electrophoretically 
pure and or filtered through Whatman no. 4 filters. 
Specific Specialist Reagents 
Electran molecular weight markers BDH 
Chemicals, Poole, Dorset. 
DEAE- Sephacel Ion Exchange Gel Pharmacia 
FineChemicals 
Uppsala, Sweden. 
Human Albumin 45 % Blood Products Lab., 
Therapeutics Division 
Elstree, Herts. 
Human Cholinesterase Enzyme Sigma Chemical Co. 
St. Louis, MO, USA 
Phenyl Valerate (purity confirmed A gift from Mrs 
by n. m. r. ) in double distilled EMutch 
Di- methylformamide synthesized by the 
method of Johnson 
(1977) 
Aspirin (acetylsalicylic acid) Sigma Chemical Co. 
MW=138.1 St. Louis, MO, USA 
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Dietary Supplements 
Build up 
Maxijul 
Provide 
Ensure 
Equipment 
Nestle Health Care 
St. George's House 
Croydon 
Surrey 
SHS Ltd 
38, Queensland St. 
Liverpool 
Fresenius Ltd 
6/8 Christleton Court 
Stuart Road 
Cheshire 
Abbott laboratories Ltd 
Abbott House 
Moorbridge road 
Maidenhead 
Berks 
Phillips Pye Unicam pu 8800 uv/vis spectrophotometer used for end point 
assays and those incubations at 370C. 
Kontron Uvikon 930 spectrophotometer used for incubations at 300C. 
Pharmacia XK 26 glass column. 
Gilson fraction collector 202 
Biorad power supply 500/200 
Gel electrophoresis slab diffusion destainer Biorad 222 
Biorad vertical electrophoresis unit and casting kit. 
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Appendix II 
Enzyme Kinetics 
The distinguishing feature of enzyme-catalysed reactions from a chemical 
reaction is that they show saturation. At low substrate concentrations nearly 
all enzyme catalysed reactions show first-order dependence which ultimately 
becomes zero-order. Michaelis and Menten (1913) proposed a mechanism 
for this reaction which is shown as 
Ko 
E+A=EA--->E+P 
where A is substrate; E is enzyme; EA is enzyme - substrate complex and P 
is the product. 
Briggs and Haldane (1925) extended this theory by postulating a steady-state 
situation in which the binding of substrate was assumed to be reversible but 
not necessarily at equilibrium during the reaction. 
This resulted in the fundamental equation of enzyme kinetics: the Michaelis- 
Menten equation 
Vmax (S) 
V= -------- (1) 
Km + (s) 
V= reaction rate; (S) is the substrate concentration; Vmax is the maximum 
velocity of the reaction at saturating substrate concentrations and Km is the 
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Michaelis-Menten constant for the reaction. 
When V= 1/2 Vmax 
Vmax 
2 
and 
1 
2 
therefore 
Vmax (S) 
Km + (S) 
(S) 
Km+(s) 
(3) 
Km + (S) = 2(S) (4) 
Km = (S) (5) 
(2) 
At half the maximum velocity Km is equal to the substrate concentration. 
Km is the value which reflects the affinity of an enzyme for a substrate, 
where affinity is proportional to the reciprocal of the constant. 
Eadie-Hofstee Analysis 
This equation is derived from linear transformation of the original 
Michaelis -Menten formula. Although not entirely free from distortion it is 
less affected than the double-reciprocal plot (Lineweaver - Burke). 
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V 
V= Vmax - Km - (6) 
S 
Thus when V is plotted against V/S, a straight line with a negative slope, 
Km, and y-axis intercept of Vmax is obtained. 
The Eadie - Hofstee plot is a useful means of identifying a reaction which 
may exhibit biphasic enzyme kinetics. Such a reaction has two Km and two 
Vmax values: 
VV 
V= (Vmaxl - Kml -)+ (Vmax2 - Km2 -) + ......... (7) 
SS 
Kml and Vmaxl are the apparent Km and Vmax for the high affinity 
component and can be calculated by least squares regression analysis of the 
slope of the terminal phase and its y-axis intercept respectively. 
Extrapolation of this line to the y-axis produced an estimate of the 
contribution of the high affinity component of the reaction to the low affinity 
component. This value is substracted from each data point on the first phase 
of the Eadie - Hofstee plot to obtain a second straight line frone which the 
kinetic parameters of the low affinity component (Km2 and Vmax2) can be 
calculated. 
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The direct-linear plot 
This has been advocated as the least biased estimate of Vmax and Km when 
there is only one enzyme (Eisenthal and Cornish-Bowden, 1974). 
Vmax Km 
---- - --- =1 (S) 
V (S) 
Each observation is plotted as a straight line rather than a point. If Vmax and 
Km are treated as variables and V and (S) as constants, this reaction defines a 
straight-line with intercepts V on the Vmax axis and - (S) on the Km axis. 
Thus all possible pairs of values for Km and V which satisfy this observation 
are shown. A second line drawn in the same way does likewise. The point 
of intersection of all the observation lines provides the coordinates (Km, 
Vmax) which satisfies all the observations . 
In practice, the lines fail to intersect at exactly one point due to experimental 
error. Each intersection point is marked on the Km and Vmax axis and the 
median of these values is taken to be the best estimate of each parameter. 
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Appendix III 
Statistical Tests 
Where the average of a group of variables is given, it is expressed as the 
arithmetic mean ± the standard error of the mean (SEM). The SEM relates 
to the precision of the sample mean as an estimate of the population mean, 
and is especially relevant when one mean is compared with another. 
The studies undertaken involve the statistical testing of a formulated 
hypo thesis of no difference is made. Statistical manipulation allows the 
estimation how far above or below zero a difference or relationship can be 
expected to lie due to random sampling error. 
A 'significant' difference between the means of two or more groups exists 
when the probability that the observed difference is due to chance is less than 
a certain value. For example if two means differ at the 5% level of 
significance ie p<0.05, this means that 95 times out of 100 a difference of 
this size will n_Ql be due to chance alone. 
The term of 'not significant' does not necessarily imply no true difference 
exists, merely that there is greater than, say, a5% chance that the observed 
differences are due to chance. 
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The tests used in the previous studies were one-way Analysis of Variance 
(ANOVA) and ANOVA for repeated measures. The former is an equivalent 
of the unpaired t-test and the latter is an equivalent of the paired t test. Both 
are used to test the level of significance of the difference between two or 
more samples if a difference exists, the Scheffe f-test identifies which of the 
means actually differ. 
The significance of a correlation between two values was tested for using the 
formula below. The quantity 't' is a Students' t with n-2 degrees of freedom 
and is referred to in the usual tables. 
r (n-2)1/2 
t= 
(1-r2)1/2 
r= correlation coefficient 
n= number of paired data points. 
Stat works 512 on a Mackintosh computer was used for all statistical 
calculations. 
